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CHAPTER I: INTRODUCTION
1.1 OESOPHAGEAL CANCER
Oesophageal cancer is the eighth most common cancer and sixth most common cause 
o f death from  cancer w orldw ide1. It is estimated th a t 16,980 people w ill be diagnosed 
w ith  and 14,710 men and wom en w ill die o f cancer o f the oesophagus in the USA in 
20112. Despite im provem ent in five-year survival rates from  4% in the 1970s3' 4, the  
prognosis o f oesophageal cancer remains poor and current European overall five-year 
survival rates are at best 11%5.
| 1 .1 .1  GEOGRAPHICAL DISTRIBUTION
There is a significant variation in geographical incidence. Approxim ately 83% o f all 
cases and 86% o f the deaths occur in developing countries1. A 15-fold variation in 
incidence is observed in males between high-risk southern Africa and low-risk western 
Africa and 20-fold variation in females between southern Africa and 
Micronesia/Polynesia1. The area w ith  the highest reported incidence fo r oesophageal 
cancer is the so-called Asian 'oesophageal cancer belt', which stretches from  eastern 
Turkey through north-eastern Iran, northern Afghanistan and southern Russia to  
northern China6,7. High rates have also been reported fo r South-east and South Africa, 
parts o f South America and W estern Europe1' 6,7. Squamous cell carcinoma is the most 
prevalent histological type worldw ide but the incidence o f adenocarcinoma is rapidly 
increasing in firs t w orld countries8,9.
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There is a w ide variation in incidence not only between countries but also in d ifferent 
ethnic groups and populations w ith in  a particular country. For example, in the USA, the  
incidence o f adenocarcinoma is almost fo u r times higher in w hite  men than in black 
men, while the incidence o f squamous cell carcinoma is almost six times higher in black 
men than in w hite  m en10.
1 .1 .2  OESOPHAGEAL CANCER IN IRELAND
Oesophageal cancer is the tenth  most common male and fourteenth  most common 
female cancer (excluding non-melanoma skin cancers) in Ireland11. Between 2000 and 
2004, there were on average 296 male and 183 female cases o f oesophageal cancer 
(excluding cardia cancer) diagnosed in Ireland each year11. During the same period, 
there  were 296 male and 174 female deaths per year (giving an incidence:m ortality  
ratio o f 0.98)11. This is a frigh tfu l ind ictm ent on the efficacy o f current therapeutic  
strategies. It is also similar to  the num ber o f m otor-vehicle related deaths in Ireland 
each year12 which receives a considerably more media and legislative a ttention. 
Oesophageal cancer accounts fo r only 2% of all cancers in Ireland, but 4% of cancer 
deaths11 and the incidence rates are 1.2 to  3 times higher in Ireland than in the United 
States or the European Union13. Between 1994 and 2009, the incidence rate fo r 
squamous cell carcinoma increased by 0.9% and 1.4% annually fo r females and males 
respectively, while the  incidence rate fo r adenocarcinoma increased by 2.2% and 3.0% 
fo r females and males respectively14; a trend  seen in most developed countries.
In Ireland, the  m ajority o f cases o f oesophageal cancer occur in elderly patients. 
Roughly 70% o f cases occur in patients over the age 65 and 50% in the  over 70s11. The
12
relative 5-year survival in Ireland is a dismal 14%, but this compares favourably w ith  
international data5,13. In Ireland, the num ber o f cases o f cancer o f the oesophagus is 
projected to  increase by 69% (2% annually) fo r females and 187% (6% annually) fo r  
males between 2005 and 203515.
11 .1 .3  GENDER DISTRIBUTION
Oesophageal cancer is tw o  to  fo u r times more common in males in most regions1' 6, but 
can vary tremendously. For example the male to  female sex ratio is 7:1 in Eastern 
Europe complared w ith  3.5:1 in the USA16. In the high-risk areas o f Asia and Africa, 
however, the sex ratio is much closer to  unity8.
| 1 .1 .4  AGE DISTRIBUTION
The risk o f oesophageal cancer increases w ith  age, w ith  less than 3% being diagnosed 
under the age o f 454. The mean age at diagnosis in the USA is 67 in males and 73 in 
females, or 68 overall4. Approxim ately 75% o f the people who die from  oesophageal 
cancer are over the age o f 6513.
| 1 .1 .5  CHANGING TRENDS
During the past several decades im portant changes have occurred in the epidemiologic 
patterns o f oesophageal cancer. Until the 1970s, squamous cell carcinoma accounted 
fo r the vast m ajority o f oesophageal cancers diagnosed and continues to  do so in 
developing countries8' 9. Since the 1970s, however, the incidence o f squamous cell 
carcinoma has remained stable or decreased in most western countries while tha t o f
13
adenocarcinoma has rapidly become the dom inant histology in developed countries 
such as the UK, USA and in Europe7'10,17’ 18.
I 1 .1 .6  PATHOLOGY AND ETIOLOGY 
| 1 .1.6.1 PATHOLOGY
Adenocarcinoma and squamous cell carcinoma account fo r approximately 90% o f 
oesophageal cancers w ith  rarer tum ours such as melanomas, leiomyosarcomas, 
carcinoids and lymphomas making up the rem ainder19. The m ajority of 
adenocarcinomas are found in the distal one th ird  o f the oesophagus and cardia, 
whereas squamous cell carcinomas are usually located between the m iddle and distal 
th irds20,21. The proximal one th ird  o f the  oesophagus is a relatively uncommon site o f 
disease19.
Although most clinical studies have not d ifferentia ted between the tw o  m ajor 
histological types, increasing evidence supports the concept th a t they d iffe r in term s o f 
pathogenesis, epidemiology, tum our biology, and prognosis. Current series suggest 
th a t the prognosis o f adenocarcinoma is be tte r than th a t o f squamous cell carcinoma, 
particularly in earlier disease21*26. One reason may be th a t lymphatic spread occurs less 
frequently in Barrett's-associated cancer than in squamous cell carcinoma24, 27. In 
acknowledgement o f these differences, the  most recent AJCC cancer staging system28 
provides separate stage groupings fo r  adeno- and squamous cell carcinoma (Table 1, 
Table 2, Table 3)
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1.1.6 .2 .1  SMOKING AND ALCOHOL CONSUMPTION
Smoking is one o f the m ajor risk factors associated w ith  both squamous cell carcinoma 
and adenocarcinoma o f the oesophagus. The risk o f oesophageal cancer correlates 
directly w ith  the quantity o f cigarettes smoked per day and the duration o f smoking29' 
30. This is thought to  be related to  the resulting contact of nitrosamines w ith  
oesophageal mucosa31. Alcohol m ultiplies the effect o f tobacco consumption but also 
independently increases the risk o f squamous cell carcinoma in the absence o f 
smoking32.
1 .1 .6 .2 .2  RADIOTHERAPY
Previous radiotherapy to  the mediastinum, as fo r the trea tm ent o f breast and lung 
cancers, lymphoma and o ther neoplasms, predisposes patients to  both  
adenocarcinoma and squamous cell oesophageal carcinoma, which typically develop 
ten or more years a fter radiation therapy exposure33,34.
1 .1 .6 .2 .3  MEDICATIONS
A num ber o f common medications, such as calcium channel blockers, tricyclic 
antidepressants and certain asthma medications such as theophylline and beta 
agonists, prom ote gastro-oesophageal reflux by relaxing the lower oesophageal 
sphincter. One study examined the role o f medications as risk factors fo r the  increasing 
incidence o f oesophageal and gastric cardia adenocarcinomas35. They found tha t the
I 1 . 1 . 6 . 2  E T I O L O G Y
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increase in incidence o f these tum ours were not likely to  be related to  the use o f lower 
oesophageal sphincter-relaxing drugs as a group but did suggest tha t persons treated  
fo r  long-standing asthma may be at increased risk o f oesophageal adenocarcinoma35, 
possibly reflecting the fact th a t gastro-oesophgeal reflux disease and asthma are 
inextricably linked36. A later study, however, has suggested tha t the widespread use o f 
low er oesophageal sphincter-relaxing drugs may have contributed to  the increase in 
incidence o f oesophageal adenocarcinoma37.
1 .1 .6 .2 .4  DIETARY FACTORS
Studies in high risk areas o f northern Iran and China have identified a number o f dietary  
risk factors fo r oesophageal cancer. These include opium use, nutritional deficiencies 
particularly zinc, diets deficient in fru it and vegetables, certain foods which contain 
high levels o f mycotoxins and nitrosamines and therm al injury from  consumption o f 
very hot beverages38, 39. In South Africa, where oesophageal cancer is the most 
common cancer in black males, one m ajor contributory factor is thought to  be the  
consumption o f im ported maize which has replaced sorghum as the main staple d ie t40. 
The ingestion o f this maize when contaminated w ith  fungus, especially Fusarium 
monHiforme, and the resultant mycotoxins has been implicated in the increase in 
incidence o f oesophageal cancer in this population40.
1.1 .6 .2 .5  BARRETT'S OESOPHAGUS
Barrett's oesophagus is the eponym used to  describe the change from  the normal 
stratified squamous epithelium  o f the lower oesophagus to  a polarised, columnar-lined  
epithelium  w ith  intestinal-type d ifferentia tion. Norman R. Barrett (1903-1979), was a
16
distinguished thoracic surgeon in London who w ro te  an article in 1950 entitled  
"Chronic Peptic Ulcer of the Oesophagus ond 'Oesophagitis"*1. In fact Barrett did not 
fu lly  understand what he was describing and he did not recognise intestinal features 
(goblet cells) in the columnar-lined oesophagus. In 1953 Phillip Allison, a thoracic  
surgeon from  Leeds in England, published an article entitled The Oesophagus Lined 
with Gastric Mucous Membrane*2. Magnanimously, the  authors suggested tha t the  
term  “ Barrett ulcers" be used to  describe ulcer craters in the columnar cell-lined 
oesophagus and the term  Barrett's Oesophagus became enshrined as the eponym  
thereafter.
Intestinal metaplasia develops in the context o f chronic gastro-oesophageal reflux 
disease and bile reflux. Barrett's metaplasia represents the firs t step o f the metaplasia- 
dysplasia-adenocarcinoma sequence, but despite the  initia l almost universal 
acceptance th a t intestinal metaplasia is a prerequisite fo r the development o f 
oesophageal adenocarcinoma, there is continued debate, w ith  some authors finding it 
unlikely th a t adenocarcinoma would develop in its absence and others strongly  
disagreeing43'46.
Overall, Barrett's is associated w ith  an approximate 0.12-1%  annual progression rate to  
oesophageal adenocarcinoma47'49 but accurate estimates o f the annual incidence of 
high-grade dysplasia and adenocarcinoma in patients w ith  Barrett's oesophagus have 
been d ifficu lt to  establish, due to  the considerable variation in reported rates. In tw o  
o f the more recent reviews, the pooled incidences o f adenocarcinoma were estimated 
to  be up to  6 cases per 1000 person-years, w ith  much higher incidence estimates o f up 
to  10 cases per 1000 person-years fo r high-grade dysplasia50,51. Several studies have
17
dem onstrated a higher incidence o f adenocarcinoma associated w ith  longer-segment 
Barrett's oesophagus, especially when greater than 6 -8  cm52'55, but has also been 
shown to  be similar in short-segment Barrett's by large UK based study56 and others44. 
Patients w ith  known Barrett's oesophagus are thought to  have 30 to  60 times the risk 
of developing oesophageal adenocarcinoma than the general population57'60 but data 
from  a recent study calls into  question the rationale fo r ongoing surveillance in patients  
w ho have Barrett's oesophagus w ith o u t dysplasia49. Hvid-Jensen et al analysed the  
data o f all 11,028 patients w ith  Barrett's oesophagus in Denmark during the period 
from  1992 through 2009 and conducted fo llow -up  fo r a median o f 5.2 years. During 
the  study period, only 7.6% o f adenocarcinomas diagnosed nationwide were diagnosed 
in patients known to  have Barrett's oesophagus. The authors acknowledged Barrett's 
oesophagus as a strong risk facto r fo r oesophageal adenocarcinoma, but found tha t the  
absolute annual risk o f 0.12%, or 1 case o f adenocarcinoma per 860 patient-years, was 
several times low er than the assumed risk o f 0.5%, which form s the basis fo r current 
surveillance guidelines61,62.
Surveillance programs have yet to  show any effect on survival50,63'67. In fact, due to  the  
low risk o f malignant progression o f Barrett's oesophagus, most patients w ith  Barrett's 
die due to  causes o ther than oesophageal adenocarcinoma50. The results o f the most 
recent large studies and meta-analyses49'51 call a ttention  to  the questionable rationale  
and cost-effective ness o f surveillance o f Barrett's oesophagus and thus highlight the  
need fo r valid risk stratification to  allow focus on the  m inority o f patients th a t are likely 
to  benefit from  surveillance.
18
1 . 1 . 6 . 2 . 6  O B E S I T Y
Adenocarcinoma has become the  predom inant tum our type in the Western w orld7'10, 
17. The most likely explanation fo r this rapid increase in incidence seems to  be the  
increasing prevalence o f Barrett's oesophagus as a consequence o f gastro-oesophageal 
reflux, which, in tu rn , is becoming more common w ith  the increasing incidence o f 
obesity68'70. The exact biological mechanisms by which obesity increases the  risk of 
oesophageal cancer remain unknown and are likely to  be m ultifactorial.
It has been suggested tha t obesity increases intra-abdom inal pressure and gastro- 
oesophageal reflux71. Several studies have shown an association between obesity and 
gastro-oesophageal reflux and its complications 68'70,72, although one study found this  
hypothesis to  be true  only in w om en73, while another found it to  be true  chiefly in 
males74.
Adipose tissue has long been considered to  be prim arily responsible fo r energy storage 
and was thought to  be m etabolically passive75. It is now known th a t along w ith  its role 
in energy homeostasis, adipose tissue also functions as an intricate endocrine and 
immune organ which secretes a w ide variety o f cytokines, hormones, and other 
biochemically active substances which regulate insulin sensitivity and glucose 
homeostasis, hypothalamic activity, central sym pathetic output, vascular tone, and 
reproduction, through endocrine, autocrine and paracrine effects75. Abdominal visceral 
adipose tissue in particular is now known to  be metabolically active and to  secrete a 
variety o f molecules im portant in the pathogenesis o f glucose intolerance and insulin
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resistance, cardiovascular risk factors such as dyslipidemia and hypertension76. It is 
thought th a t the  altered immunological, metabolic and endocrine environm ent present 
in obesity facilitates pro-in flam m atory and pro-tum ourigenic pathways thought to  play 
a crucial role in the developm ent o f oesophageal adenocarcinoma77.
11 .1 .7  CLINICAL PRESENTATION
The most common symptoms o f oesophageal cancer are dysphagia, which occurs in 
th ree  quarters o f patients20 and w eight loss which is present in tw o  th irds78. It may also 
present w ith  a range o f o ther symptoms such as odynophagia, vom iting, heartburn, 
regurgitation, epigastric pain, gastrointestinal bleeding, vom iting, dyspepsia and 
nausea. W hile 8% o f patients w ith  oesophageal cancer can present w ith  hiccups as 
th e ir in itia l sym ptom 79, some patients are entirely asymptomatic and are diagnosed on 
surveillance endoscopy fo r Barrett's oesophagus.
One o f the reasons fo r the  poor prognosis o f oesophageal cancer is the advanced stage 
of disease at diagnosis in most patients80 w ith  one th ird  o f patients having m etastatic  
disease at presentation78. One o f the explanations fo r this is the  aggressive biological 
nature o f this disease, resulting in rapid dissemination. Another, and more m odifiable  
reason, is the lack o f awareness, especially among the  public, o f the symptoms of 
oesophageal cancer. FitzGerald et al81 found th a t only 12% o f patients questioned  
were aware o f the main symptoms o f oesophageal cancer. Grannell et al82 reported  
th a t only 17 per cent fe lt th a t cancer was a probable explanation fo r dysphagia 
compared w ith  80 per cent w ho would consider cancer a likely cause o f breast lump. 
Rothwell at al83 reported th a t delay in patient presentation and resultant defin itive
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trea tm ent (median 15 weeks) was m ulti-factoria l. Not only did lack o f patient 
awareness o f the disease lead to  delayed presentation to  the general practitioner, but 
ineffic ient management by both fam ily doctors and hospital services were implicated 
emphasising the importance o f "fast-tracking" patients w ith  the sinister symptoms and 
highlighting the need fo r increased awareness o f oesophageal cancer.
11 .1 .8  DIAGNOSIS
Oesophageal cancer is an aggressive disease and only a quarter to  one th ird  o f cases 
are diagnosed while the cancer is still confined to  the  prim ary site; one th ird  are 
diagnosed after the  cancer has spread to  regional lymph nodes or directly beyond the  
primary site; and a th ird  are diagnosed a fte r the cancer has already metastasised4' 78.
Patients presenting w ith  dysphagia and weight loss should undergo urgent 
investigation. A barium swallow may show a suspicious ulcer or stricture but definitve  
diagnosis o f oesophageal cancer, however, can only be made on endoscopy and biopsy. 
On endoscopy, macroscopic evaluation o f the abnormality, accurate docum entation o f 
the  level o f the tum our and sufficient biopsies (we would suggest at least ten) are key 
factors. Histological analysis then confirms malignancy. In the presence o f a 
macroscopic abnorm ality or clinical suspicion, endoscopy must be repeated if biopsies 
do not confirm  malignancy. The defin ition  o f malignancy versus high-grade dysplasia, 
however, is contentious and what is diagnosed as malignant in Japan may be defined as 
high-grade dysplasia in the W est84.
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Not all patients present sym ptom atically and many early cancers are detected on 
surveillance endoscopy fo r Barrett's oesophagus. The endoscopist must be vigilant in 
patients w ith  both long- and short-segment Barrett's oesophagus and in those w ith  
dysplasia as these patients are at higher risk o f oesophageal cancer44,53'56. Indeed up to  
half o f patients w ith  severe dysplasia have co-existent invasive carcinoma85.
11 .1 .9  STAGING AND RESTAGING
Patients are staged at diagnosis and should be restaged fo llow ing treatm ent. The stage 
determines w hether the in ten t o f the  therapeutic approach w ill be curative or 
palliative.
| 1 .1.9.1 STAGING
A num ber o f d ifferent staging systems are used to  classify oesophageal tumours. The 
TNM staging system assesses tum ours in three ways: extent o f the primary tum our (T), 
absence or presence o f regional lymph node involvement (N), and absence or presence 
o f distant metastases (M). Once the T, N, and M are determ ined, a stage o f I, II, III, or 
IV is assigned, w ith  stage I being early and stage IV being advanced disease. The 
histologic grade assigned to  a tum our reflects its biologic activity and is graded as well, 
moderately, poorly or undifferentiated.
The American Joint Committee on Cancer (AJCC) was established in 1959 to  form ulate  
and publish evidence-based systems o f classification o f cancer, including staging and 
end results reporting, to  be used by health professionals to  guide management and
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determ ine prognosis o f cancer patients. The AJCC Cancer Staging Manual and 
Handbook is currently in th e ir 7th editions and the latest com m entary o f oesophageal 
cancer staging was published in 201028. The defin ition o f TNM staging is outlined in 
Table 1. The individual adenocarcinoma and squamous cell carcinoma groupings are 
outlined in Table 2 and Table 3 respectively.
Table 1: Definition of TNM  Adapted From AJCC Cancer Staging Manual 7th Edition28.
DEFINITION OF TNM
Primary Tumour (T)
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis High grade dysplasia (HGD), formerly known as in situ
T1 Tumour invades lamina propria or submucosa
Tla Tumour invades mucosa or lamina propria
Tib Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades adventitia
T4 Tumour invades adjacent structures
T4a Resectable cancer invades adjacent structures such as pleura, 
pericardium, diaphragm
T4b Unresectable cancer invades adjacent structures such as aorta, vertebral 
body, trachea
Regional Lymph Nodes (N)
NX Regional lymph nodes (i.e. any perioesophageal lymph node from 
cervical to celiac nodes) cannot be assessed
NO No regional lymph node metastasis
N1 1-2 positive regional lymph nodes
N2 3-6 positive regional lymph nodes
N3 *7 positive regional lymph nodes
Distant Metastasis (M)
MX Distant metastasis cannot be assessed
MO No distant metastasis
M l Distant metastasis
Histologic Grade (G)
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
G4 Undifferentiated
Cancer Location
Upper thoracic 20-25cm from incisors
Middle thoracic >25-30cm from incisors
Lower thoracic >30-40cm from incisors
Oesophagogastric Includes cancers whose midpoint is in the distal thoracic oesophagus,
Junction oesophago-gastric junction, or within the proximal 5cm of the stomach 
(cardia) that extend into the oesophago-gastric junction or distal 
thoracic oesophagus (Siewert III). These stomach cancers are stage 
grouped similarly to adenocarcinoma of the oesophagus
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Table 2: Adenocarcinoma Stage Groupings Adapted From AJCC Cancer Staging Manual 7 th
Edition28.
Adenocarcinoma
AJCC Stage Tumour (T) Node (N) Metastases (M) Grade (G)
0 is (HGD) 0 0 1
(A 1 0 0 1-2
IB 1 0 0 3
2 0 0 1-2
IIA 2 0 0 3
IIB 3 0 0 Any
1-2 1 0 Any
IJIA 1-2 2 0 Any
3 1 0 Any
4a 0 0 Any
IIIB 3 2 0 Any
me 4a 1*2 0 Any
4b Any 0 Any
Any N3 0 Any
IV Any Any 1 Any
Table 3: Squamous Cell Carcinoma Stage Groupings Adapted From AJCC Cancer Staging
Manual 7th Edition28.
Squamous Cell Carcinoma
AJCC Stage Tumour (T) Node (N) Metastases (M) Grade (G) Location
0 is (HGD) 0 0 1 Any
IA 1 0 0 1 Any
IB 1 0 0 2-3 Any
2-3 0 0 1 Lower
IIA 2-3 0 0 1 Upper, middle
2-3 0 0 2-3 Lower
IIB 2-3 0 0 2-3 Upper, middle
1-2 1 0 Any Any
IIIA 1-2 2 0 Any Any
3 1 0 Any Any
4a 0 0 Any Any
IIIB 3 2 0 Any Any
MIC 4a 1-2 0 Any Any
4b Any 0 Any Any
Any N3 0 Any Any
IV Any Any 1 Any Any
The most clinically useful methods o f staging are endoscopic ultrasonography (EUS), 
computerised tom ography (CT), 18F-fluoro-2-deoxy-D-glucose positron emission 
tom ography (FDG-PET) and laparoscopy, although all of these are known to  have the ir 
lim itations, especially in detecting small tum our deposits.
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1 . 1 . 9 . 1 . 1  E N D O S C O P I C  U L T R A S O N O G R A P H Y
Endoscopic ultrasonography (EUS) is often used to  determ ine the depth o f tum our  
invasion (T stage) and the presence o f malignant regional and celiac lymph nodes in 
patients w ith  oesophageal cancer (N stage). EUS, however, has a lim ited depth o f 
penetration o f approximately 5 cm and metastases in distant lymph nodes or organs 
can often be overlooked w ith  this fo rm  o f imaging86. A recent meta-analysis comparing  
the diagnostic performances o f various staging techniques, however, found tha t EUS 
was significantly more sensitive but less specific than computerised tomography (CT) 
and 18F-fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) fo r the  
detection o f regional lymph node metastases but was shown to  be particularly useful 
fo r the exclusion o f regional lymph node metastases87. EUS may be combined w ith  fine  
needle aspiration cytology (FNAC) to  establish if questionable lymph nodes contain 
malignancy.
1 .1.9.1 .2  COMPUTERISED TOMOGRAPHY
Computerised Tomography (CT) is commonly used to  determ ine the degree o f 
involvement and w hether malignant lymph nodes or distant metastases are present. 
However, in N staging, CT relies largely on "size criteria" which reduces its sensitivity 
and specificity in its ability to  distinguish between lymph nodes enlarged by metastases 
or by a benign process, or detect tu m our in a normal sized lymph node and also in 
detecting tum our deposits88,89. The sensitivity o f CT fo r detection o f distant metastases 
ranges between <50% and >90%90.
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1.1.9 .1 .3  18F-FLUORO-2-DEOXY-D-GLUCOSE POSITRON EMISSION 
TOMOGRAPHY
18F-fluoro-2-deoxy-D-glucose positron emission tom ography (FDG-PET) is used to  
detect the presence o f malignant lymph nodes or distant metastases. Detection o f 
tum our deposits by FDG-PET is based on an altered tissue glucose metabolism and has 
been shown to  detect additional sites o f m etastatic disease at initia l evaluation91. 
Tum our deposits less than 1cm in d iam eter may not be detectable by FDG-PET92 and it 
is d ifficu lt to  discriminate between lymph nodes adjacent to  the primary oesophageal 
cancer and the prim ary tu m our itself w ith  FDG-PET due to  its lim ited spatial 
resolution88' 93.
Despite these lim itations, a recent meta-analysis found tha t the diagnostic 
performance o f FDG-PET was significantly higher than tha t o f CT fo r distant 
metastases87. FDG-PET has been shown to  detect m etastatic disease in approximately 
20% o f patients who are considered as having only loco-regional disease on CT90. The 
accuracy fo r correct identification o f recurrence in oesophageal cancer is also higher fo r 
FDG-PET than fo r CT scan90. Additionally, CT and EUS have been reported to  be less 
effective than FDG-PET imaging at predicting long-term survival94,95.
1 .1 .9 .1 .4  PET/CT
Due to  the lim itations o f CT and FDG-PET outlined above, integrated FDG-PET/CT 
scanners have been developed and are now comm only used. The in troduction o f 
integrated PET/CT has improved accuracy over the use o f PET and CT imaging
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conducted separately96,97. PET/CT significantly improves the sensitivity, accuracy and 
negative predictive value o f FDG-PET imaging in the assessment o f locoregional lymph 
nodes96. The accuracy o f PET/CT can lead to  up and down-staging o f patients resulting 
in a change in management in up to  17% o f patients due to  the detection o f occult 
metastases or earlier disease than suspected w ith  conventional imaging m odalities98. 
Another study reported tha t the  tum our length-SUV index could d ifferentia te  patients 
w ith  unresectable disease and those w ho are potentia lly curable w ith  a specificity o f 
90% and a sensitivity o f 93%; and by combining this index w ith  visual analysis, 
specificity could be increased to  96% ".
1 .1 .9 .1 .5  LAPAROSCOPY
Diagnostic laparoscopy has been used to  determ ine resectability and to  avoid 
unnecessary surgery in patients w ith  advanced oesophageal cancer. Diagnostic 
laparoscopy has been found to  be particularly useful fo r detecting and confirm ing  
nodal involvement and distant m etastatic disease th a t potentia lly would a lter 
trea tm ent and prognosis in patients w ith  oesophageal cancer. One study by Heath et 
al100 found th a t 76% o f patients w ith  abnormal-appearing nodes at laparoscopy were  
confirm ed by biopsy to  have node-positive disease, whereas 78% o f patients w ith  
normal-appearing regional or celiac nodes, were confirm ed by biopsy to  be tum our 
free. In this study, laparoscopy changed the trea tm ent plan in 17% o f patients. 
Another larger series by de Graaf e t a l101 found tha t sensitivity o f laparoscopy fo r 
resectability was 88% and th a t staging laparoscopy avoided unnecessary laparotom y 
and changed patient management in 20.2% o f patients. Laparoscopy was found to  be 
most useful in adenocarcinoma, distal oesophageal and oesophago-gastric junction  
tum ours and gastric cancers and was found to  be probably unnecessary in lesions o f
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the upper tw o-th irds  o f the oesophagus101. The addition o f peritoneal lavage and 
cytology to  laparoscopy has been shown to  detect both peritoneal macro- and micro- 
metastases so small as to  evade the resolution o f all current imaging techniques102.
11 .1.9.2  RE-STAGING
1.1 .9 .2 .1  ENDOSCOPY
Endoscopy is an easily perform ed, well to lerated and a readily available investigation. 
Studies using endoscopy to  determ ine luminal response in re-staging patients fo llow ing  
neoadjuvant chem oradiotherapy have produced varying results. Brown et al103 
reported th a t an endoscopically normal lumen correlated w ith  a 50% likelihood o f a 
complete pathological response but neither biopsy o f the  lumen nor CT scanning were  
perform ed which may have reduced the accuracy o f these assessments. The findings o f 
a study from  the M em orial Sloan-Kettering Cancer Center104 were more disappointing  
where a negative endoscopy and biopsy was only 31% predictive o f a complete  
pathological response. In this paper, however, only 71% o f patients were biopsied 
fo llow ing chemoradiotherapy, and neither the num ber o f biopsies or the experience o f 
the endoscopist were not commented upon.
1.1 .9 .2 .2  ENDOSCOPIC ULTRASONOGRAPHY
There is one report in the literature which suggests th a t endoscopic ultrasonography 
was more accurate than CT in staging patients post-neoadjuvant chemoradiotherapy, 
w ith  an accuracy o f 77-81% 105 but routine restaging endoscopic US has not gained 
traction  in the  lite ra tu re106,107, largely due to  its inability to  distinguish inflamm ation
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and fibrosis from  residual cancer107. In one study T stage accuracy was only 29% w ith  a 
sensitivity o f positive nodes o f only 52%106.
1.1.9.2 .3  COMPUTERISED TOMOGRAPHY
CT is useful post neoadjuvant therapy fo r ruling out solid organ metastases and has up 
to  a 78% accuracy in detecting nodal disease but was not found to  be as accurate as 
PET/CT in reliably detecting nodal or residual disease or complete responders post 
neoadjuvant chem oradiotherapy108'110.
1 .1.9.2 .4  18F-FLUORO-2-DEOXY-D-GLUCOSE POSITRON EMISSION 
TOMOGRAPHY
Studies evaluating tum our response w ith  PET during and at the com pletion o f 
neoadjuvant therapy have yielded encouraging results91, 109, u l *118. These studies 
suggest th a t changes in FDG uptake in response to  therapy correlate w ith  the  
pathological response as well as predicting the risk o f local recurrence and survival. 
Levine et al117, perform ed an FDG-PET at diagnosis and fo llow ing chemoradiotherapy in 
31 patients w ith  oesophageal cancer. They found tha t the standardised uptake value 
(SUV) decreased significantly more in those patients w ho responded (pathological 
complete response or microscopic residual disease) than in those who did not (p=0.05).
1 .1 .9 .2 .5  PET/CT
PET/CT has been found to  be unhelpful fo r restaging post-chem oradiotherapy due to  
the response to  inflam m ation meaning tha t m icro-deposits o f tum our may remain 
undetected108,109. Another prospective study, however, identified FDG-PET/CT as being
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more accurate than EUS-FNA and CT scan fo r predicting nodal status and complete  
response fo llow ing neoadjuvant therapy in patients w ith  oesophageal cancer110. In this 
study FDG-PET/CT and CT alone were found to  provide targets fo r biopsy, but results 
were often found to  be falsely positive110.
1 .1 .10  TREATMENT STRATEGIES
A m ultidisciplinary approach, including the input from  fam ily practice physicians, 
surgeons, gastroenterologists, radiologists, medical and radiation oncologists and 
specialist nurses, is necessary to  improve the outlook fo r patients w ith  this disease. 
Many trea tm ent strategies are available and each newly diagnosed patient requires 
ta ilored therapy according to  th e ir stage o f disease and overall health.
| 1 .1.10.1  SURGERY ALONE
Techniques o f curative oesophageal resection range from  endoscopic mucosal ablation 
and mucosal resection to  radical en bloc oesophagectomy.
1 .1 .1 0 .1 .1SURGICAL RESECTION
Surgery alone has long been the preferred trea tm ent m odality fo r loco-regional control 
o f oesophageal cancer. The natural history o f this disease, however, is to  disseminate 
early and over 80 percent o f patients undergoing potentia lly curative resection have 
micrometastases in th e ir bone m arrow at the tim e o f resection119. Few patients w ith  
oesophageal cancer present early enough, or are f it  enough, to  undergo and to  benefit 
from  surgical resection. Only about 20% o f oesophageal cancer patients have operable
30
localised disease (stages 0 , 1 and II)120 and only the m inority o f patients are considered 
suitable fo r resection78,12\
Despite advances in surgical techniques and aftercare, the  m orta lity  rate o f surgery 
remains form idable. A recent SEERs database122 reported a 14% m orta lity  rate fo r  
resection in North America, and the m orbid ity o f resection remains significant123. It 
incurs a considerable im pairm ent o f quality o f life124,125. Survivors are exposed to  a 
life tim e risk o f the complications o f oesophago-gastric resection; recurrent laryngeal 
nerve injury w ill result in vocal cord paralysis and aspiration126, 127, resection o f the  
low er oesophagus and the lower oesophageal sphincter w ill result in reflux 
oesophagitis128'130, vagotom y w ill result in "early" and "la te" dum ping131,132 and delayed 
gastric em ptying133 and post-operative anorexia, odynophagia and eating difficulties  
result in nutritional consequences134.
A 1980 review by Earlam et al o f 122 papers described the surgical care o f 83,783 cases 
o f squamous cell carcinoma o f the oesophagus and revealed a dismal 5-year survival 
rate o f 4%3. A decade later, a sim ilar review article by M uller et al135 quoted a 5-year 
survival rate o f 10%. Overall, the  current survival fo llow ing surgery alone remains poor. 
W hile most series report a 5-year survival rate o f around 20% to  40%136'139, even 
fo llow ing en-bloc resection, these data are drawn from  hospital series o f resectable 
patients w ith  early disease. The current overall 5-year survival o f all patients, including 
those treated by surgery, based on com m unity data is a dismal 5%140.
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Super-selection o f patients who are f i t  enough fo r surgery and have early disease, 
which may represent as few  as 5.4% o f patients undergoing resection141, can lead to  a 
decrease in m orta lity  and post-operative m orbid ity and an increase in survival142, 141. It 
is clear th a t even those w ith  early T ib  disease frequently succumb to  loco-regional 
recurrence or métastasés142,141. Super-selection o f patients fo r surgery can produce 
fla tte ring  long-term survival rates but cannot lead to  an increase in the  overall survival 
rate o f oesophageal cancer and has little  impact on the disease as a whole.
An RO resection is defined as one in which all margins are histologically free o f tum our 
and is the aim of all en-bfoc resections, especially in those w ith  early disease. Even in 
patients w ith  early disease, however, Bosset et al143 found a significantly lesser rate o f 
curative resection in those who had surgery alone versus those who had neoadjuvant 
chemoradiotherapy. Similarly, Burmeister et al123 described significantly few er RO 
resections in the surgery alone group versus those who had neoadjuvant 
chem oradiotherapy. Since RO resectability impacts favourably on overall survival, the  
low er rate o f RO resection in those undergoing surgery alone is concerning, particularly  
in those staged as having early disease.
One o f the trad itiona l arguments in favour o f surgery alone over neoadjuvant 
chem oradiotherapy fo r oesophageal cancer is th a t the la tte r increases the m orbid ity  
and m orta lity  o f oesophageal resection but the literature on this contention is 
conflicting. In th e ir randomised controlled tria l comparing neoadjuvant 
chem oradiotherapy and surgery to  surgery alone, Burmeister et al123 reported surgical 
complications in 55% o f patients undergoing primary surgery compared w ith  49% in 
those receiving neoadjuvant chemoradiotherapy. There was an equal rate o f
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anastom otic leaks (5%) and a sim ilar rate o f cardiac complications in both groups. 
There were more pulmonary complications (28 vs. 20%) and an increase rate in 
anastomotic strictures (24 vs. 19%) in the surgery alone group compared w ith  the  
chem oradiotherapy group. The m orta lity  rate and median length o f stay was the same 
in both groups. Similarly Berger et al144, Lin et al145, Kane et al146, Kelsen e t al147 and 
Medical Research Council Oesophageal Cancer W orking Group148 reported no increase 
in m orbid ity or m orta lity  fo llow ing induction therapy.
Conversely, studies such as those o f Eguchi et al149 described an increase in m orbid ity  
and m orta lity  in those who received chemotherapy before surgery versus those who  
had surgery alone. In th e ir study, this was increased fu rthe r in the group tha t received 
tw o  cycles versus those w ho had only one cycle. There was also an increase in 
m orbid ity and m orta lity  associated w ith  preoperative chemoradiotherapy, especially 
when a higher dose o f radiotherapy was administered. Hagry et al150 and Bosset et al143 
also described an increase in m orbid ity and m orta lity  in those undergoing preoperative 
chemoradiotherapy.
W hile a few  studies show an increase in m orb id ity  and m orta lity  in those undergoing 
neoadjuvant chem oradiotherapy before resection, the w eight o f evidence seems to  
suggest th a t preoperative therapy does not impact negatively on m orbid ity or m orta lity  
while perm itting  a greater incidence o f R0 resection.
W hilst surgery alone may be curative in th a t small subset o f patients w ith  true early 
disease, these patients cannot be identified w ith  current pre-operative staging
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techniques. Instead, it must be assumed th a t all patients w ith  disease th a t has spread 
beyond the mucosa have systemic micrometastases, and o ther modalities are required 
to  trea t such patients who present at a more advanced stage o f disease and fo r those 
w ho are unfit fo r surgery.
1 .1 .10 .1 .2  ENDOSCOPIC RESECTION AND ABLATION TECHNIQUES 
Because o f the malignant potentia l o f Barrett's oesophagus, screening endocopy is 
perform ed to  allow the detection o f dysplasia before it progresses to  adenocarcinoma. 
Traditionally, an oesophagectomy would be offered to  patients w ith  high-grade 
dysplasia but more recently endoscopic ablation and resection techniques have been 
developed. Endoscopic ablation techniques such as radiofrequency ablation, 
electrosurgery, and photodynam ic therapy have been developed to  destroy the 
neoplastic tissue and allow healthy squamous epithelium  to  re-grow w ith  some 
success151'154 w ith  outcomes comparable to  surgery155. However, there are concerns 
th a t residual areas o f metaplasia may remain hidden beneath the newly grown  
squamous epithelium  which may advance to  invasive carcinoma151,156 and th a t this 
technique may not adequately trea t foci o f invasive carcinoma th a t may have been 
missed on initia l pre-treatm ent evaluation biopsies.
Endoscopic mucosal resection is an alternative endoscopic technique w ith  which the  
neoplastic epithelium  is excised, allowing fo r both more accurate histopathologic 
diagnosis and curative therapy. This technique has been used safely and effectively in 
high-grade dysplasia and small intramucosal carcinomas157161 and can be comparable 
to  surgery162 w ith  5-year survival rates o f up to  98% reported160. However, as w ith
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surgery, since so few  patients present w ith  suitably early disease141, this technique is 
unlikely to  impact on the  overall trea tm ent and survival o f oesophageal cancer 
sufferers.
| 1 .1.10.2  CHEMOTHERAPY ALONE
Palliative chemotherapy is w idely used as an alternative or additional treatm ent, w ith  
the in tent to  control tum our growth, improve quality o f life and prolong survival in 
those w ith  m etastatic oesophageal cancer. Both squamous-cell and adenocarcinoma 
o f the oesophagus are responsive to  chem otherapy and in 15 to  55 percent o f patients, 
undergoing various chem otherapeutic regimes, shrinkage o f the  tum our by at least 50 
percent may occur163'169. The response to  chem otherapy is usually short-lived, 
however, and survival rarely exceeds one year. There is a lack o f evidence tha t 
chem otherapy improves survival and /or quality o f life fo r these patients19. Despite the  
numerous phase II trials, only tw o  randomised controlled trials comparing  
chemotherapy versus best supportive care have been published170' m . These trials had 
conflicting results, had small patient numbers (156 and 24 respectively), and used 
different types o f chemotherapy. There is a need fo r a randomised phase III tria l 
comparing chem otherapy versus best supportive care to  assess the impact o f palliative  
chem otherapy on quality o f life and survival.
I 1 .1.10.3  RADIOTHERAPY ALONE:
As the long-term  survival fo r surgery alone is so poor, many fe lt th a t it could be 
equalled or improved on by radiotherapy alone, especially since radiotherapy alone 
was so effective in head and neck cancer.
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Oesophageal cancer trea tm ent w ith  radium was firs t described by Exner in 1904172 but 
the results fo r radiotherapy alone, however, have trad itionally  been disappointing. In a 
review of 49 early series involving more than 8400 patients treated w ith  radiotherapy  
alone, survival rates at one, tw o, and five years were 18, 8, and 6%, respectively173.
Trials comparing radiotherapy alone w ith  surgery alone and chem oradiotherapy are 
d ifficu lt to  interpret, since many involve patients w ith  advanced and irresectable 
disease, w idely varying doses o f radiotherapy are used and many were performed  
before the modern radiotherapy era. Better results are reported in later studies from  
single institutions in well-defined patient populations, especially in early disease, using 
more modern radiotherapy protocols174' 175 w ith  up to  59% 5-year survival174 but are 
lim ited by small numbers o f patients174' 175.
Badwe et al176 compared radiotherapy alone w ith  surgery alone in a randomised 
controlled tria l. In this tria l, survival in the  surgery arm was significantly better than in 
the radiotherapy arm (p=0.002), although again the  small num ber o f patients recruited  
confounds interpretation. Previous to  this, an MRC prospective randomised tria l o f 
radiotherapy versus surgery fo r operable squamous cell carcinoma of the oesophagus 
was discontinued at 18 months fo llow ing recruitm ent o f only 31 patients in 16 
centres177.
Okawa et al178 conducted a randomised controlled tria l comparing radiotherapy alone 
w ith  radiotherapy and intralum inal brachytherapy fo r oesophageal squamous cell 
carcinoma and described an overall 5-year survival rate o f 20%. There was no
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statistically significant im provem ent in survival between the tw o  groups, except on 
subgroup analysis o f those w ith  a tu m o ur less than 5cm in length, where the addition  
o f brachytherapy incurred a significant survival advantage (p=0.025).
There are more phase III trials comparing chem oradiotherapy w ith  radiotherapy, but 
results fo r radiotherapy alone are disappointing w ith  5 year survival rates in the  region 
of 0-14.5%179’ 180.
A Cochrane review o f 19 randomised trials comparing chem oradiotherapy alone w ith  
radiotherapy alone fo r localised oesophageal carcinoma181 dem onstrated an absolute 
survival benefit fo r chem oradiotherapy at years one and tw o  o f 9 and 4% respectively. 
Additionally, there  was an absolute increase in local recurrence fo r radiotherapy. 
According to  this review, concom itant radiotherapy alone was in ferio r to  
chemoradiotherapy, when a non-operative approach was selected.
1 .1.10.4  DEFINITIVE CHEMORADIOTHERAPY
The disappointing rates o f survival and local control associated w ith  single m odality  
therapy, and the observation th a t at least one quarter o f surgical specimens have 
shown complete tum our eradication fo llow ing neoadjuvant chem oradiation182 and the  
need fo r more effective non-surgical management led to  the developm ent o f defin itive  
chem oradiotherapy regimes fo r oesophageal cancer.
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The landmark RTOG tria l compared concurrent chem oradiotherapy ((5-fluorouracil) 5- 
Fluorouracil, Cisplatin and 50 Gy radiotherapy) to  radiotherapy alone (64 Gy) in 
patients w ith  locoregional thoracic oesophageal cancer (90% squamous cell 
carcinoma)179. This tr ia l was stopped afte r interim  analysis dem onstrated a significant 
advantage fo r chem oradiotherapy w ith  a significant reduction in both locoregional and 
distant fa ilure fo r chemoradiotherapy. Long-term fo llow -up  o f this tr ia l183 
dem onstrated a 5-year survival rate fo r chem oradiotherapy o f 26% compared w ith  0% 
fo llow ing radiotherapy alone.
Minsky et al184 conducted a tria l to  compare the local/regional control, survival and 
tox ic ity  o f com bined-m odality therapy using high-dose (64.8 Gy) versus standard-dose 
(50.4 Gy) radiation therapy fo r the trea tm ent o f patients w ith  oesophageal cancer. 
They enrolled 236 patients w ith  stage T1 to  T4, N0/1, MO squamous cell carcinoma or 
adenocarcinoma who had been selected fo r a non-surgical approach. This study 
showed th a t the  higher radiation dose did not increase survival or local/regional 
control.
A Cochrane review examined 19 randomised controlled trials (eleven concurrent and 
eight sequential chem oradiotherapy studies) comparing combined chemotherapy and 
radiotherapy (w ithou t surgery) w ith  radiotherapy alone in localised carcinoma o f the 
oesophagus181. This w ork concluded th a t concurrent chem oradiotherapy provided a 
significant reduction in m orta lity, w ith  an absolute survival benefit at years one and 
tw o  fo r chem oradiotherapy o f 9% and 4% respectively and an absolute reduction of 
local recurrence rate o f 12%. The results o f sequential chem oradiotherapy studies,
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however, showed no significant benefit in survival or local control but significant
181
toxicities
It is uncertain w hether definitive chem oradiotherapy can achieve treatm ent outcomes 
com parable to surgery, since there is only one small randomised controlled trial to date 
com paring chem oradiotherapy alone and surgery alone185. In this trial, involving eighty 
patients, a tw o- or three-stage oesophagectom y with two-field dissection was 
performed in the surgery alone group (N=44) and patients in the chemoradiotherapy 
group (N=36) received 5-FU, Cisplatin and concurrent 50-60 Gy radiotherapy. Although  
it failed to reach statistical significance, standard oesophagectom y or 
chem oradiotherapy offered similar early clinical outcome and survival. Similar results 
were noted by a Japanese group who performed a non-randomised retrospective  
com parison between definitive chem oradiotherapy and radical surgery in 82 patients 
with resectable oesophageal squamous cell carcinom a186. Thirty-three patients were 
treated with chemoradiotherapy and forty-nine with surgery and were followed up for 
a median of 36 months. The patients in the chem oradiotherapy group received 5-FU, 
Cisplatin and 50.4 Gy radiotherapy and those in the surgery group were treated by 
oesophagectom y with radical node dissection. Eighteen patients in the surgery alone 
group went on to have post-operative chemotherapy. The overall survival rates and 
disease-free survival rates at 3-years were 48% and 44% in the CRT group and 65% and 
59% in the surgery group, respectively. Although this non-randomised study lacked 
statistical significance, it showed that chem oradiotherapy could result in survival 
com parable with conventional surgery. Another similar study of 98 patients showed a 
trend favouring definitive chem oradiotherapy over surgery in the treatm ent of
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oesophageal carcinoma, even though those receiving chem oradiotherapy had more 
advanced disease187.
Bedenne et al188 reported on a randomised trial in which patients with locally advanced 
tum ours and who were responding to induction therapy (two cycles of 5-fluorouracil 
and Cisplatin and either conventional or split-course concom itant radiotherapy) were 
randomised to chemoradiation alone or chemoradiation followed by surgery. Two 
hundred and fifty-nine patients who responded to treatm ent and who had no 
contraindication to either therapy were randomly assigned to surgery or continuation  
of chemoradiation. This study found that chemoradiation alone and chemoradiation  
followed by surgery were equivalent in both term s of survival and quality of life in 
responders. These results are consistent with the results from the study by Stahl et 
al189 in which 172 patients with oesophageal cancer were randomly assigned to either 
chemoradiation with surgery or chemoradiation without surgery. Median survival time 
was 16.4 months with surgery com pared with 14,9 months without surgery, and 2-year 
survival rates were 39.9% and 35.4%, respectively (p=0.007).
Definitive CRT is now used in the USA in nearly as many patients as undergo surgery (30 
vs. 34% )80 and is now being offered in several centres for patients with potentially 
resectable tum ours183,187,19°. A recent phase II trial of chem oradiotherapy for stage I 
oesophageal squamous cell carcinom a conducted In Japan dem onstrated a complete  
response rate of 87.5% with a 4-year survival of 81% and thus verified the effectiveness 
of chemoradiation in very early disease191.
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Larger-scale randomised trials com paring radical chem oradiotherapy with surgery 
alone in both adenocarcinom a and squamous cell carcinoma are necessary but may 
pose difficulties in recruitm ent of patients and treating clinicians alike.
11 .1 .1 0 .5  N EO A D JU V A N T C H EM O TH ER A P Y
As the majority of resected patients succum b to cancer80,13S' 192, most likely due to the  
persistence of micrometastases undetectable by current staging m odalities119, the 
elimination of m icroscopic disease has become a key consideration. Giving 
chem otherapy pre-operatively urgently addresses this putative m icroscopic burden of 
disease before it can become any greater.
A number of trials have investigated whether neoadjuvant chem otherapy followed by 
surgery leads to an im provement in cure rates (Table 4), but the results have been 
conflicting and subsequent meta-analyses have also failed to reach a consensus with 
some, including the largest of the randomised trials, dem onstrating a survival 
advantage148,193,194 and some not195,196.
The largest randomised controlled trial to date, the MRC trial148, randomised 802 
patients with squamous cell (31%) and adenocarcinom a (66%) of the oesophagus, in
42 European centres, to two cycles of neoadjuvant chem otherapy with Cisplatin and 5- 
fluorouracil (5-FU). This trial found that the overall survival was better in the 
neoadjuvant chem otherapy group (p=0.004) than in the surgery alone group. Long­
term follow up of this trial confirmed that neoadjuvant chem otherapy improved 
survival in operable oesophageal cancer (p=0.03) with a 5-year survival of 23% for 
neoadjuvant chem otherapy com pared with 17% for surgery alone197.
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The most recent meta-analysis examined eleven randomised controlled trials involving 
2019 patients com paring neoadjuvant chem otherapy with surgery alone198. This m eta­
analysis concluded that neoadjuvant chem otherapy may offer a survival advantage 
compared to surgery alone for resectable thoracic oesophageal cancer of either 
histological subtype, but that further research was necessary. The authors found that 
there was no evidence of a difference in rate of resections, tum our recurrence, or post­
operative morbidity with the addition of neoadjuvant chem otherapy and proposed that 
the most beneficial chem otherapy combination appeared to be Cisplatin and 5- 
Fluorouracil based.
Table 4: Randomised Controlled Trials Comparing Neoadjuvant Chemotherapy And Surgery 
With Surgery Alone In Oesophageal Cancer.
Author Year Tumour Type Treatment No. of Patients Survival Advantage 
(p Value)
Schlag199 1992 SCC C/5FU 22 NS
Surgery 24
Nygaard200 1992 SCC CB 44 NS
Surgery 41
Maipang201 1994 SCC BVC 24 NS
Surgery 22
Law202 1997 see C/5FU 74 NS
Surgery 73
Kelsen147. 1998 . AC/see C/5FU 213 NS
Surgery 227
Ancona203 2001 SCC C/5FU 47 NS
Surgery 47
MRC148 2002 Ac/see C/5FU 400 <0.01
Surgery 402
C/5FU= Cisplatin/5-Fluorouracil
CB= Cisplatin/bleomycin
BVC= Bleomycin/Vindesine/Cisplatin
NS= Not statistically significant
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11 .1 .1 0 .6  N EO A D JU V A N T R A D IO TH ER A P Y
In many patients who have early recurrent disease, the disease recurs locally. It is 
reasonable therefore to attem pt to "sterilise" the tum our bed prior to resection. 
Neoadjuvant radiotherapy has been explored as a possible means of reducing local 
spread, thereby, improving survival. By down-staging the tumour, it was hoped to 
increase tum our resectability and improve survival.
Five prospective randomised controlled trials have investigated the effects of 
preoperative radiotherapy using varying doses of radiotherapy200,204 207 (Table 5). All 
but one trial examined the role of neoadjuvant radiotherapy in squamous cell 
carcinoma alone.
A meta-analysis of these five trials with long-term follow-up data suggested that 
neoadjuvant radiotherapy may provide a small survival advantage for patients with 
potentially resectable cancer of the oesophagus208. This meta-analysis found that there  
was no clear evidence that neoadjuvant radiotherapy was detrimental in terms of 
survival. Any small benefit derived from preoperative radiotherapy could be offset, 
however, by the increased morbidity, cost, and duration of treatm ent associated with 
giving radiotherapy pre-operatively. It was concluded in this meta-analysis, therefore, 
that neoadjuvant radiotherapy could not be routinely recom m ended outside of 
controlled clinical trials.
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T a b le  5: R a n d o m i s e d  C o n t r o l l e d  Tria ls  C o m p a r in g  N e o a d j u v a n t  R a d i o t h e r a p y  A n d  S u r g e ry
W ith  S u r g e r y  A lo n e  In O e s o p h a g e a l  C a n c e r .
Author Year Tumour
Type
Treatment No. of 
Patients
Radiotherapy
Dose
Survival
Advantage
, ■ 20<! Launois 1981 see NART
Surgery
67
57
39-45Gy NS
Gignoux205 1988 sec NART
Surgery
102
106
33Gy NS
Wang206 1989 sec NART
Surgery
104
102
40Gy NS
Nygaard200 1992 see NART
Surgery
48
41
35Gy NS
Arnott207 1992 see &
AC
NART
Surgery
90
86
20Gy NS
NART=Neoadjuvant radiotherapy 
NS=Not statistically significant
j 1 .1 .1 0 .7  N EO A D JU V A N T C H EM O R A D IO T H E R A P Y
The aim of combining neoadjuvant chem otherapy and radiotherapy is to exploit the 
radiosensitising effects of chem otherapy to reduce the tum our size and maximise local 
control179, in addition to acting against m icrometastases and leading to better curative 
resection rates and im provement in survival123,143. Neoadjuvant chem oradiotherapy 
has recently become the focus of interest in an effort to prolong survival and reduce 
recurrence rates in patients with oesophageal cancer.
Patients who have a com plete pathological response to neoadjuvant 
chem oradiotherapy are known to have a significant survival advantage over incomplete 
responders209*212. There have been significant advances in increasing the complete 
response rates of between 43 and 87.5% 191,213 depending on disease stage and regimen
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employed, with the highest com plete response rates reported for patients with earliest 
disease stage191.
To date, there have been many randomised controlled trials com paring neoadjuvant 
chem oradiotherapy and surgery (multimodal therapy) with surgery alone (Table 6). 
The results have been conflicting and subsequent m eta-analyses (Table 7) and even 
meta-analysis of meta-analyses214 have also failed to reach a consensus with some, 
dem onstrating a survival advantage182' 215 222 and some not123' 143' 200' 211' 213' 214' 223' 224. 
Most such randomised trials of neoadjuvant chem oradiotherapy versus surgery alone 
do not have enough power to show smaller yet worthwhile survival improvements. It 
has also been suggested that that due to the substantial variation of outcomes after 
surgery alone - due to case selection, variation in staging techniques, advances in peri­
operative care and surgical expertise - the benefits achieved by a moderately effective 
neoadjuvant therapy might be obscured222. As such, conclusions from trials showing 
benefit from neoadjuvant therapy have been criticised because outcomes in the 
control (i.e. surgery alone) group have been regarded as suboptim al225*230.
Traditionally, meta-analysis has been used to increase the precision of the comparisons 
of such trials and the estimation of treatm ent benefit. Interpretation of these meta­
analyses has been limited, however, due to treatm ent heterogeneity (e.g. use of 
different chem otherapeutic agents and concurrent versus sequential radiotherapy), 
grouping of different tum our types together, small patient numbers and short-term  
follow-up. The trend is, however, that neoadjuvant chem oradiotherapy seems to 
improve outcom e in oesophageal cancer with the most recent meta-analysis showing 
an absolute survival benefit at 2 years of 8.7%, with similar survival benefits in
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adenocarcinom a (p=0.02) and squamous cell carcinoma (p=0.004)222. The com plete  
results of the most recent randomised controlled trial must be awaited and may shed 
new light on the current controversy221.
Table 6: Randomised Trials Comparing Neoadjuvant Chemoradiotherapy And Surgery 
(Multimodal Therapy) With Surgery Alone In Oesophageal Cancer
Trial No. of 
Patients
Tumour
Type
Chemotherapy Radiotherapy CPR
Rate
Conclusion
Nygaard 1992200 SCC Cisplatin 35 Gy -
■ Multimodal 47 Bleomycin Sequential NS
■ Surgery 41
Apinop 1994223 ' SCC Cisplatin 40 Gy 27%
■ Multimodal 35 5-FU Concurrent NS
■ Surgery 34
Le Prise 1994224 SCC Cisplatin 20 Gy 9.8%
■ Multimodal 41 5-FU Sequential NS
■ Surgery 45
Walsh 1996182 AC Cisplatin 40Gy 25%
■ Multimodal 58 5-FU Concurrent Multimodal
■ Surgery 55 superior
Bosset 1997143
p<0.01
SCC Cisplatin 37 Gy 21%
■ Multimodal 143 Split course NS
■ Surgery 139
Urba 2001211 AC Cisplatin 45 Gy 28%
• Multimodal 50 SCC 5-FU Hyperfractionated NS
■ Surgery 50 Mixed Vinblastine
Lee 2004213 SCC Cisplatin 45.6 Gy 43%
■ Multimodal 51 5-FU Hyperfractionated NS
■ Surgery 50
Burmeister 2005123 AC Cisplatin 35 Gy 16%
■ Multimodal 128 SCC 5-FU Concurrent NS
■ Surgery 128 Mixed
Tepper 2008215 AC Cisplatin 50.4 Gy 40%
■ Multimodal 30 SCC 5-FU Concurrent Multimodal
■ Surgery 26 superior
Mariette 2010231
p=0.002
AC Cisplatin 45 Gy - NS
■ Multimodal 97 SCC 5-FU Concurrent
■ Surgery 98
Van der Gaast 2010221* AC Paclitaxel 41.4 Gy 33%
» Multimodal 273 SCC Carboplatin Concurrent Multimodal
■ Surgery 86 superior
p=0.011
AC = Adenocarcinoma
SCC = Squamous Cell Carcinoma
5-FU = 5 Fluorouracil
CPR = Complete Pathological Response
NS = not statistically significant
^Preliminary results
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T a b le  7: M e t a - A n a l y s e s  o f  N e o a d j u v a n t  C h e m o r a d i o t h e r a p y  A n d  S u r g e r y  ( M u l t im o d a l
T h e r a p y )  V e r s u s  S u r g e ry  A lo n e  In O e s o p h a g e a l  C a n c e r
Author Year No. of Trials No. of Patients Conclusion
Urschel216 2003 9 1116 Multimodal superior 
p=0.038*
Kaklamanos193 2003 5 669 Multimodal superior*
Fiorica217 2004 6 764 Multimodal superior 
p=0.03*
Malthaner230 2004 8 1008 Trend towards multimodal superior at 1 yeart
Greer232 2005 6 738 Multimodal superior* 
p=0.07t
Geh218 2006 26 1335 Increasing radiotherapy increases CPR 
p=0.006
Gebski219 2007 10 1209 Multimodal superior 
p=0.002**
Graham233 2007 6 733 Multimodal superior: QALY
Lv220 2009 14 1737 Multimodal superiort 
p=0.015
Sjoquist222 2011 13 1932 Multimodal superior
p<0.0001
*3-year survival benefit over surgery alone
**2-year survival benefit
+5-year survival benefit over surgery alone
♦Not statistically significant
CPR = Complete pathological response
QALY = Quality-adjusted life-years
! 1 .1 .1 0 .8  A D JU V A N T C H E M O T H E R A P Y  AND A D JU V A N T R A D IO TH ER A P Y  
Not all patients undergoing resection will require chem otherapy or radiotherapy. 
Clearly if the tum our is confined to the mucosa, local involvement is unlikely and 
adjuvant treatm ent unnecessary. Oesophageal cancer, however, can spread early to 
lymph nodes and adjacent structures and all too frequently surgery alone is not enough 
to offer a positive long-term outcom e for patients with this disease.
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Variations of post-operative or adjuvant treatm ents have been explored extensively in 
the literature and are sum m arised below. Such adjuvant treatm ents however are 
infrequently used in clinical practice.
1 .1 .1 0 .8 .1  A D JU V A N T C H EM O TH ER A P Y
Adjuvant chem otherapy is provided after surgery to eliminate systemic 
micrometastases which are present in over 80% of patients at resection119. This 
approach over surgery alone, however, is not supported in two randomised trials234,23S. 
Another randomised trial evaluated adjuvant chem otherapy versus adjuvant 
radiotherapy following curative oesophageal resection and found no difference in 3- 
year survival between the groups236.
1 .1 .1 0 .8 .2  A D JU V A N T R A D IO TH ER A P Y
The rationale for post-operative radiotherapy is that this may help eliminate residual 
local disease following incomplete resection, or following retention of residual 
microscopic disease.
One randomised trial compared neoadjuvant radiotherapy with adjuvant radiotherapy 
following curative oesophageal resection237. No difference in the survival rate was 
detected, but there was increased morbidity with neoadjuvant radiotherapy.
Other randomised trials com pared surgery and adjuvant radiotherapy with surgery237' 
24\  Overall, there was no significant difference in the risk of mortality with post­
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operative radiotherapy and surgery at one year compared with surgery alone. 
Although the rate of local recurrence with radiotherapy was lower in three trials238,239, 
241, two of the trials noted this benefit was achieved at the expense of increased  
morbidity238,239.
i
11 .1 .1 0 .9  A D JU V A N T C H EM O R A D IO T H ER A P Y
To date, no randomised trial has evaluated adjuvant chem oradiotherapy versus surgery 
alone, despite the success of neoadjuvant chem oradiotherapy regimes. A survival 
benefit has been suggested, however, when modern adjuvant chem oradiotherapy is 
com pared with historical experience242,243. In a recent series, Rice et al244 sought to 
determine whether chem oradiotherapy improved outcom e after oesophagectom y. In 
this review the addition of post-operative adjuvant chemoradiotherapy to 
oesophagectom y alone doubled survival time, time to recurrence and recurrence-free  
survival in patients with locoregionally advanced (T3-4, N l, or M ia) oesophageal 
carcinoma.
One prospective randomised trial com pared the outcomes of adjuvant radiotherapy 
with adjuvant chem oradiotherapy245. This study did not dem onstrate a survival 
advantage of radiotherapy adm inistered concurrently with chem otherapy compared  
with chem otherapy alone.
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| 1 .1 .1 0 .1 0  SA LV A G E SU R G ER Y
Definitive chemoradiotherapy is being used more frequently especially in patients with 
early disease. Often surgery is not intended as part of the treatm ent plan for patients 
undergoing definitive chem oradiotherapy, but salvage oesophagectom y may be 
offered in an attempt to cure those with an incomplete response or recurrent disease. 
Five-year survival rates of up to 25-35%  can be achieved by salvage oesophagectom y 
after local failure of CRT246, but it is a formidable procedure and there must be careful 
patient selection.
| 1 .1 .1 0 .1 1  P A LLIA TIV E  TH ER A P Y
At least one third of patients with oesophageal cancer have metastases at presentation 
and many without metastases are not fit for further treatm ent78. Self-expanding metal 
stent p lacem ent external beam radiotherapy, intraluminal radiotherapy 
(brachytherapy), laser therapy, blood transfusion and nutritional optimisation are some 
of the com monly used palliative modalities to improve dysphagia and other symptom s 
of oesophageal cancer247' 248.
As outlined in section 1.1.10.2, palliative chem otherapy is also used to control tumour 
growth, improve quality of life and prolong survival in patients with metastatic 
oesophageal cancer. Although shrinkage of the tum our by 50 percent may occur163 169, 
there is a lack of evidence that this treatm ent modality improves quality of life and 
survival beyond one year is rare19.
i
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Approximately 20 to 30% of patients with early stage epithelial cancers who have 
curative surgery develop overt metastases within 5 to 10 years249'252. Similarly, in 
oesophageal cancer, surgery alone can be curative for patients with true loco-regional 
disease but the majority of patients currently staged as having tum our confined to the 
oesophagus and regional lymph nodes succum b to oesophageal cancer80,135,253. Even 
the most selective surgical series cannot achieve long-term survival in the majority of 
their patients. This late metastatic relapse seems to be mainly due to a phenomenon 
described as early dissemination of tum our cells from the primary tumour, occurring at 
an unknown time prior to surgery. These m icrom etastatic cancer cells reside mainly in 
the bone marrow after their dissemination, and are believed to carry the potential to 
develop into overt and usually fatal metastases.
At present, the sensitivities of conventional histopathological, biochemical and 
radiological staging techniques is sub-optim al for the detection of minimal residual 
disease and latent m etastases254. To improve detection of disseminated epithelial 
malignancy, im m uno-histochem ical and m olecular methods have been employed that 
search for epithelial cell-specific proteins in non-epithelial tissue. These are not yet 
incorporated into routine clinical practice however, for many reasons, most notably 
due to the lack of standardisation and automation of the technology and techniques 
employed.
1.2 MICROMETASTASES
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M icrometastases within the bone marrow have been shown to indicate a poor 
prognosis in patients with epithelial tumours. The detection of m icrometastases in 
tum our types such as colon255, lung256 and breast257 cancers is Indicative of poorer 
outcome. The presence of m icrometastases is also associated with the depth of 
penetration of the primary tum our258,259, degree of cytological differentiation260, and 
increased tum our microvessel density261, recognised to correlate with poor survival in 
oesophago-gastric cancer262. The degree to which m icrometastases represent true  
residual disease or cell shedding and metastatic potential, however, is unclear263,264.
These epithelial deposits are easily identified within the bone marrow, as cytokeratin- 
positive cells119,265 and have been identified in the majority of patients presenting with 
oesophageal cancer119,266. Several studies have investigated the prognostic significance 
of bone marrow m icrometastases in oesophageal cancer with variable results119,267 269. 
This may reflect the marrow site which has been studied. Most have examined iliac 
crest marrow, which is a site remote from the tum our source. O'Sullivan et al119 
examined marrow flushed from the resected rib segm ent at thoracotom y and found 
that micrometastases were present in 88% of 50 patients with oesophageal cancer. 
This study established that haematogenous spread of these metastatic cells was 
independent of histological type of tum our or nodal status. These micrometastatic 
cells were found to be viable, tum ourigenic (in nude mice) and resistant to neoadjuvant 
therapy. Ryan et al269 found viable tum our cells in more than half of all marrow  
cultures from patients who had recieved chem oradiotherapy and surgery, also 
suggesting resistance of these cells to chemoradiation. Thorban et al 268 prospectively 
studied 225 patients with squamous cell carcinoma of the oesophagus. This study 
showed a significant survival difference between patients with and without epithelial
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cells in bone marrow (p<0.001) and found that bone marrow status was an 
independent prognostic factor.
There is accum ulating evidence that the detection of m icrometastases may provide 
independent prognostic information and these m icrometastases may be used as 
targets in the developm ent of novel modes of treatm ent252,254, but their exact role in 
oesophageal cancer and its prognosis currently remains to be determined.
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1.3 H IS T O L O G IC A L  P R E D IC T O R S  OF R E S P O N S E  A N D  R E S IS T A N C E  
Chem oradiotherapy holds the most promise for positive outcom es in oesophageal 
cancer care. Randomised trials have shown a survival advantage for neoadjuvant 
chem oradiotherapy over surgery alone182, 215, 22\  Chem oradiotherapy can induce a 
complete pathological response in over one quarter of patients182' 211,215,221,223 with 
more recent regimens achieving even higher com plete response rates191,213. The chief 
shortcom ing of neoadjuvant chem oradiotherapy it that is still not possible to know, in 
advance of treatment, which patients will respond and which patients will not benefit 
or indeed be harmed by the treatm ent143.
There is an urgent need, therefore, for markers of response or resistance to treatment, 
especially considering the now widespread use of neoadjuvant therapy in oesophagal 
cancer care. Those patients deemed to have tumours responsive to 
chem oradiotherapy could be identified prospectively and be considered for 
neoadjuvant treatm ent with or without surgery. Those patients predicted to respond  
poorly could be spared the potential morbidity, inconvenience, time and financial 
burden of undergoing such treatm ent, and may opt for alternative treatm ent regimes 
or palliative measures alone.
Much work has been done in this area using histological indices, clinical parameters, 
radiological imaging, and a wide range of tissue and serum m arkers270. Whilst many 
methods have shown potential, no one technique has com e to the fore or has been 
adopted into routine clinical practice. Imm unohistochem istry is a convenient and
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inexpensive technique used in the routine diagnostic laboratory which is simple to 
conduct and straightforward interpret. Individual tissue markers have therefore been 
extensively studied in human cancers and indeed in oesophageal cancer and have 
shown potential for clinical application270'286. To date, however, they have not been 
shown to be sufficiently accurate on their own, and comparison of studies is difficult 
due in part to differing techniques, different tum our types, variability of results and 
lack of standardisation.
If suitable im m unohistochem ical markers are identified, they may provide invaluable 
information for patients and and their multidisciplinary team.
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Response and resistance of cancer cells to chem otherapy and/or radiotherapy may be
i
influenced by their propensity to undergo apoptosis which, when induced by 
chemoradiotherapy, Involves various biological processes such as DNA repair, altered 
drug metabolism, inflammation and alteration of the cell cycle287,288. The molecular 
markers p53, metallothionein and vascular endothelial growth factor (VEGF) all play a 
central role in this process and may be detected by im m unohistochem ical means in 
tumours.
) 1 .3 .1 .1  P53
The p53 gene, and the protein it expresses (also known as protein 53, or tum our 
protein 53), is amongst the most widely investigated genes and proteins in humans. 
p53 has many anti-cancer m echanism s289 and is often referred to as the "guardian of 
the genom e"290. It can activate DNA repair proteins when DNA has sustained damage. 
It can induce growth arrest by holding the cell cycle at the G l/ S  regulation point on 
DNA damage recognition allowing DNA repair before allowing it to continue the cell 
cycle. It plays a role in genetic stability. It can inhibit angiogenesis and can initiate 
apoptosis, or programmed cell death, if the DNA damage proves to be irreparable. If 
p53 is damaged or defective, tum our suppression is severely reduced. More than 50 
percent of human tum ours contain a mutation or deletion of the p53 gene291. p53 has 
been the subject of investigation in many human cancers, including oesophageal cancer 
and it has been implicated, at least in part, in therapeutic resistance and prognosis.
| 1 .3.1 P53, METALLOTHIONEIN AND VEGF
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1.3.1.1.1 P53 EXPRESSION AND PROGNOSIS
The protein that p53 encodes has been found to be one of the prognostic indicators in 
various cancers such as prostate292, breast293 and lung294, where accumulation of the 
protein correlated with a poor prognosis. There is growing evidence that abnormalities 
of p53 expression in oesophageal cancer might have a relationship with survival.
Studies evaluating the prognostic significance of p53 expression have focused primarily 
in oesophageal squamous cell carcinom a271'279 and to a lesser extent 
adenocarcinom a280'283 with few including both tum our types284,285 and the results have 
been conflicting271'286. Several studies have identified p53 as a good prognostic 
indicator for tum our invasiveness and propensity to metastasise or recur274,275,286 and 
improved survival has been dem onstrated in tum ours with negative expression for p53 
over those positive for p53 expression271,273’275' 277< 278< 282< 285< 286. in contrast however, 
several other studies have not found p53 to have prognostic significance272,276,280,284 
with one study suggesting that failure to find a significantly shorter disease free survival 
in p53 positive tumours may actually reflect the ability of neoadjuvant 
chem oradiotherapy to improve outcom e280.
1.3.1.1.2 P53 AND RESPONSE AND RESISTANCE TO CHEMORADIOTHERAPY 
Response or resistance of cancer cells to chem otherapy and or radiotherapy may be 
influenced by their propensity to undergo apoptosis, or programmed cell death. p53 is 
one of the most important regulators of this process289 and therefore it is possible that
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p53 expression may play a central role in treatm ent resistance. Several studies have 
explored this concept, with mixed results.
Seitz et al278 examined p53 expression in squamous cell carcinom a and identified a 
significant association between p53 over-expression and a lower complete response 
rate. Krasna et al283 also found that p53 protein expression in pre-treatment 
endoscopy specimens may predict response to trimodality therapy and survival in these 
patients, but this study was limited by small numbers. Sunada et al279 found p53 
positivity or negativity, in association with other markers, predictive of sensitivity to 
definitive chemoradiotherapy (5-fluorouracil, cisplatin and 60Gy radiotherapy) in 
squamous cell carcinoma. In contrast with Seitz et al278, Sarbia et al277 found that 
tumours without p53 expression showed a trend towards more frequent response to 
treatm ent than p53 positive tumours, but this failed to achieve statistical significance.
Similarly, in oesophageal adenocarcinom a, Duhaylongsod et al280 studied p53 
im munoreactivity in 42 patients with adenocarcinom a who underwent neoadjuvant 
chemoradiotherapy. In this study, p53 positivity significantly correlated with the  
presence of residual disease after neoadjuvant cisplatin, 5-flourouracil and 
radiotherapy (p=0.01). This study also showed a trend towards significance between 
p53 over-expression and lymph node metastasis. With greater numbers, the 
correlation between p53 and lymph node metastasis may have shown significance and 
thus could be a very useful marker of response and down-staging to treatment.
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1.3.1.1.3 P53 EXPRESSION AND BARRETT'S OESOPHAGUS
Barrett's oesophagus is a well recognised risk factor for oesophageal carcinoma and 
there has been much investigation into role of p53 in the progression of Barrett's 
oesophagus to adenocarcinom a. p53 expression is significantly higher in patients with 
Barrett's oesophagus (up to 50%) versus controls (1-10%) (p < 0.005)295. Duhaylongsod  
at al280 examined p53 expression in 42 patients with oesophageal adenocarcinom a, 22 
of whom had Barrett's metaplasia and found that the frequency of p53 expression 
occurred equally if Barrett's metaplasia was present or absent. A recent study by 
Binato et at296 indicated that over-expression of p53 could be associated with the 
development and progression to oesophageal adenocarcinom a in patients with gastro- 
oesophageal reflux disease. An extensive review of the significance of p53 in Barrett's 
oesophagus concluded that p53 function plays a major and com mon role in the 
transition of Barrett's metaplasia to dysplasia to cancer297.
1 .3 .1.2  M ETA LLO TH IO N EIN
The metallothioneins are a family of low m olecular weight, cysteine-rich proteins, 
which have a high affinity for metal ions298. M etallothioneins are known to be involved 
in many pathophysiological processes, including metal ion homoeostasis, protection 
against oxidative damage and cell proliferation and apoptosis299,300. Over-expression of 
metallothionein has been described in a variety of human tum ours, in relation to 
different stages of tum our developm ent, progression and m etastasis301 and is also 
known to be involved in chem o-resistance and radiotherapy resistance302
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1.3.1.2.1 METALLOTHIONEIN EXPRESSION AND PROGNOSIS
Metallothionein, like p53, has been considered as a potential prognostic marker in 
various carcinomas. Over-expression of metallothionein correlates significantly with a 
poorer prognosis in breast carcinom a303'305, and more aggressive and advanced  
tumours, such as pancreatic carcinom a306 and malignant m elanom a307. In oesophageal 
squamous cell carcinoma, over-expression of metallothionein has been shown to 
correlate with metastatic tum our activity and proliferative potential308. Expression of 
metallothionein in tumours from patients with oesophageal cancer treated with 
neoadjuvant chem oradiotherapy has been shown to have prognostic significance  
especially in association with other markers279, 309 but results from another study 
showed no such association with prognosis310.
1 .3 .1 .2 .2  M ETA LLO TH IO N EIN  EX PR ESSIO N  AND R ESPO N SE AND R ESISTA N C E TO  
CH EM O R A D IO TH ER A P Y
The ability of metallothionein to inhibit apoptosis311 and its free radical scavenging
property299 are thought protect tum our cells from radiation and chem otherapeutic
agents. Thus, metallothionein is implicated in chem o-resistance and radiotherapy
resistance302. Its over-expression has been linked with resistance to cisplatin in many
tum our types such as small cell lung312, prostatic313, hepatocellular314 and testicular
cancer315. It has also been implicated in oesophageal squamous cell carcinom a309,316,
317, where cisplatin forms the cornerstone of the most successsful treatm ent regim es182,
215
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1 .3 .1 .2 .3  M ETA LLO TH IO N EIN  EXPR ESSIO N  AND B A R R ET T 'S  O ESO P H A G U S
Li et al318 reported that metallothionein expression was significantly increased with 
histological progression towards adenocarcinom a. This study also suggested that 
metallothionein may contribute to cytoprotection, thereby inhibiting apoptosis and 
leading to carcinogenesis of Barrett's oesophageal cells. Another, but far smaller study, 
dem onstrated that there was no association between the metallothionein levels in 
Barrett's epithelium and the presence of inflammatory cells, metaplasia or dysplasia319. 
This group concluded that metallothionein is a marker of progression from normal to 
Barrett's epithelium but is not increased in oesophageal adenocarcinoma.
I 1 .3 .1 .3  V A SCU LA R  EN D O T H E LIA L G RO W TH  FA CTO R
Vascular endothelial growth factor (VEGF) belongs to a sub-family of growth factors 
that are important signalling proteins involved in angiogenesis. VEGF is one of the 
most powerful and specific inducers of new vasculature in malignant neoplasms and 
plays a vital role in inhibiting tum our cell apoptosis320. This angiogenesis has an 
important role in metastasis and tum our grow th321. It has anti-apoptotic activity320 and 
has been implicated in treatm ent resistance322.
1 .3 .1 .3 .1  V EG F EXPRESSIO N  AND PR O G N O SIS
VEGF expression has been shown to correlate with poor prognosis in many cancers 
such as breast323,324, lung325,326 and colon327. The data in oesophageal cancer mainly 
refers to squamous cell carcinoma, where a positive correlation between VEGF 
expression and presence of local lymph node metastases, depth of tum our invasion
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and the presence of distant métastasés has been dem onstrated328'333. Low levels are 
associated with improved long-term outcom e334.
1 .3 .1 .3 .2  V EG F EXPRESSIO N  AN D R ESPO N SE AND R ESISTA N C E TO  
CH EM 0  R A D IO TH ER A PY
Tum our microcirculation and vessel permeability have a strong influence on tissue 
oxygenation, drug delivery and radio-sensitisation of cancer cells335. For these reasons 
VEGF expression in oesophageal tum ours has been explored as a means of predicting 
response to chemoradiotherapy. Research has shown that levels of VEGF in pre­
treatm ent biopsies are significantly higher in non-responders than in individuals who 
respond to chem oradiotherapy336,337. Similarly, weak VEGF immunoreactivity in pre­
treatm ent biopsies is associated with a higher incidence of com plete tum our regression  
and improved long-term survival after neoadjuvant chem oradiotherapy with 5- 
fluorouracil, cisplatin and 36 Gy radiotherapy334. Interestingly, circulating VEGF levels 
in patients with oesophageal cancer are unchanged following neoadjuvant 
chem oradiotherapy, which may explain in part the failure of chem otherapeutic 
regimens to deal with the circulating m icrom etastatic burden, even in the setting of a 
com plete local response338.
1 .3 .1 .3 .3  V EG F EX PR ESSIO N  AND B A R R ET T'S  O ESO P H A G U S
Angiogenesis is one of the key processes in tum ourigenesis and growth of cancers. The  
acquisition of angiogenic properties may identify a subset of pre-invasive lesions such  
as in Barrett's oesophagus, as suggested for colon carcinom a339. Angiogenic factors, 
such as VEGF, therefore, may prove to be useful prognostic markers for the 
m anagem ent of pre-neoplastic lesions and adenocarcinom as in Barrett's oesophagus.
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One study by Couvelard et al340 quantified vascularisation in a large surgical series of 
Barrett's adenocarcinom a and associated pre-neoplastic lesions. Using 
im m unohistochem istry, they examined the expression of VEGF and correlated these  
results with clinico-pathological data and prognosis. This study showed that while high- 
grade dysplastic Barrett's mucosa presented with a higher microvessel density 
compared with non-dysplastic Barrett's mucosa, and while expression of VEGF 
correlated with vascularisation, it had no independent prognostic relevance.
In conclusion, of all the treatm ent strategies, chem oradiotherapy holds the most 
promise for positive outcom es in oesophageal cancer and is a rapidly advancing area of 
oncological research. Predicting who will respond to treatment, which regimes are 
most effective and who, if anyone, can benefit from surgery remain to be uncovered.
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C H A P T E R  II :  A I M S
The aims of this body of work were:
1 To review the currently available treatm ent strategies for oesophageal cancer 
in the literature.
2 To review prognostic and predictive indicators for oesophageal cancer.
3 To study the long-term results of two randomised controlled trials of 
neoadjuvant chem oradiotherapy and surgery versus surgery alone in oesophageal 
adeno- and squamous cell carcinoma and determ ine if the short-term survival 
advantage of neoadjuvant chem oradiotherapy previously shown in adenocarcinom a is 
durable and extends to squamous cell carcinoma.
4 To determine the value of endoscopy and biopsy in predicting complete  
pathological response and outcom e following chemoradiotherapy.
5 To determ ine w hether the addition of rib-m icrom etastatic status to luminal 
response to neoadjuvant chem oradiotherapy would more accurately predict long-term  
survival in oesophageal cancer.
6 To examine the response, survival and outcom e of patients over the age of 70 
with oesophageal cancer who have undergone chemoradiotherapy.
7 To examine the role of p53, VEGF and metallothionein as predictive markers 
for response to neoadjuvant chem oradiotherapy and outcom e in oesophageal cancer.
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C H A P T E R  I I I :  S T U D Y  1
IS THE SHORT TERM SURVIVAL ADVANTAGE OF NEOADJUVANT 
CHEMORADIOTHERAPY SUSTAINED? LONG-TERM FOLLOW-UP OF TWO 
RANDOMISED TRIALS.
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Introduction. Oesophageal cancer is a systemic disease at presentation in the majority 
of patients necessitating system ic treatm ent. Neoadjuvant chem oradiotherapy  
provides a complete pathological response (CPR) in over 25% of patients and a short­
term survival advantage in meta-analyses but its overall role is disputed because of the 
small numbers of patients enrolled into randomised trials, the heterogeneity of 
treatm ent protocols and the short follow-up of all such studies.
Aim . To study the long-term results of two randomised trials of neoadjuvant chem o­
radiotherapy and surgery versus surgery alone.
M ethods. Between 1990 and 1997 two randomised trials were undertaken in one 
institution on 211 patients. Patients with adenocarcinom a (AC)(n=113) or squamous 
carcinoma (SCC)(n=98) were separately randomised to identical protocols of 
chem oradiotherapy of two courses chem otherapy, on weeks 1 and 6 (fluorouracil, 
15mg/kgx5 days and cisplatin, 75m g/m 2 day 7) and radiotherapy (40Gy) before surgery 
(multimodal therapy (MMT)) or to surgical monotherapy (SM).
Results. Follow-up ranged up to 206 months (median 163 months). Of the 211 
patients, 58 and 46 patients were randomised to the MMT limb and 55 and 52 to SM in 
the AC and SCC trials respectively. The CPR rates were 25% and 30% for AC and SCC 
respectively, incurring a survival advantage overall (p=0.03). Twice as many patients in 
the M M T group were lymph node negative as the surgical m onotherapy group (74% vs. 
36%) (p=0.002) reflecting significant downstaging in this group and had a survival 
advantage (AC: p<0.001, SCC: p=0.041). In the AC trial, 12 patients who had received  
M M T were alive 10 years or longer compared to 2 that had SM. In the SCC trial the
3.1 ABSTRACT
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respective figures were 5 and 2. M M T conferred a long-term survival advantage over 
SM in both trials (AC pcO.OOl) and SCC (p=0.036). A survival advantage for M M T was 
also seen on intention to treat analysis in both trials (AC p<0.004, SCC p<0.02).
Conclusion At least 25% of patients had a CPR to this treatm ent protocol. The survival 
advantage previously identified in AC at 3 years persisted long-term, and extended to 
SCC suggesting that neoadjuvant chem oradiotherapy be considered the standard of 
care for patients with locoregionally-advanced disease.
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The first ever randomised trial of therapy was carried out by the British Medical 
Research Council in 1947 to examine the effect of streptomycin for the treatm ent of 
tuberculosis341. The addition of streptomycin to the traditional treatm ent of bed-rest 
was associated with a survival advantage in the short-term and hailed as a medical 
breakthrough. A subsequent study, however, by Fox et al342 revealed that this short­
term survival advantage was lost with time. This led to the development of multidrug 
therapy which provided a sustained treatm ent advantage. Short-term  benefit is no 
guarantee of long-term success in infection or indeed cancer therapy.
Surgery has long been considered the best hope for cure for locoregionally advanced 
oesophageal cancer but the morbidity and mortality rates associated with 
oesophagectom y has restricted its role to a minority of patients with limited disease 
and who are fit for resection. Although improvement in surgical technique has led to a 
decrease in post-operative morbidity and hospital mortality, it has not resulted in an 
increase in overall survival rates3,5' 135,343. Reported 5-year survival rates for surgery 
alone of 40-50% reflect more on patient selection than any dram atic advance in the 
curative potential of more extensive surgery137,138,140 and still only translate to a 5% 
overall survival even when an R0 resection has been achieved136,140,344.
The natural history of oesophageal cancer is to disseminate early and present with 
system ic spread345 with only about 20% of patients having localised disease120. When 
data for entire com munities is scrutinised, it is clear that only a small minority of 
patients with oesophageal cancer present early enough, or are fit enough, to undergo
3.2 INTRODUCTION
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and benefit from surgical resection, ranging from 30% 78,12\  to as low as 10% in some 
studies120, 140, 142, 346. Even when we confine our attention to patients undergoing 
potentially curative resection, the great majority of patients have bone marrow  
m icrometastases at the time of resection119 precluding cure. In one review of almost 
ten thousand patients, only 5.4% had pTis or T1 disease141. Despite early disease, even 
in this small minority, local and distant recurrence dominates after resection142 and the 
majority succum b within 5 years141.
As the disease is system ic in the majority at presentation, systemic therapy is 
mandatory. W hen given preoperatively, systemic treatm ent has the advantage of 
addressing the systemic com ponent of the disease earlier than if given after surgery 
and post-operative recovery. A com bined modality approach allows additive or 
synergistic effects to be exploited to both intensify the effect on the local disease and 
reduce subsequent distant failures due to resurgent metastatic disease. When 
administered with radiotherapy, some chem otherapeutic agents have the added 
advantage of enhancing the local effect of radiotherapy347, maximizing tum our cell kill 
thereby down-staging the tum our179,181 and permitting a higher rate of RO resections123, 
143. However randomised controlled trials123, 143, 182' 211, 213/ 215,221, 223,224, 231' 348 and 
subsequent meta-analyses193, 217‘220- 222- 230' 232 have not definitively established a 
consensus on management strategy.
We have previously reported a randomised trial showing a short-term survival 
advantage for neoadjuvant chem oradiotherapy in adenocarcinom a, but we expressed  
our reservations about the durability of this advantage182. Other criticisms of this trial 
included the short duration of follow -up225,226 and the poor results of surgery alone225'
230
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The aim of this study was to examine long-term results of two randomised trials of 
neoadjuvant chem oradiotherapy and surgery versus surgery alone, one of which has 
not previously been reported in full182, and to determ ine w hether the short-term  
survival advantage identified for neoadjuvant therapy for adenocarcinom a is sustained 
and extends to squamous cell carcinoma.
3.3 AIMS
3 .4  P A T IE N T S  A N D  M E T H O D S
The recruitment of patients and conduction of these original trials do not form part of 
the work submitted for this thesis. The work completed for this thesis consisted  
instead of com pleting the long-term follow-up of the patients involved in the original 
trials and the analysis of data to com pare the outcome of multimodal therapy and 
surgery alone on long-term survival. The short-term data of the adenocarcinom a trial 
was published in 1996 by Walsh et al182, but the squamous cell trial data has to date 
never been published in full.
3 .4 .1  P A T IE N T S
Patients with oesophageal adenocarcinom a (AC) or squamous cell carcinoma (SCC) 
were separately enrolled into two randomised controlled trials to compare the 
outcom e of neoadjuvant chem oradiotherapy and surgery (multimodal therapy, MMT) 
with the outcom e of surgery alone for oesophageal AC and SCC.
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The randomised trials were approved by the St Jam es's Hospital Ethics Comm ittee and 
informed consent was obtained from all patients. Individual patient data was entered 
into a prospectively-accrued oesophageal cancer database containing dem ographic, 
clinical, operative, pathological and follow-up data.
For the purposes of this study, all patients were followed-up until the date of death or 
last clinical interaction. Follow-up and cause of death, if applicable, was determined by 
telephone com munication with their General Practitioner, review of patient records or 
searches in the Archives of the National Death Registry Offices, Dublin, Ireland. Follow- 
up was calculated from the date of randomisation.
| 3 .4 .2  IN C LU S IO N  C R IT E R IA
Patients who met all of the following criteria were included in the original trials: biopsy 
proven AC or SCC of the oesophagus (excluding cervical oesophagus requiring 
laryngectomy), age less than 76 years, leukocyte count of greater than 3500/m m 3, 
platelet count of greater than 100,000/m m 3 and serum creatinine concentration below
1.4 mg/dL. Patients with evidence of distant metastases, an Eastern Cooperative 
Oncology Group (ECOG) performance status of 3 or 4, previous chem otherapy or 
radiotherapy, previous m alignancy (excluding skin cancer) or co-m orbidities 
contraindicating surgery were excluded from this study. There was no restriction on 
the length of tum our or on the presence or location of lymph node metastases.
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| 3 .4 .3  P R E O P E R A T IV E  T U M O U R  ST A G IN G
Tum our staging was determined by physical examination, chest x-ray and abdominal 
ultrasound scanning. Computerised Tom ography (CT) of the thorax and abdomen was 
performed only in selected cases due to the limitation of availability at this time. 
W here symptom s indicated, a bronchoscopy or isotope bone scan was obtained.
hhhhhhhhhhh
13 .4 .4  C H E M O R A D IO T H E R A P Y
Identical concurrent chem oradiotherapy was given to patients randomised to the 
multimodal therapy arms of both trials.
13.4.4.1  C H EM O TH ER A PY
The chem otherapy regime consisted two cycles of 5-fluorouracil and cisplatin as 
described previously182. These were administered during weeks one and six. On days 
one to five of each course, patients received an infusion of fluorouracil (15mg/kg of 
body weight/day) over a period of 16 hours. Cisplatin (75m g/m 2 of body surface area) 
was infused over eight hours on day seven.
3 .4 .4 .2  R A D IO TH ER A PY
Concurrent radiotherapy was com m enced on day one of the first cycle of 
chem otherapy and adm inistered on days 1-5, 8-12 and 15-19, a total of 15 days, each 
patient receiving a total of 40Gy external beam radiation. All patients underwent 
treatm ent with megavoltage therapy units with 4- or 8-M V photons (Cobalt model
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SEM 100, Fairy Engineering, or Phillips model SL75-5 or Dynaray model 10, Radiation 
Dynamics, respectively). Radial and longitudinal margins of the tum our were defined 
endoscopically and radiologically and the treatm ent fields extended 2-3cm and 5cm  
beyond the radial and longitudinal margins respectively.
Prior to 1994, al patients were treated with parallel-opposed fields (anteroposterior 
and posteroanterior) with a midline dose of 40Gy in 15 fractions. This was then 
modified to a three-field approach (anterior and left- and right-posterior oblique 
fields), thereby reducing exposure of the spinal cord to radiation. Using a computerised 
treatm ent-planning system (AECL/Theratronics Therplan), a dose of 40Gy (+/-10%) ¡n 
15 fractions was delivered to the entire treatm ent volume giving 2.67Gy per fraction in 
both regimes. There was no correction for transmission of radiation to the lungs during 
either treatm ent delivery method. The patients assigned to surgical monotherapy had 
neither preoperative chemotherapy nor radiation therapy.
13 .4 .5  S U R G E R Y
In the surgical monotherapy (SM) group, surgery was performed on average one week 
post-randomisation and eight weeks after treatm ent was com m enced in the M M T 
group, with a delay if the leukocyte count was less than 2500/m m 3 or platelet count 
was less than 100,000/m m 3. Five operative approaches were employed. Tumours of 
the upper and middle oesophagus were resected with a three-stage operation whereby 
gastric mobilisation was performed via a midline laparotomy, the oesophagus was 
mobilised via a right thoracotom y and the anastomosis was performed in the neck. 
The Lewis-Tanner operation (right-sided thoracotom y and laparotomy) was employed
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for tumours in the lower third of the oesophagus. Cardia tum ours were resected using 
an abdominal approach and a left thoracotomy. In patients who had poor respiratory 
function, a transhiatal approach was used with the anastomosis fashioned in the neck. 
Selected patients had an abdominal approach with gastrectom y and distal 
oesophagectom y.
¡ 3 .4 .6  P A T H O L O G IC A L  ST A G E
Cancer staging was based on pathologic findings referenced to the classification of the 
American Joint Comm ittee on Cancer guidelines for oesophageal cancer349. Following 
chem otherapy and radiotherapy patients were staged based on the location and extent 
of any residual disease. If no residual disease was identified in the resected specimen 
or in the lymph nodes, this was defined as a com plete pathological response (CPR) 
(stage 0). If there was residual tum our in the mucosa or submucosa in the absence of 
disease in the lymph nodes, it was classified as stage 1. If any residual deposits 
involved the muscularis propria or adventitia in the absence of tum our in the lymph 
nodes, it was classified as stage 2a. Stage 2b was defined as the absence of residual 
tum our in the oesophagus but with tum our in the lymph nodes. If the tumour 
breached the oesophageal wall the wall and lymph nodes were positive for tumour, 
this was defined as stage 3. Stage 4 referred to distant metastasis beyond the 
locoregional lymph nodes.
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Statistical analyses were performed with using the statistical package SPSS version 15.0 
for Windows (SPSS, Inc., Chicago IL). Continuous variables were expressed as median ± 
standard deviation or mean ± standard error of the mean as appropriate and were  
com pared using a two-sample t-test. Categorical variables were compared using a c2 
test, with Fishers exact test used where appropriate. Survival probabilities for clinical, 
pathological, and treatm ent variables were estimated using the Kaplan-M eier 
m ethod350 and pairwise com parisons were made using a log-rank test. The effects of 
treatm ent modality (neoadjuvant chem otherapy and external-beam radiation therapy 
followed by surgical resection vs. surgical monotherapy), tum our histology, size and 
stage, the presence of positive lymph nodes on survival were examined using logistic 
regression, and optimal cut-offs were determined using the maximal chi2 method. 
Significant univariate factors were included in a Cox proportional hazards regression  
model to establish independent predictors of survival. Further substratification analysis 
was performed using the M antel-Haenszel test351. P values of less than 0.05 were 
considered statistically significant.
3.4 .7  STATISTICS
75
| 3 .5 .1  D E M O G R A P H IC  D A TA
Beginning in May 1990, 113 patients with AC and 98 patients with SCC of the 
oesophagus were enrolled into two randomised trials in a single institution comparing 
neoadjuvant chem oradiotherapy and surgery (multimodal therapy, MMT) with surgery 
alone.
In the AC trial, 158 patients were assessed for eligibility; 45 of whom were excluded  
due to not meeting the inclusion criteria, patient choice and other or unknown reasons 
(Figure 1). Fifty-eight patients were randomised into the M M T arm and received 
neoadjuvant chem otherapy and external-beam radiation therapy prior to surgical 
resection; 55 patients were randomised into the surgical m onotherapy (SM) arm and 
received primary surgery as the sole treatm ent modality.
In the SCC trial, 147 patients were assessed for eligibility; 49 of whom were excluded 
due to not meeting the inclusion criteria, patient choice and other or unknown reasons 
(Figure 2). Forty-six patients were randomised into the M M T arm, and 52 patients into 
the SM arm. The AC and SCC trials were concluded in Septem ber 1995 and February 
1997 respectively; the first because interim analysis of the data identified a statistically 
significant difference between the groups and the latter when both senior surgical 
authors ceased work in this hospital.
3.5 RESULTS
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The median age of patients in the AC trial was 65 years (range 37-75 years); with a 
median age in the M M T group of 65 years (range 47-75 years) and in SM group also of 
65 years (range 37-75 years). In the SCC trial the median age of patients was 66 years 
(range 33-75 years); median age in the MMT group was 65 years (range 40-73 years) 
and that in the SM group was 67 years (range 33-75 years). Seventy-three percent 
(n=83) and 51% (n=50) were male in the AC and SCC trials respectively. Follow-up  
ranged from 0.25-205 months and from 0.25-206 months in the AC and SCC trials 
respectively (overall median 163 months). Overall, the age and sex profiles did not 
differ significantly between the groups (p=0.643 and p=0.182 respectively). A sum mary 
of the dem ographic data is displayed in Table 8.
Table 8: Demographics And Operative Approach
Adenocarcinoma Squamous Cell Carcinoma
Multimodal
Therapy
Surgical
Mono­
therapy
Total MultimodalTherapy
Surgical
Mono­
therapy
Total
No. of 
Patients {%)
No. of 
Patients 
(%)
No. of 
Patients (%)
No. of 
Patients (%)
Sex Male 39(67) 44(80) 83 19 (41) 31 (60) 50
Female 19(33) 11(20) 30 27(59) 21 (40) 48
Total 58(100) 55(100) 113 46(100) 52(100) 98
Age at Median (years) 65 65 65 67
Diagnosis Range (years) 47-75 37-75 40-73 33-75
Aged >70 years 15 (26) 15(27) 30 10 (22) 18(35) 28
Aged <70 years 43 (74) 40 (73) 83 36(78) 34(65) 70
Total 58(100) 55 (100) 113 46 (100) 52(100) 98
Surgical
Approach
Laparotomy and 
left thoracotomy 14 (30) 17(31) 31 3(8) 4(8) 7
Lewis-Tanner 20 (42) 22 (40) 42 14(35) 22 (44) 36
Transhiatal 0(0) 2(4) 2 2(5) 0(0) 2
Three stage 13 (27) 11 (22) 24 21 (53) 24 (48) 45
Abdominal 1(2) 2(4) 3 0(0) 0(0) 0
Total 48(101*) 54 102 40(101*) 50(100) 90
♦due to rounding to nearest percentage
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13 .5 .2  D E V IA T IO N S  FRO M  P R O T O C O L
There were a total of eleven incidences of deviation from protocol in the AC trial, ten in 
the MMT group and one in the SM group. In the SCC trial there were a total of eight 
protocol deviations, six in the MMT group and two in the SM group. These are outlined 
in Table 9. For the purposes of this study, these patients were excluded from further 
analysis in order to analyse the true outcom e of therapy. Survival analysis based on 
intention to treat is performed in Section 3.5.5.4.
Table 9: Deviations From Protocol
Age(years)/Sex ChemoradiotherapySurgery Coment Folow-up(months)MULTIMODAL THERAPYAdenocarcinoma75/F None No Died of probable myocardial infarct before0.2Streatment comenced68/M Not completed Yes Complete dysphagia developed 0.569/M Not completed Yes Pericardits developed on treatment 870/F Not completed No Deterioration in performance staus 563/M Not completed Yes Uper gastrointestinal haemorhage during1treatment73/M Not completed No Fatl haemorhage from tumour bed, no 1tumour at post mortem75/F Completed No Deterioration of performance status 374/M Completed No Developed lung métastasés 360/M Completed No Myocardial infarction after treatment 6540/M Completed No Developed lung métastasés 10Squamous Ceil Carcinoma72/F None Yes Patient choice 7852/M Completed No Disease progresion on treatment 868/F Completed No Development of lung métastases 871/F Completed No Complete remision on endoscopy, patient28choice72/M Completed No Patient choice 1853/M Completed No Development of lung métastasés 7SURGICAL MONOTHERAPYAdenocarcinoma64/M N/A Yes, Iatrogenic perforation, delayed refral 0.5emergencySquamous Ceil Carcinoma53/F N/A No Tumour invading bronchus 15/M N/A No Tumour invading bronchus 4
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Enrollment
Assessed for eligibility (n= 158)
Excluded (n= 45)
■ Not meeting inclusion criteria (n= 22) 
• Patient choice (n= 10)
■ Other reasons (n= 7)
■ Unknown (n= 6)
Randomized (n= 113)
I
----------------------------* ------------------------  Allocation *
ah,.—»--i -------1»;---- - >i--------/— ca\ . . lllnrjitprl tn Riiminal mnnnlhpriinw fn=nnuuiiou iu iiiuiuimuuoi uioiapy i^i— jo /
■ Received allocated intervention (n= 46) 
(See Table 9 for reasons)
■ Received allocated intervention (n= 55)
Lost o folow-up (n= 0) Follow-Up Lost to follow-up (n= 0)
Analysis
Analysed (n= 48)
■ Excluded from analysis (n= 10) 
(See table 9 for reasons)
Intention to treat analysis (n=58)
■ Excluded from analysis (n=0)
Analysed (n= 54)
■ Excluded from analysis (n= 1) 
(See Table 9 for reasons)
Intention to treat analysis (n=55)
■ Excluded from analysis (n=0)
Figure 1: A Flow Diagram Depicting The Passage of Patients Through The Adenocarcinoma 
Randomized Trial Of Multimodal Therapy Versus Surgical Monotherapy
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Figure 2: A Flow Diagram Depicting The Passage of Patients Through The Squamous Cell 
Carcinoma Randomized Trial Of Multimodal Therapy Versus Surgical Monotherapy
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3 .5 .3  R E S P O N S E  TO  C H E M O R A D IO T H E R A P Y
Significant down-staging was seen in the patients treated with MMT in both trials. 
There was a complete pathological response (CPR) rate of 25% (12/48) in the A C and 
30% (12/40) in the SCC trials respectively.
In the AC, trial 65% (31/48) of patients receiving MMT who underwent resection were 
node negative (NO) compared to 20% (11/54) undergoing SM (p<0.001). In the SCC 
trial, 85% (34/40) of patients receiving MMT were node negative com pared to 52% 
(26/50) undergoing SM (p<0.001). The AJCC staging of both tum our types at the end of 
treatm ent is outlined in Table 10.
When both tum our types are analysed together, a significant downstaging was seen 
overall in the patients treated with MMT. There was an overall CPR rate of 27%  
(24/88). Furthermore 74% of the MMT group (65/88) were node negative compared to 
36% (37/104) in the SM group (p=0.002).
8 1
T a b le  10:  P a th o lo g ic a l  S t a g e  A t  End O f  T r e a t m e n t .
ADENOCARCINOMA SQUAMOUS CELL CARCINOMA
Multimodal Therapy Surgical Multimodal Surgical
Monotherapy Therapy Monotherapy
No. of patients No. of patients No. of patients No. of patients
AJCC 0 12 0 12 0
Stage 1 1 2 6 12a 18 8 14 192b 7 2 1 0
3 10 37 S 27
4 0 5 2 2
Unknown 0 0 ' 0 1
Total 48 54 40 50
Nodal Positive 17 43 6 23
Status Negative. 31 11 34 26
Unknown 0 0 0 1
Total 48 54 40 50
3 .5 .4  H O S P IT A L  M O R T A LIT Y  R A TE
There was no statistical difference in post-operative mortality noted between the 
treatm ent arms in either trial (AC;p=0.254, SCC;p=0.434). There was an overall hospital 
mortality rate of 11% (21/192).
There were four in-hospital mortalities in the AC trial resulting in an overall in-hospital 
mortality of 4% (4/102), including one patient who had a CPR. Of the three mortalities 
in the MMT group, one patient died of an anastom otic leak, one of post-operative  
haemorrhage and one of a chylothorax. In the SM group, one patient died from post­
operative chylothorax.
In the SCC trial, there were 17 in-hospital mortalities resulting in an overall in-hospital 
mortality of 19% (17/90), including 2 patients who had had a CPR. Of the nine patients 
in the M M T group, two patients died of post-operative haemorrhage, two of
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anastom otic leak, one of disseminated intravascular coagulation, one of cerebral 
metastases, one of subphrenlc abscess and two of multi-organ failure. Of the eight in- 
hospital mortalities in the SM group, one died of a cerebro-vascular accident, three of 
respiratory failure, one of post-operative haemorrhage, one of ischaem ic stomach and 
sepsis, one of anastomotic leak and one of multi-organ failure.
The hospital mortality of those with a CPR was 13% (3/24).
13 .5 .5  S U R V IV A L  
I 3 .5 .5 .1  A D EN O C A R C IN O M A
AC patients who received M M T had a statistically significant survival advantage over 
those who received SM (p<0.001) (Figure 3) with a median survival of 33 (range 0.1- 
203) months and 23 (0.25-145) months respectively. In the AC trial M M T group, the 
overall three, five and ten-year survival was 48 (n=23), 40 (n=19) and 27% (n=13) 
respectively. The three, five and 10-year survival rate of the 12 patients who had a CPR 
was 75% (n=9), 58% (n=7) and 25% (n=3) respectively. This com pares with 42% (n=14), 
33% (n=12) and 19% (n=7) respectively in the 36 patients with an incomplete response  
and 13% (n=7), 11% (n=6) and 4% (n=2) in the 54 patients in the SM group. Thus 
patients with adenocarcinom a who had downstaging to a CPR had a significant survival 
advantage over incomplete responders (p=0.01) (Figure 4). Overall, those who were 
lymph node negative had improved survival over those who were lymph node positive 
(p<0.001) (Figure 5). Patients with AC who received M M T and who were node negative 
had a significantly longer median survival time of 67 months com pared with 16 months 
for SM patients who were lymph node negative (p=0.005). In lymph node-positive  
patients, those who had M M T had similar survival compared with those who had SM
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with a median survival of 12 and 16 months respectively but this did not reach 
statistical significance (p=0.266).
At conclusion of this study, 14 patients of the AC cohort were alive at 205, 200, 192, 
191, 178, 163, 163, 161, 160, 155, 147, 147, 145 and 120 months post diagnosis, 12 of 
whom received MMT and two had 5M.
Time from first presentation (months)
Months 0 50 100 150 200 250 Alive at 5 years (%) Alive at 10 years [%)
MMT 48 22 14 11 2 0 19/48 (40%) 13/48 (27%)
SM 54 6 2 0 0 0 6/54 (11%) 2/54 (4%)
Figure 3: Kaplan-Meier Plot Of Overall Survival Of Patients With Adenocarcinoma: 
Multimodal Therapy Versus Surgical Monotherapy. The Corresponding Table Indicates 
Number Of Patients At Risk At Each Time Point.
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Figure 4: Kaplan-Meier Plot Of Overall Survival Of Patients With Adenocarcinoma: Complete 
Pathological Response Versus Incomplete Pathological Response.
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Figure 5: Kaplan-Meier Plot Of Overall Survival Of Patients With Adenocarcinoma: Lymph 
Node Negative versus Lymph Node Positive.
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| 3 .5 .5 .2  SQ U A M O U S C E LL  C A R C IN O M A
SCC patients who received M M T had a statistically significant survival advantage over 
those who received SM (p=0.036), with median survivals of 13 (range 2-206) and 9 
(range 0.2-194) months respectively (Figure 6). In the SCC trial M M T group, the overall 
three, five and ten year survival was 33% (n=13), 30% (n=12) and 10% (n=4) 
respectively. The three, five and 10-year survival rate of the 12 patients with a CPR was 
50% (0=6), 42% (n=5) and 17% (n=2) respectively. This com pares with 25% (n=7), 25% 
(n=7) and 7% (n=2) respectively in the 28 patients with an incomplete response and 
14% (n=7), 10% (n=5) and 4% (n=2) in the surgery alone group (p=0.099). Overall, 
patients who were lymph node negative had improved survival (p=0.041) (Figure 7). 
Patients with SCC who received M M T and who were node-negative had a similar 
median survival time of 14 months compared with 8 months for SM (p=0.138). In 
lymph node positive patients, those who had M M T had a median survival of 6.5 
compared with 9 months in the SM group.
Of the SCC cohort at the conclusion of this study, 7 patients were alive at 206, 202 ,19 4, 
173, 146, 132 and 98 months post diagnosis, 5 of whom received MMT and two had 
SM.
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Tim e from  first presentation (m onths)
Months 0 50 100 150 200 250 5-Year Survival (%) 10-Year Survival(%)
MMT 40 13 5 3 2 0 12/40 (30%] 4/40 (10%]
SM 50 5 2 1 0 0 5/50 [10%] 2/50 (4%)
Figure 6: Kaplan-Meier Plot Of Overall Survival Of Patients With Squamous Cell Carcinoma: 
Multimodal Therapy versus Surgical Monotherapy. The Corresponding Table Indicates 
Number Of Patients At Risk At Each Time Point.
88
Tim e from  first presentation (m onths)
Figure 7: Kaplan-Meier Plot Of Overall Survival Of Patients With Squamous Cell Carcinoma: 
Lymph Node Negative Versus Lymph Node Positive.
B .5.5.3 CO M B IN ED  A N A LYSIS  OF A D EN O C A R C IN O M A  AND SQ U A M O U S CELL  
CA R CIN O M A
Overall, patients that received M M T had a statistically significant survival advantage 
over those that received SM (p<0.001) (Figure 8). The overall three, five and ten year 
survival for all groups was 26% (50/192), 22% (42/192) and 11% (21/192), with a 
median of 13 months (range 0.1-206). In the M M T group as a whole, the overall three, 
five and ten-year survival was 41% (36/88), 35% (31/88) and 19% (17/88) respectively. 
The three, five and 10-year survival rate of the 24 patients who had a CPR was 58%, 
50% and 21% respectively based on treatm ent received. This com pares with 33%, 30%
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and 14% respectively in the 64 patients with an incomplete response and 13%, 11% and 
4% in the SM group (p=0.003) (Figure 9).
Tim e from  first presentation (m onths)
Months 0 50 100 150 200 250 5-Year Survival (%) 10-Year Survival (%)
MMT 88 35 19 14 4 0 31/88 (35%) 17/88 (19%)
SM 104 11 4 1 0 0 11/104(11%) 4/104 (4%)
Figure 8: Kaplan-Meier Plot Of Overall Survival Of Patients With Adenocarcinoma And 
Squamous Cell Carcinoma Combined: Multimodal Therapy Versus Surgical Monotherapy. The 
Corresponding Table Indicates Number Of Patients At Risk At Each Time Point.
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Tim e from  first presentation (m onths)
Figure 9: Kaplan-Meier Plot Of Overall Survival Of Patients With Adenocarcinoma And 
Squamous Cell Carcinoma Combined Who Had An Incomplete Pathological Response to 
Multimodal Therapy, compared with Patients Who Underwent Surgical Monotherapy .
When both trials are pooled and patients who were lymph node negative after 
neoadjuvant therapy were compared with those who were lymph node negative 
following SM the 3, 5, and 10 year survivals were 48% (31/65), 42% (27/65), and 22%  
(14/65) respectively compared with 21% (8/37), 19% (7/37) and 11% which was 
statistically significant suggesting a systemic effect for neoadjuvant therapy (p=0.009).
Patients who received M M T and who had node-negative disease had a significantly 
longer median survival time of 32 months compared with 11 months for SM (p=0,009) 
(Figure 10). In lymph node positive patients, those who had MMT had a median
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survival time of 8 months com pared with 10 in the SM group, with no difference in 
survival (p=0.18).
10~ Node-negati\© Adenocarcinoma and 
Squamous Cell 
Carcinoma 
Combined 
Trial Limbs
“• Multimodal therapy 
"•Surgical monotherapy 
Multimodal therapy- 
censored
Surgical monotherapy- 
censored
p = 0.009
Tim e from  first presentation (m onths)
Figure 10: Kaplan-Meier Plot Of Overall Survival Of Node-Negative Patients With 
Adenocarcinoma And Squamous Cell Carcinoma: Multimodal Therapy Versus Surgical
Monotherapy.
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On intention to treat analysis, AC trial patients who received M M T had a statistically 
significant survival advantage over those who received SM (p=0.004) (Figure 11). In the  
AC MMT group, the overall three, five and ten-year survival was 41% (n=24), 34%  
(n=20) and 22% (n=13) respectively, compared with 13% (n=7), 11% (n=6) and 4% (n=2) 
in the SM group.
Based on intention to treat, SCC patients who received M M T also had a statistically 
significant survival advantage over those who received SM (p=0.02) (Figure 12), with 
three, five and ten-year survival was 30% (n=14), 28% (n=13) and 9% (n=4) respectively, 
compared with 13% (n=7), 10% (n=5) and 4% (n=2) in the SM group.
Combined analysis of both trials on an intention to treat basis, also revealed a 
statistically sigificant long-term survival advantage of M M T over SM (p<0.001) (Figure  
13), with three, five and ten-year survival rates of 37% (n=38), 32% (n=33) and 16% 
(n=17) compared with 13% (n=14), 10% ( n = l l )  and 4% (n=4) respectively.
I 3.5.5.4 INTENTION TO TREAT SURVIVAL ANALYSIS
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0 50 10 ISO 20 250
Time from first presentation (months)
Months 0 50 100 150 200 250 5-Year Survival (%) 10-Year Survival (%)
MMT 58 23 14 11 2 0 20/58 (34%) 13/58 (22%)
SM 55 6 2 0 0 0 6/55 (11%) 2/55 (4%)
Figure 11: Kaplan-Meier Plot Of Overall Survival Based On Intention To Treat Analysis Of 
Patients With Adenocarcinoma: Multimodal Therapy Versus Surgical Monotherapy. The 
Corresponding Table Indicates Number Of Patients At Risk At Each Time Point.
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0 50 10 150 20 250
Time from first presentation (months)
Months 0 50 100 150 200 250 5-Year Survival (%) 10-Year Survival (%)
MMT 46 14 5 3 2 0 13/46 (28%) 4/46 (9%)
SM 52 5 2 1 0 0 5/52 (10%) 2/52 (4%)
Figure 12: Kaplan-Meier Plot Of Overall Survival Based On Intention To Treat Analysis Of 
Patients With Squamous Cell Carcinoma: Multimodal Therapy Versus Surgical Monotherapy. 
The Corresponding Table Indicates Number Of Patients At Risk At Each Time Point.
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Time from first presentation (months)
Months 0 50 100 150 200 250 5-Year Survival (%) 10-Year Survival [%)
MMT 104 37 19 14 4 0 33/104 (32%) 17/104 (16%)
SM 107 11 4 1 0 0 11/107 (10%) 4/107 (4%)
Figure 13: Kaplan-Meier Plot Of Overall Survival Based On Intention To Treat Analysis Of 
Patients With Adenocarcinoma And Squamous Cell Carcinoma (Pooled Data): Multimodal 
Therapy Versus Surgical Monotherapy. The Corresponding Table Indicates Number Of 
Patients At Risk At Each Time Point.
The main finding of this study is that the short-term survival advantage for neoadjuvant 
chem oradiotherapy for AC in the previously published randomised trial182 is sustained 
long-term. This is reassuring and suggests that the survival benefit is due to the 
elimination of m icrometastases rather than merely inducing dorm ancy352 or destroying 
the majority of chemo-sensitive cells, leaving resistant clones to re-emerge, and for 
patients to succum b to recurrent disease353. Of all randomised trials reported to date 
the median follow-up only ranged from 2 to 8 years123,143,182,211,213,215,221,223,224,231,348. 
Concerns expressed by others about the short duration of follow-up of randomised 
trials225,226 may finally be laid to rest with our 17 year follow-up. The concern that pre­
operative systemic therapy may simply "delay system ic relapse"354 can no longer be 
considered a justification for withholding neoadjuvant therapy.
As adenocarcinom a and squamous cell carcinoma are two distinct tumours with 
different aetiologies, different distribution within the oesophageal lumen, and different 
incidence of lymph node metastases, we cannot assume that squamous cell carcinoma 
will have a similar response as adenocarcinom a to the 40Gy radiotherapy and 5-FU and 
cisplatin protocol, or that response will be sustained. It is reassuring that the short­
term survival advantage previously seen in adenocarcinom a extends to oesophageal 
squamous cell carcinoma and is sustained in the longer term.
Our original report of a survival advantage for neoadjuvant chem oradiotherapy over 
surgery alone22 has been criticised because of the poor results for surgery alone225'230 
and inadequate pre-operative sta g in g 214' 355' 356. such criticism, we believe, is misplaced
3.6 DISCUSSION
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as the results for surgery alone reflect recruitment criteria. The best results for surgery 
will be achieved in patients with earlier stage disease. But to restrict recruitm ent to 
patients with the earliest stage disease would mean abandoning the patients in most 
need of system ic therapy. When the original trial was designed, the authors elected  
pursue a liberal recruitment policy in an attempt to embrace the largest possible 
percentage of patients. Inclusion criteria were all medically fit patients under 76 years 
of age who were fit for surgery, excluding only those patients with overt metastases. 
As access to CT was limited, it is likely that many of these patients had early 
macrom etastases. Access to more sophisticated staging techniques might have 
restricted the trial to earlier stage disease and would undoubtedly have been achieved  
better results for surgery alone, but there would be no additional benefit to the 
oesophageal cancer community. This was dram atically dem onstrated in a study from  
the Groningen University Medical Center140 where surgeons in academ ic centres 
appeared to provide a 5-year survival rate (49%) twice as good as surgeons in non­
teaching centres (27%), but academ ic surgeons operated on only 10% of referred  
patients compared to 20% in non-teaching units. The overall impact of surgery was the 
same for both communities.
Most trials have had stricter recruitm ent criteria with earlier tum our stage221, or 
younger mean age143,200,223' 224. But while restricting trials to patients with earlier 
disease will ensure a greater percentage survival from surgery alone, it is ultimately 
counterproductive as fewer patients will have system ic disease and cannot benefit 
from system ic therapy. Patients without macro- or m icro-m etastases do not require 
system ic therapy. Surgery will have little relevance to a disease where the majority are 
too old, too sick or have disease too advanced to be salvaged by surgery alone.
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Restricting trials to patients with the earliest disease will require larger numbers as 
greater number in each limb will be cured by surgery alone, exposing trials to a risk of 
type 2 error.
The survival advantage identified in these two trials is consistent with the findings of 
three previous randomised trials. When all randomised trials123,143,182' 211,213,215,221,223, 
224, 23i, 348^  com parjng neoadjuvant chemoradiotherapy and surgery with surgery alone 
are scrutinised, three have shown a clear survival advantage for neoadjuvant 
therapy182, 215, 221 and these share certain characteristics; they are 5-fluorouracil or 
taxane based, in adequate dosage, with concurrent treatm ent radiotherapy. When 
these criteria have been met all trials have shown a survival advantage favouring 
multimodality therapy. We believe that the failure of treatm ents reflects the use of 
ineffective therapeutic agents rather than failure of concept.
There have been a number of meta-analyses216,217,219,222,232 and even meta-analysis of 
meta-analyses214 which have consistently shown a survival advantage for neoadjuvant 
therapy218'220, 222. The results of these meta-analyses are underm ined by treatment 
protocol heterogeneity, variation of inclusion criteria, grouping of different tumour 
types, analysis of means rather than individual patient data and by short-term follow- 
Up2i4,225,226 M eta_ana|ysis pools effective182,215 with ineffective regim ens224, or indeed 
potentially harmful regim ens143 and pooling these data can little enhance our 
understanding of the sensitivity of oesophageal cancer cells to specific agents. We 
would not accept a meta-analysis of different antibiotics for a specific infection so it 
should not be acceptable in oncology. The most recent meta-analysis has shown an 
overall 8.7% survival advantage for chem oradiotherapy over surgery alone with equal
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survival benefits in both adeno- and squamous cell carcinoma, providing additional 
proof of principle for the role of systemic treatm ent for loco-regionally advanced 
disease222.
Overall 25% of patients with adenocarcinom a and 30% of those with squamous cell 
carcinoma had a com plete pathological response. In the absence of tum our in the 
resection specimen, patients cannot benefit from resection but are exposed to the risks 
of major surgery. These patients should ideally avoid surgery. More disturbing is the 
finding that in these studies 13% of patients with a CPR died following an (unnecessary) 
resection and the rest remain exposed the morbidity and life-long negative quality of 
life impact of surgery. With increasing rates of CPR being reported, the issue of 
unnecessary oesophageal resection becomes ever more pressing. Since 25-87.5% 182,191, 
213 of patients that undergo neoadjuvant chem oradiotherapy have a complete  
response, depending on initial disease stage, the identification of patients who do not 
require resection following neoadjuvant therapy becomes ever more urgent.
Complete pathological response gave a survival advantage, especially to those with 
adenocarcinom a. Incomplete responders, however also benefitted as the survival 
advantage for incomplete responders was 17% (11/64) com pared with 2.8% (3/104) for 
surgery alone (p=0.003) at 10 years. Our concern182, and that of others225,226, that the 
results may not be durable has been proved groundless by this 17-year follow-up study. 
Patients who have achieved a complete pathological response following neoadjuvant 
chem oradiotherapy have an associated improved 5-year survival of up to 60% 29'31. 
Recent advances have led to com plete response rates from 25% in the 1990s182 to up to
43 to 87.5% 191,213 in more recent times. The message emerging from these trials is that
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both adenocarcinoma and squamous cell carcinoma are exquisitely sensitive to 
chemoradiotherapy and gives the best hope of a favourable outcome.
Having identified a survival advantage for neoadjuvant chemoradiotherapy we must 
explore which cohort of patients needs it and those who are cured by surgery only. 
Clearly if patients have non-metastatic disease they can be cured by surgery alone. 
Unfortunately oesophageal cancer behaves aggressively in the majority. Only 5.4% of 
patients in one study undergoing surgery for squamous cell carcinoma had T1 tumours 
or earlier141. Even when patients with T1 tumours were subselected, the subset with 
submucosal tumours have a 5-year survival of less than 50%141. We must now 
recognise that all patients with disease beyond the mucosa need systemic therapy.
3.7 CONCLUSION
In conclusion, neoadjuvant chemoradiotherapy allows the best chance of long-term 
survival for a larger proportion of oesophageal cancer patients. There is an urgent 
need to optimise chemoradiotherapy regimens to increase the rate of complete 
pathological response and identify these patients and ultimately spare many the 
morbidity and mortality of surgery altogether.
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CHAPTER IV: STUDY 2
COMPLETE CLINICAL RESPONSE ON ENDOSCOPIC BIOPSY FOLLOWING 
NEOADJUVANT CHEMORADIOTHERAPY PREDICTS OUTCOME IN 
OESOPHAGEAL CANCER
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Background: Patients with oesophageal cancer who have a complete pathological 
response (CPR) to neoadjuvant chemoradiotherapy have a survival advantage over 
incomplete responders and patients treated with surgery alone. CPR patients cannot 
benefit from resection, but are exposed to  all of its risks. However, CPR patients are 
difficult to identify with current staging techniques.
Aims. This study aimed to determine the predictive value of a negative upper- 
gastrointestinal endoscopy and biopsy in identifying CPR following chemoradiotherapy.
Methods. A prospectively maintained oesophageal cancer database was queried to 
identify patients with loco-regional disease who had undergone neoadjuvant 
chemoradiotherapy and who had subsequently been restaged. Patients with a 
complete clinical response (CCR) had negative endoscopy and biopsy and computerised 
tomography (CT). Luminal findings were correlated with histopathological response in 
the resection specimen of patients treated surgically and with long-term survival in 
patients treated non-operatively.
Results: Ninety patients fulfilled the selection criteria; 55 had a CCR; 31. underwent 
resection and 24 declined or were not offered resection but were followed-up for life. 
Of these, five had interval oesophagectomy following disease re-emergence and 58% 
survived more than 3 years and had a similar mean survival compared with those who 
had residual disease and immediate resection post neoadjuvant therapy (24 and 27 
months respectively). Those who had a CCR and immediate resection had improved 
survival over those who had residual disease, with a mean survival of 53 months 
compared with 27 months in those with residual disease undergoing immediate
4.1 ABSTRACT
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resection. CCR was 74% predictive of a CPR (p < 0.0001) and 80% predictive of node­
negative disease (p = 0.002).
Conclusions: Pre-operative endoscopy with multiple tumour-bed biopsy identified with 
74% accuracy a cohort of patients who had a CPR. While 26% harboured residual 
disease, many had systemic spread precluding cure; some were salvaged by 
subsequent resection but, critically, many were spared the morbidity and mortality 
risks of resection and survived long-term.
104
While resection alone is curative for true loco-regional oesophageal cancer138' 357, this 
embraces only a minority of patients78' 120,142' 346. Mortality rates for resection remain 
up to 14%122 and the morbidity of surgery and long-term complications continue to be 
significant123 134. Overall survival rates for surgical monotherapy remain low182, 215, 
suggesting that its contribution to oesophageal cancer therapy is minimal.
The success of surgery, however, can be enhanced by the addition of effective 
neoadjuvant therapy196' 198, 217' 219' 221' 222' 358, which induces tum our down-staging, 
increases RO resection rates123' 143' 217 and improves survival182' 196' 215' 217' 219' 221' 222' 232' 359. 
Depending on disease stage and the regimen employed, complete response rates 
between 25% and 87.5%182' 191 have been reported, with the highest rates in patients 
with earliest disease191.
The best overall and disease-specific survival rates are found amongst complete 
pathological responders203,209,210,212,360'365. These patients, however, are not readily or 
reliably predicted by current staging techniques and thus the role for surgery in this 
sub-group is not clearly defined. We hypothesised that as the disease has originated in 
the mucosa, it is intuitive that extensive biopsies of the mucosa at re-staging following 
chemoradiotherapy would provide valuable information as to  the clinical response.
4.2 INTRODUCTION
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The aim of this study was to correlate clinical response with histological response in the 
resected specimen and overall survival and outcome for patients including those 
treated non-operatively.
4.3 AIMS
4.4 METHODS
4.4.1 PATIENTS
We queried a prospectively-accrued database to identify 90 consecutive patients who
î
presented to Connolly Hospital with a diagnosis of primary oesophageal squamous or 
adenocarcinoma who had completed neoadjuvant chemoradiotherapy for loco- 
regional advanced disease; who had pre-and post-treatment upper-gastrointestinal 
endoscopy and biopsy; and who had negative dual-contrast abdomino-pelvic 
computerised tomography (CT) fo r systemic métastasés. Where indicated, patients 
also underwent endoscopic ultrasound and or positron-emission tomography (PET).
All patients were entered on diagnosis into a prospectively-accrued oesophageal cancer 
database containing demographic, clinical, endoscopic, operative, pathological and 
follow-up data.
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| 4.4.2 NEOADJUVANT CH EMO RADIOTHERAPY
Neoadjuvant chemoradiotherapy consisted of two cycles of 5-FU and Cisplatin with 
40Gy radiotherapy as previously reported182. In brief, this consisted of two cycles of 5- 
fluorouracil and cisplatin during weeks one and six, w ith concurrent radiotherapy (40 
Gy) in 15 fractions.
Subsequently, these patients were re-staged with repeat endoscopic biopsy and CT, 
and PET where indicated. Patients consenting to surgery underwent en bloc resection 
within eight weeks of completion of neoadjuvant therapy by a single surgeon.
4.4.3 ENDOSCOPIC AND PATHOLOGICAL EVALUATION
All patients underwent pre- and post-treatment upper-gastrointestinal endoscopy 
using the same endoscopy equipment and performed by the same expert endoscopist. 
Pre-treatment, the site and length of the tum our were documented and multiple 
biopsies - at least 10 per endoscopic session - were taken for histological analysis for 
categorisation into subtype and differentiation. All biopsies were taken with Olympus 
standard oval disposable biopsy forceps (2.8mm diameter).
Post-neoadjuvant chemoradiotherapy endoscopy with multiple biopsies was repeated 
after four weeks as part of our restaging protocol. Endoscopic findings were 
categorised as either complete clinical response (CCR) or incomplete clinical response 
(ICR). CCR was identified when no tumour was identified on post-treatment
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endoscopic evaluation, with multiple (>10) biopsies of the tum our bed (Figures 14A 
and & B). An ICR was identified when tum our was present on post-treatment 
endoscopy and/or in the resection specimen.
Patients selected for surgery underwent en bloc oesophagectomy four to eight weeks 
after completion of chemoradiotherapy. Resection specimens were analysed for the 
presence or absence of residual disease. A complete pathological response (CPR) was 
identified in patients undergoing resection when no tumour was identified in the 
resected specimen. Final histopathology reports confirmed the presence of a primary 
oesophageal adenocarcinoma or squamous cell carcinoma in each of the endoscopic 
biopsy or en bloc surgical specimens included in this study, and the anatomic location 
of the tumour was recorded. Primary tum our size was recorded as the largest diameter 
axis through the sectioned specimen. The total number of lymph nodes harvested and 
the number containing metastatic cells were recorded. Cancer staging was based on 
pathologic findings referenced to the sixth edition of the American Joint Committee on 
Cancer guidelines for oesophageal cancer28.
Figure 14: White-light endoscopic images of a 54 year old male with squamous cell carcinoma 
of the oesophagus (A) pre-treatment diagnostic upper-gastrointestinal endoscopy; this 
demonstrates a 1cm tumour. (B) post-neoadjuvant chemoradiotherapy. This patient had a 
complete luminal and complete pathological response to neoadjuvant chemoradiotherapy.
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14.4.4 SURVEILLANCE
Patients opting for an observational approach or who were considered at increased risk 
for surgery due to age or co-morbidity were closely followed with 3-monthly 
endoscopy and multiple (>10) biopsies, 6-monthly CT scanning for 3 years, following 
which the endoscopic intervals were extended to  6-monthly to 5 years with annual 
follow-up thereafter and were offered interval oesophagectomy if disease re-emerged.
| 4.4.5 ETHICAL APPROVAL
Ethical approval was obtained for this study from the Connolly Hospital Ethics 
Committee.
| 4.4.6 STATISTICAL ANALYSIS
Overall survival was calculated from the date of recruitment until the date of death or 
the last recorded clinical interaction. All-cause mortality was dichotomously tabulated 
for extent of pathologic response, histologic variants, completion operative versus non­
operative treatment and overall.
Statistical analyses were performed with PASW version 18.0 for Windows. Continuous 
variables were expressed as median ± standard deviation or mean ± standard error of 
the mean as appropriate and were compared using a two-sample t-test. Categorical 
variables were compared using a chi-squared test, w ith Fishers exact test used where 
appropriate. Survival probabilities for clinical, pathological, and treatment variables 
were estimated by the Kaplan-Meier method350 and pairwise comparisons were made
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using a log-rank test. The effect of extent of pathological response to  neoadjuvant 
chemotherapy and 3D-conformal external-beam radiation therapy (either followed by 
surgical resection or surveillance), tumour histology, nodal status, size and stage on 
survival were examined using logistic regression, and optimal cut-offs were determined 
using the maximal chi-squared method. Significant univariate factors were included in 
a Cox proportional hazards regression model to establish independent predictors of 
survival. Further substratification analysis was performed where necessary using the 
Mantel-Haenszel test351. P values of less than 0.05 were considered statistically 
significant and the study was powered to detect a 20% difference between groups at a 
beta of 0.8.
4.5 RESULTS
| 4.5.1 PATIENT AND TUMOUR CHARACTERISTICS 
I 4.5.1.1 PATIENT CHARACTERISTICS
Ninety patients who completed neoadjuvant chemoradiotherapy for locoregionally 
advanced adenocarcinoma or squamous cell carcinoma of the oesophagus fulfilled the 
study criteria. The mean age was 61 years (range 38-81 years). The male to female 
ratio was 2.5:1. Follow-up ranged between 2-144 months from date of diagnosis with a 
median of 38 months.
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Fifty-seven (63%) patients had adenocarcinoma (AC) and 33 (37%) patients had 
squamous cell carcinoma (SCC). Five tumours (6%) were well differentiated, 49 (54%) 
were moderately differentiated and the remaining 36 (40%) were poorly differentiated. 
The average tumour length, measured on initial endoscopy, was 4cm (range l-10cm). 
Initial tumour length was poorly-predictive of post-treatment CCR (p = 0.272) and of 
lymph node metastasis (p = 0.43).
| 4.5.1.2 TUMOUR CHARACTERISTICS
4.5.2 RESPONSE
4.5.2.1 COMPLETE CLINICAL RESPONSE
Fifty-five patients in this series (61%) had a CCR. Fifty-three percent of AC (30/57) and 
76% of SCC (25/33) had a CCR. Of the 55 CCRs, 31 (56%) underwent resection while 24 
(44%) declined (10/24) or were deemed unsuitable (14/24) fo r surgery and were placed 
on surveillance. Resection specimens analysed in these operative patients 
demonstrated an absence of lymph node metastasis in 25/31 (80%) of patients who 
had a pre-operative endoscopic CCR, compared with only 16/36 (44%) in those with a 
preoperative endoscopic ICR (p = 0.002, chi-square = 9.192). Five of the cohort placed 
on surveillance underwent interval oesophagectomy following detection of recurrence, 
leaving 19 that did not need or were not offered resection. All 35 patients who had an 
incomplete clinical response (ICR) went on to have surgical resection, and all those 
specimens demonstrated residual tumour.
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Thirty-one patients with a CCR underwent resection, of whom 23 (74%) had a CPR, 
while 8 (26%) had residual disease in the resected specimen. Overall, 26% percent of 
all AC (15/57) and 24% of SCC (8/33) in this series had a CPR. CCR on endoscopy was 
found to be highly significantly predictive of node-negative status (p=0.002) and of a 
CPR in the resection specimen (p<0.0001).
The post-treatment AJCC disease stage in these patients with residual disease was 
stage 2a in 2 patients, stage 2b in 5 patients and stage 3 in 1 patient. Six of the 8 
patients were lymph node positive, with five patients having only one positive lymph 
node and one patient with three positive nodes.
j 4.5.2.3 NON-OPERATIVELY-MANAGED PATIENTS
Twenty-four patients declined or were deemed unsuitable fo r resection and were 
followed-up clinically and endoscopically until the completion of this study. Immediate 
surgery had not been performed due to co-morbidities or deterioration in performance 
status (10/24), progressive disease (4/24) or patient choice (10/24). Five of these latter 
10 had an interval oesophagectomy when recurrence was detected at 3-monthly 
surveillance endoscopy; one at 9 months, two at 11 months and two at 12 months. The 
remaining 19 patients continued to be followed-up until completion of this study.
| 4,5.2.2 PATHOLOGICAL RESPONSE
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14.5.3 SURVIVAL
The mean overall survival of the 90-patient cohort was 41 months.
I 4.5.3.1 COMPLETE CLINICAL RESPONSE
i
The mean overall survival fo r the 55 CCR patients was 47 months (range 2-144 
months); 76% were alive at 1 year (n=42); 58% at 2 years (n=32), 49% at 3 years (n=27) 
and 38% at 5 years (n=21). Twenty patients (36%) were alive and disease free at 
completion of this study. Patients with SCC and AC had a mean survival of 46 and 48 
months respectively.
The mean survival of the 31 CCR patients who had immediate resection post­
neoadjuvant therapy was 53 months. Twelve of these patients were alive at the 
conclusion of this study with a mean survival of 99 months post diagnosis (range 40- 
144). Eight patients died of metastatic or recurrent disease, two of broncho­
pneumonia, one each of a tracheo-esophageal fistula, anastomotic leak post colonic 
interposition, metastatic colon cancer and upper gastro-intestinal bleed. There were 
four in-hospital mortalities, two of whom died of multi-organ failure following surgery, 
one from a pulmonary embolus and one from a cerebrovascular accident. The cause of 
death in one patient was unknown.
I 4.5.3.2 COMPLETE PATHOLOGICAL RESPONSE!
The mean survival of the 23 CPR patients was 68 months (range 4-144). Of CPR 
patients 78% (n=18) were alive at 1 year, 74% at 2 years (n=17), 65% at 3 years (n=15) 
and 61% at 5 years (n=14). Patients who had a CPR to neoadjuvant chemoradiotherapy
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had a statistically significant survival advantage over those patients who had residual 
disease (p=0.043) (Figure 15).
Of 23 patients with a CPR, 11 were alive at the conclusion of this study at a mean of 
103 months (range 75-144). Of those who died, four patients died of metastatic or 
recurrent disease at 8, 22, 86 and 98 months, two from pneumonia at 7 and 81 months, 
one from a tracheo-oesophageal fistula at nine months, one from metastatic colon 
cancer at 52 months and one from unknown cause at 35 months. Three died post- 
operatively: one from sepsis, one from a pulmonary embolus and one from an 
anastomotic leak following colonic interposition.
Figure 15: Kaplan-Meier Plot Comparing Overall Survival Of Patients With Complete And 
Incomplete Pathological Response Following Neoadjuvant Chemoradiotherapy.
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The mean survival fo r all 43 patients found to have residual disease on the resection 
specimen following immediate resection was 27 months (range 3-111), with 1, 2, 3 and 
5-year survival of 70% (n=30), 40% (n=17), 23% (n=10) and 12% (n=5) respectively. 
Twenty-three (53%) died of recurrent or metastatic disease and ten were alive at 
completion of this study. The remainder died of pneumonia (n=4), cerebro-vascular 
accident (n=2), upper gastro-intestinal bleed (n=2), metastatic rectal cancer (n=l), 
myocardial infarction (n=l) and sepsis (n=l).
I 4.5.3.4 NON-OPERATIVELY MANAGED PATIENTS
The mean overall survival for 19 patients with a CCR who did not undergo immediate or 
interval resection was 43 months (range 6-116) with 89% of these surviving 1 year 
(n=17), 68% survived 2 years (n=13), 58% surviving 3 years (n = ll)  and 42% survived 5 
years (n=8).
Of these 19 patients, seven were alive at completion of this study at 38, 39, 53, 61, 64 
and tw o at 88 months post diagnosis. Of those who died, 5 died of metastatic disease, 
one of aspiration pneumonia, one of multi-organ failure, one of lung cancer and one of 
thoracic empyema366 and in three the cause is unknown.
Of the 19 patients treated conservatively, 11 (58%) survived disease free for more than 
3 years suggesting a complete clinical response in this cohort. This sub-group's overall 
mean survival was 65 months.
| 4.5.3.3 INCOMPLETE RESPONSE
115
The mean survival of patients undergoing interval oesophagectomy was 24 months 
post-diagnosis. One patient was still alive at completion of this study at 47 months. 
The remaining patients survived 10, 12, 24 and 28 months and died of metastatic or 
recurrent disease.
| 4.5.3 5 INTERVAL OESOPHAGECTOMY
4.5.3.6 HOSPITAL MORTALITY
Overall mortality rate following surgery was 8%. The mortality rate in those who had a 
CPR was 9%; this was not statistically significantly different (p = 0.834).
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Figure 16: Flow Diagram Of Patient Distribution Following Completion Of Neoadjuvant 
Chemoradiotherapy. Mean Survival In Months In Parentheses.
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The management of early tumours of the upper oesophagus and oropharynx has 
increasingly relied on definitive chemoradiotherapy, reserving surgery for patients with 
persistent disease. For SCC of the lower oesophagus and for AC, neoadjuvant therapy 
followed by surgery has remained the standard of care. Following neoadjuvant 
chemoradiotherapy, the identification of persistent disease in the oesophageal lumen 
in these latter patients at restaging presents clear, dichotomous treatment pathways. 
In the absence of detectable metastatic disease, resection is advised, unless precluded 
by co-morbidity or patient choice. A significant percentage of these patients will 
survive long-term following resection but the majority will succumb to metastatic 
disease as failure to respond is considered a negative prognotic factor354,367.
When no residual tum our is identified endoscopically or radiologically at restaging, the 
clinician is placed in a therapeutic and ethical dilemma. If resection is performed and 
no tumour is detected in the resected specimen, the patient has been exposed to 
significant mortality risk of 14%122 and acute morbidity risks as well as the risks of 
chronic complications of oesophageal resection123'133, but has gained no benefit. If no 
operation is performed, there may be a risk of accusation of mismanagement if the 
disease later re-presents at an incurable stage.
The CPR rate depends on the regimen employed and the stage of disease. Most studies 
report CPR rates in the order of 25 to 43%182,213 for loco-regionally advanced tumours. 
For earlier disease, a much higher CPR rate can be inferred as a recent report of
4 .6  DISCUSSION
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patients with T ib  disease so treated had a complete response rate of 87.5% with a 4- 
year survival of 81%191. We can anticipate a greater percentage of complete 
responders, especially as more effective and targeted therapies are employed and 
extended to  earlier disease stages.
The greater the CPR rate, the greater the ethical imperative to identify and avoid 
surgery in complete responders. A recent study of 299 patients with a CPR revealed 
that these patients had a 5.7% mortality rate, despite the cases being drawn from 6 
centres of excellence368. Several studies suggest an increased surgical morbidity and 
mortality for patients undergoing preoperative chemoradiation143,149' 150 identifying a 
further argument against submitting all these patients to resection. We observed a 9% 
mortality rate in those with a CPR which was similar to the mortality rate of patients 
with residual disease and to overall post-operative mortality rates from large series122. 
Where resectable disease persists, a low mortality is acceptable but it is less defensible 
in patients with a CPR, especially when a regimen with a known high CPR rate is 
employed or in patients with earlier disease stage.
The ability to identify accurately which patients have responded completely to 
chemoradiotherapy is immensly desirable. Based chiefly on imaging, the accuracy of 
current cancer staging is poor since imaging techniques rely on a minimal disease 
burden and no current technique can reliably detect systemic microscopic disease. 
Thus, when untreated patients are staged as curable by surgery and undergo en bloc 
resection the majority will still die of their disease, succumbing to systemic 
micrometastases80,135' 138,357. Restaging after neoadjuvant chemoradiotherapy is even
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more challenging due to the difficulty distinguishing fibrotic or necrotic or 
inflammatory tissue from tumour deposits, even with advanced techniques106,107 109.
Others have examined luminal response with varying results. Brown et al103 reported 
that an endoscopically normal lumen correlated with a 50% likelihood of a CPR but 
neither biopsy of the lumen nor CT scanning were performed which may have reduced 
the accuracy of these assessments. The findings of a study from the Memorial Sloan- 
Kettering Cancer Center104 were more difficult to understand as a negative endoscopy 
and biopsy was only 31% predictive of a CPR. In their paper, only 71% of patients were 
biopsied following chemoradiotherapy, and neither the number of biopsies nor the 
experience of the endoscopist were commented upon.
In this study, we examined the simple strategy of restaging with endoscopy, extensive 
biopsy and CT scanning and found that 74% of CCRs had a CPR following resection. 
Furthermore, 80% of the en bloc resection specimens from CCRs who underwent 
oesophagectomy demonstrated no microscopic nodal disease, arguing for a complete 
tum our field-sterilisation in response to the neoadjuvant chemoradiotherapy. Arguably 
a similar percentage of conservatively-managed patients had a complete response, as 
19 of 24 did not re-present with locoregional disease and 58% survived long-term. The 
persistence of disease in 26% of patients who have a CCR is obviously a concern. This 
should not be equated with the loss of 26% of survivable patients, however, as a 
significant percentage of the patients who harbour occult disease in the oesophageal 
wall will also have systemic micrometastases264, which will ultimately decide their 
survival. The avoidance of hospital mortality within the entire cohort who avoided 
surgery will further ameliorate the potentially negative effect of a conservative policy.
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By offering 3-monthly interval endoscopy, interval oesophagectomy can be offered to  a 
significant proportion of patients if the disease re-emerges with curative intent for 
those without systemic disease.
While we strive fo r greater accuracy, we are obliged to use the information from our 
current restaging protocols to our patients' advantage. We subscribe to the policy of 
engaging patients as partners in their own care. We therefore explain to our patients 
with a CCR that they have a 74% chance of having a CPR and therefore a 74% chance of 
having an unhelpful operation. While encouraging younger and fitte r patients to 
proceed with resection, we actively encourage patients over the age of 70 and patients 
with significant co-morbidity to consider a "watch and wait" approach with close 
surveillance and interval endoscopy if necessary.
4.7 CONCLUSION
In conclusion, current neoadjuvant chemoradiotherapy protocols yield a complete 
response in an increasing number of patients. These patients cannot benefit from 
resection but are exposed to significant mortality and morbidity risks. The simple 
approach of endoscopy with multiple (>10) tum our bed biopsies and CT will identify 
with 74% accuracy a cohort o f patients who will have a CPR. More accurate methods 
to detect a complete response are needed but the issue of what to do with complete 
clinical responders, especially those who are older or less fit for resection, remains 
controversial and in the absence of a randomised trial must be guided by common 
sense and patient choice.
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CHAPTER V: STUDY 3
MICROMETASTASES AND LUMINAL RESPONSE TO NEOADJUVANT 
CHEMORADIOTHERAPY ARE PREDICTORS OF LONG-TERM SURVIVAL IN 
OESOPHAGEAL CANCER
1 2 2
Introduction: The majority of patients with oesophageal cancer die of their disease 
despite apparently curative resection. The addition of neoadjuvant chemoradiotherapy 
enhances survival. Complete responders have the best prognosis and loco-regional 
response is used as a surrogate marker of response and outcome but many complete 
responders still succumb to systemic recurrence, most likely due to persistant or 
resistant micrometastases.
Aims: to  determine whether the addition of micrometastastic status from rib bone 
marrow to  luminal response would more accurately predict long-term survival in 
oesophageal cancer.
Method: A prospectively-accrued database was used to identify a cohort of patients 
who had completed neoadjuvant chemoradiotherapy for oesophageal adeno- and 
squamous cell carcinoma, who had pre- and post-treatment endoscopy and biopsy and 
who had rib marrow examined for the presence of micrometastases using 
immunohistochemical staining with cytokeratin-18 and the alkaline phosphatase-anti- 
alkaline technique. Luminal response to treatment was recorded by endoscopy and 
biopsy. Patients were followed up until date of death or last clinical interaction.
Results: Twenty-three patients with adenocarcinoma (AC) and 20 with squamous cell 
carcinoma (SCC) fulfilled the selection criteria. Of 43 patients who had neoadjuvant 
treatment, 33% had a CPR. Twenty-seven patients had surgical resection and one had 
no surgery but had a post-mortem 5 years post neoadjuvant treatment. Median 
follow-up was 57 months (range 2-115 months). Presence of rib-marrow 
micrometastases predicted significantly shorter survival time in AC (p=0.017), but not in
5.1 ABSTRACT
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SCC (p=0.47). Improved survival was predicted by CCR (p=0.009). Lymph node and 
marrow micrometastases negative patients with CCR were significantly more likely to 
be alive at study-end (p<0.05). Patients who had a CCR and were negative for rib 
micrometastatic disease were twice as likely to survive versus rib metastasis positive 
patients (5 year survival of 38% vs. 17%).
Conclusion: The determination of micrometastatic status improves accuracy of luminal 
response as a prognostic indicator. Techniques fo r detection of micrometastases 
should be standardised and evaluated in large prospective studies before incorporating 
micrometastatic status into pathologic staging.
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The majority of patients with oesophageal cancer die of their disease despite 
apparently curative resection135, 192. Whilst the addition of chemoradiotherapy 
provides a survival advantage182,219,369, many complete responders still succumb to 
systemic recurrence363, 370. This may be as a result of persistent or resistant 
micrometastases which occur early in oesophageal cancer119,266,371,372 indicating that 
oesophageal cancer is a systemic rather than local-regional disease.
Neoadjuvant chemoradiotherapy targets both the local and systemic disease burden 
and complete pathological response (CPR) is a surrogate marker of its efficacy209,210' 212, 
362. We have previously shown that when a complete clinical response (CCR) is 
identified by negative endoscopy and biopsy, 74% of such patients have a CPR and this 
is predictive of long-term survival373. With no residual disease, these patients cannot 
benefit from resection, but are exposed to the same morbidity and mortality risks as 
those with residual disease. Over recent years, there has been a dramatic 
improvement in complete response rates from 43 up to 87.5% being reported191,213.
Because of its large blood supply and rich cellular store, bone marrow has been the 
focus of studies of micrometastic spread and has been found to reflect the 
micrometastatic disease burden374, especially rib marrow in oesophageal cancer119. 
The detection of these tum our deposits in colon255, gastric258, lung256,374 and breast257 
cancers is indicative of poorer outcome. Micrometastases are present in the majority 
of patients presenting with oesophageal cancer119,266 but while several studies have
5.2 INTRODUCTION
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confirmed the prognostic implication of these occult metastatic cells on relapse-free 
and overall survival in oesophageal cancer268,375'377/ others have not263,378. Despite 
advances in technology, these micrometastases remain undetectable by current 
staging techniques109.
With the introduction of new therapeutic regimes and increasing CPR rates, it is now 
important that we can identify those patients who cannot benefit from surgery either 
because they have no residual disease, or because they have incurable systemic spread 
and those who may benefit from adjuvant treatment.
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To determine whether the addition of micrometastastic status from rib bone marrow 
to luminal response to neoadjuvant chemoradiotherapy is more accurate in predicting 
long-term outcome in oesophageal cancer.
5.3 AIMS
5.4 PATIENTS AND METHODS
We interrogated a prospectively maintained database of patients with oesophageal 
cancer managed at Connolly Hospital to  identify a cohort of patients who had 
completed neoadjuvant chemoradiotherapy, had pre- and post-treatment endoscopy 
and biopsy and who had rib marrow examined for the presence of micrometastases as 
part of a previous study by Ryan et al269. Endoscopic findings post neoadjuvant 
chemoradiotherapy were extracted and correlated with rib marrow micrometatstatic 
status and histopathological findings of the resection specimen in those who 
underwent surgery. Rib marrow micrometastatic status and endoscopic response to 
therapy was correlated with survival. Overall survival was calculated from the date of 
diagnosis.
| 5.4.1 NEOADJUVANT CHEMORADIOTHERAPY
Neoadjuvant chemoradiotherapy consisted of two cycles of 5-FU and Cisplatin with 
40Gy radiotherapy as previously reported182. In brief, this consisted consisted two 
cycles of 5-fluorouracil and cisplatin during weeks one and six, with concurrent 
radiotherapy (40 Gy) in 15 fractions. Those who underwent oesophagectomy had 
surgery on or after week 8.
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| 5.4.2 ENDOSCOPIC AND PATHOLOGICAL EVALUATION 
All patients underwent pre-and post-treatment endoscopy. Pre-treatment, the site and 
length of the tumour were documented and multiple biopsies - at least 10 per 
endoscopic session - were taken for histological analysis fo r categorisation into subtype 
and differentiation.
Post-neoadjuvant chemoradiotherapy endoscopy was repeated after four weeks as 
part of our restaging protocol. Endoscopic findings were categorised as either 
complete clinical response (CCR) or incomplete clinical response (ICR) if endoscopy, 
complemented by colour photography, biopsy or imaging findings identified residual 
disease. A CCR was identified when no tumour was identified on post-treatment 
endoscopic evaluation, with multiple (>10) biopsies of the tum our bed.
Patients selected fo r surgery underwent en bloc oesophagectomy four to eight weeks 
after completion of their chemoradiotherapy. Resection specimens were analysed for 
the presence or absence of residual disease in the oesophageal wall and surrounding 
envelope of nodes and tissue. Patients staged according to TNM guidelines as outlined 
by the seventh edition of the American Joint Committee on Cancer Staging28 following 
histological analysis of the resection specimen. A complete pathological response (CPR) 
was identified in patients undergoing resection when no tumour was identified in the 
resected specimen.
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The retrieval and analysis of bone marrow do not form part of this Thesis.
Bone marrow was harvested from the ribs of patients who had been diagnosed with 
oesophageal cancer via endoscopy and biopsy. Retrieval of a 2-3cm segment of rib 
removed at restaging laparoscopy at completion of neoadjuvant chemoradiotherapy or 
at the time of thoracotomy for oesophageal resection, as described by Ryan et al269, 
was performed by Prof TN Walsh, Connolly Hospital, Blanchardstown. In order to avoid 
tumour micro-embolisation, the segment of rib was removed prior to surgical 
manipulation of the tumour and rib samples removed were not within the radiation 
field.
The processing and immunohistochemical staining was performed by Dr. Jacquie Kelly 
and Dr. Ruth Gleeson, University College, Cork. To detect micrometastases, 
mononuclear cells were isolated from fresh marrow and immediately stained 
immunohistochemically with an anti-cytokeratin-18 antibody using the APAAP 
technique269. Tumour cell viability was assessed by immunohistochemical staining of 
marrow cell cultures for cytokeratin-positive cells269.
| 5.4.4 STATISTICAL ANALYSIS
Statistical analyses were performed using the statistical package SPSS version 15.0 for 
Windows (SPSS, Inc., Chicago IL). Survival probabilities for clinical, pathological, and 
treatment variables were estimated by the Kaplan-Meier method350 and pairwise 
comparisons were made using a log-rank test. The effect of extent of pathological
5.4.3 DETECTION OF RIB MARROW  MICROMETASTASES
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response to neoadjuvant chemoradiotherapy, tumour histology, presence of 
micrometastases on survival were examined using logistic regression, and optimal cut­
offs were determined using the maximal chi-squared method. Significant univariate 
factors were included in a Cox proportional hazards regression model to establish 
independent predictors o f survival. Further substratification analysis was performed 
where necessary using the Mantel-Haenszel test351. P values of less than 0.05 were 
considered statistically significant.
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5.5 RESULTS
5.5.1 PATIENT CHARACTERISTICS
Forty-three patients fulfilled our selection criteria. Male to female ratio was 2.6:1 and 
age range was 37-81 years with a mean age of 61 years. Twenty three (53%) had 
adenocarcinoma and 20 (47%) had squamous cell carcinoma. Six tumours (14%) were 
well differentiated tumours, 17 (40%) were moderately differentiated and 20 (47%) 
were poorly differentiated. Follow-up ranged between 2-155 months from date of 
diagnosis with a mean of 38 months.
Fifteen patients (4 adenocarcinoma and 11 squamous cell carcinoma) did not undergo 
surgical resection due to progressive disease (n=9), patient choice (n=2) and 
deterioration in performance status (n=4).
5.5.2 FOLLOW-UP
Follow-up ranged between 2 and 115 months from date of diagnosis with no patients 
lost to  follow-up. The overall mean survival for the entire cohort was 38 months.
5.5.3 COMPLETE CLINICAL AND PATHOLOGICAL RESPONSE
Twenty-one patients (49%) treated with neoadjuvant chemoradiotherapy had CCR.
Fourteen (67%) patients who had a CCR also had a CPR.
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A CPR was achieved in fourteen patients (33%). CPR rate was 35% in adenocarcinoma 
(8/23) and 30% (6/20) in squamous cell carcinoma.
The 1, 2, 3 and 5 year survival of those who had a CCR were 81% (n=17), 67% (n=14), 
62% (n=13) and 57% (n=12) compared with 32% (n=7), 9% (n=2), 9% (n=2) and 9% (n=2) 
respectively in those with a partial response on endoscopy and biopsy. Those who had 
a CCR had a statistically significant survival advantage (p=0.009) compared with those 
who had an ICR (Figure 17).
Figure 17: Kaplan-Meier Plot Of Overall Survival Of Patients With Complete Clinical Response 
(CCR) Versus Incomplete Clinical Response (ICR).
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| 5.5.4 LYMPH NODE DISEASE
Sixty one percent (n=17) of patients were lymph node negative following 
chemoradiotherapy. Lymph node negativity significantly improved survival (p=0.006) 
with 75% 5 year survival for lymph node negative patients with adenocarcinoma and 
80% with squamous cell carcinoma versus 20% and 0% respectively for lymph node 
positive patients.
5.5.5 RIB MARROW MICROMETASTASES
Rib marrow micrometastases were identified in 60% (n=26) of patients following 
treatment.
Patients who were negative for rib micrometastases overall had improved survival over 
micrometastases positive patients (p<0.05) with 1, 2, 3 and 5 year survival of 65% 
(n = ll) , 53% (n=9), 47% (n=8) and 41% (n=7) compared with 50% (n=13), 31% (n=8), 
31% (n=8) and 23% (n=6) who had micrometastases positive disease. On subgroup 
analysis of tumour type, micrometastases predicted significantly shorter survival in 
adenocarcinoma (p=0.017) (Figure 18), but not in squamous cell carcinoma (p=0.47).
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Figure 18: Kaplan-Meier Plot Of Overall Survival Of Patients With Oesophageal 
Adenocarcinoma With (Rib +ve) And Without (Rib -ve) Rib Micrometastases
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5.5.6 COMPLETE CLINICAL RESPONSE AND RIB MICROMETASTATIC STATUS 
Patients who had a CCR and were negative for rib micrometastatic disease were twice 
as likely to survive versus rib positive patients (5 year survival of 38% vs. 17%) but this 
failed to reach statistical significance (Figure 19).
Figure 19: Kaplan-Meier Plot Of Overall Survival Of Patients With And Without Rib 
Micrometastases (Rib+ve And Rib-ve) And With Complete Clinical Response (CCR) Or 
Incomplete Clinical Response (ICR).
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Survival following resection is related to disease stage in almost all published series. 
Patients with earliest stage disease survive longest while patients with metastases have 
poorest outcomes262. Neoadjuvant chemoradiotherapy is being increasingly employed 
to  target both loco-regional and systemic disease. However even with the most 
advanced current clinical staging techniques, we are unable to differentiate between 
those who have had a complete response to treatment or those who have residual or 
micrometastatic disease106' 107, 109. Because of this, the majority of those with a 
complete clinical response to  neoadjuvant therapy and those with occult metastases 
continue to undergo arguably unhelpful373 and invasive surgeries associated with 
significant morbidity123'134 and mortality122. The ability to stage and restage disease 
with greater accuracy would be immensly desirable and patients could be offered 
appropriate treatment tailored to their stage and disease burden.
This study demonstrates that down-staging to a complete loco-regional response 
provides best hope of long-term survival, as has been shown previously191,203/209,210,212/ 
362, 379. In a recent study and in Chapter 4 we have shown that complete clinical 
response is 74% predictive of a complete pathological response373. It is unlikely that 
the accuracy of luminal response will be enhanced by imaging techniques due 
limitations in discriminating tum our from inflammatory or necrotic tissue by 
radiological means106,107,109.
5.6 DISCUSSION
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The presence of micrometastases is associated with the depth of penetration258,259 and 
grade260 of the primary tumour, which are prognostic indicators262 but the exact 
significance of micrometastases in oesophageal cancer is uncertain263,268,375'378. Some 
authors suggest that their detection merely reflects transitory shedding of cells from 
the primary tumour and does not indicate increased metastatic potential264 whereas 
others suggest that such detection reflects biologically aggressive disease with 
metastatic tendency263. In this series, 31% of patients with micrometastases in the ribs 
survive 3 years, but patients with rib marrow negative for micrometastases had a 
survival advantage with 47% surviving 3 years.
The aim of neoadjuvant chemoradiotherapy is to  reduce the tum our size and maximise 
local control179, thereby allowing a higher rate of RO resection123,143 as well as reducing 
subsequent distant failures380. Although the addition of chemoradiotherapy provides a 
survival advantage182, 219, 369, and the best survival statistics are found amongst 
complete pathological responders209,210,212,360,361 many patients with the maximum 
local response still succumb to systemic recurrence363, 370. This apparent failure to 
eradicate micrometastases may be explained by the fact that when given concurrently, 
chemotherapy enhances the effect of radiotherapy locally, including lymph node 
disease but systemic disease is not exposed to this synergistic effect. Additionally, 
because the majority of micrometastatic tumour cells may be non-pro life rating381, and 
thus display similar characteristics to cancer stem cells382, 383, standard cytotoxic 
chemotherapy may be less effective. Like micrometastases, mounting evidence 
suggests that cancer stem cells are responsible fo r tumour resistance and re-growth, 
establishment of metastases and resistance to a variety of treatments384'388. Thus with 
current treatment regimes, rib micrometastases, appear to escape the full therapeutic
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effect that is achieved in the locoregional domain, reflecting the quality of current 
chemotherapeutic agents.
The persistence of viable disseminated or micrometastatic tum our cells, some or all of 
which may indeed be cancer stem cells, following neoadjuvant chemoradiotherapy, 
including in those with an apparent complete pathological response, highlights the 
need for improved or additional systemic therapies. In this study, we explored the idea 
that by combining complete clinical response w ith micrometastatic status we might 
better identify complete treatment responders. It is clear from this, albeit small, study 
that information on micrometastases enhances the prognostic accuracy of luminal 
response. While in loco-regional incomplete-responders, rib marrow micrometastasis 
status less was less significant, those who had a complete loco-regional response and 
who had no detectable micrometastases had an improved prognosis. These patients 
have endured the morbidity of surgery to ascertain whether or not there was residual 
disease but it is questionable whether they derived any benefit. As the rate of 
complete pathological response increases with the introduction of new 
chemotherapeutic regimes, the morbidity and mortality risks that these patients are 
exposed to become difficult to justify. Similarly, whilst patients continue to succumb to 
metastatic disease in the context of good or complete loco-regional response, it is 
difficult to  rationalise the role of surgery if their disease burden is incurable. The 
findings of this study suggest rib and nodal micrometastases are predictive of systemic 
disease and that their presence predict a poorer outcome.
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The challenge remains to  develop minimally invasive, affordable and reliable 
techniques to identify those who cannot benefit from surgery, either because of the 
absence of resectable disease or due to the presence of micrometastatic disease which 
will ultimately decide the patient's outcome. Reliable and standardised methods need 
to be developed and evaluated in large prospective studies before micrometastatic 
status is incorporated in routine clinical staging. Future therapies should target local 
tum our but also focus on the systemic burden as this ultimately decides the outcome.
5.7 CONCLUSION
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CHAPTER VI: STUDY 4
TAILORING THERAPY FOR OESOPHAGEAL CANCER IN PATIENTS AGED 70 
AND OVER
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Background. Cancer is a disease of the elderly but this cohort is under-represented in 
randomised trials. Oesophageal cancer management in the elderly is challenging 
because of the morbidity and mortality risks of surgery.
Aims. To examine the outcome of a strategy of neoadjuvant chemoradiotherapy 
followed by surgery or surveillance, depending on response, in patients over 70.
Methods. A prospectively-accrued database identified 129 patients aged over 70 
presenting with oesophageal carcinoma, of whom 66 (51%) were too advanced or unfit 
for curative intervention while 63 (49%) were treated with curative intent.
Results. Of 129 eligible patients, 66 (51%) received palliative measures while 63 (49%) 
had curative intervention: 7 had surgery alone and 56 had neoadjuvant 
chemoradiotherapy +/- surgery. Of the 56 patients, 33 (59%) had adenocarcinoma (AC) 
and 23 (42%) squamous cell carcinoma (SCC). Twenty-five (44%) had a complete clinical 
response (CCR) of whom 6 had immediate resection; 4 of whom (67%) had a complete 
pathological response (CPR); 19 patients with a CCR declined, or were unfit fo r surgery, 
and underwent surveillance; of which 3 had interval oesophagectomy; while 16 were 
not offered or declined resection. Eight (50%) have survived > 3 years. The mean 
survival was 28 months for the entire cohort; 47 months fo r CCRs; 61 months for 
patients undergoing primary resection, 29 months for those undergoing interval 
resection and 46 months for CCRs who did not undergo resection. In those with a CCR, 
surgery did not provide a survival advantage (p=0.861).
Conclusion. As one third of patients have a CPR to neoadjuvant chemoradiotherapy, 
resection for these, with its attendant risks in the elderly, makes little sense. Obviating
6.1 ABSTRACT
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surgery yields an overall 3-year survival of 50%. With the additional option of salvage 
oesophagectomy for re-emergent disease, this strategy may be an attractive option for 
elderly patients.
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The global population is aging at a rate never observed before in human history with 
the older population growing at a rate considerably faster than that of the total 
population389. Within the first half of this century, the global population aged 60 years 
or older is projected to treble to nearly 2 billion389. In Europe, almost 30 per cent of the 
population is predicted to be aged 65 or over by 2050389. Cancer is a disease of the 
elderly390 and the majority of gastrointestinal cancers occur in elderly patients391. 
Oesophageal cancer is no exception with median age at diagnosis of 68 years4. Sixty- 
one percent of sufferers are over the age of 65, 33% are over the age of 75 and 8% are 
over the age of 854.
Despite being one of the fastest growing and prevalent malignancies, especially in
developed countries7'10,17,18, the outcome of treatment of oesophageal cancer in older
patients is unclear from the literature as few studies report community results78 or
results in the elderly392, 393 and the elderly are under-represented in randomised
t
trials392,393. With this rapidly increasing incidence of oesophageal cancer and an ever- 
aging population18,389, this issue becomes evermore urgent.
As the majority of patients with oesophageal cancer have systemic disease at 
presentation, systemic therapy is essential. One of the advantages of providing this 
preoperatively is that over one third of patients will have a complete pathological 
response191,213,215. These patients cannot benefit from resection but are exposed to all 
of its risks including an risk of mortality of around 14% overall122 and 20% in the
6.2 INTRODUCTION
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elderly394*396 and a lifetime exposure to the negative quality of life impact123*134. We 
have shown that a complete clinical response (CCR) is 74% predictive of a complete 
pathological response (CPR) and these patients may obviate surgery373.
6.3 AIMS
The aim of this study was to  analyse the outcome of patients over the age of 70 with 
oesophageal cancer following treatment with chemoradiotherapy.
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6.4 PATIENTS AND METHODS
6.4.1 PATIENTS
A prospectively maintained database of patients presenting to Connolly Hospital was 
interrogated to identify a cohort of patients over the age of 70 years who had 
completed chemoradiotherapy for loco-regionally advanced oesophageal 
adenocarcinoma and squamous cell carcinoma. Medical records were analysed for any 
additional data required that was not contained within the database. Patients were 
followed-up until death or last clinical interaction. Overall survival was calculated from 
the date of diagnosis.
16.4.2 CHEMORADIOTHERAPY
Neoadjuvant chemoradiotherapy consisted of two cycles of 5-FU and Cisplatin with 
40Gy radiotherapy as previously reported182. In brief, this consisted consisted two 
cycles of 5-fluorouracil and cisplatin during weeks one and six, with concurrent 
radiotherapy (40 Gy) in 15 fractions. Patients consenting to  surgery underwent 
resection within eight weeks of completion of neoadjuvant therapy.
| 6.4.3 ENDOSCOPIC AND PATHOLOGICAL EVALUATION 
All patients underwent pre- and post-treatment endoscopy. Pre- and post-treatment, 
the site and length of the tum our were documented and multiple biopsies - at least 10 
per endoscopic session - were taken for histological analysis.
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Post-treatment, endoscopic findings were categorised as either CCR or incomplete 
clinical response if endoscopy, biopsy or imaging findings identified residual disease. A 
CCR was identified when no tumour was identified on post-treatment endoscopic 
evaluation, with multiple (>10) biopsies of the tum our bed, and a negative 
computerised tomography (CT). An incomplete response was identified when tumour 
was present on post-treatment endoscopy and/or in the resection specimen.
In patients undergoing resection, specimens were analysed for the presence or absence 
of residual disease. A CPR was identified when no tum our was identified in the 
resected specimen. Patients were staged according to  TNM guidelines as outlined by 
the American Joint Committee on Cancer Staging397.
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Patients with a CCR opting for an observational approach or who were considered at 
increased risk for surgery due to age and or co-morbidity were closely followed with 3- 
monthly endoscopy and multiple (>10) biopsies, 6-monthly CT scanning for 3 years, 
following which the endoscopic intervals were extended to 6-monthly to 5 years with 
annual follow-up thereafter. Patients who were disease free for 3 or more years were 
considered complete clinical responders.
Patients known to have an incomplete response following treatment who were not 
offered or declined surgery were managed symptomatically and did not undergo 
routine investigation.
| 6.4.5 STATISTICAL ANALYSIS
Statistical analyses were performed with PASW version 18.0 fo r Windows. Continuous 
variables were expressed as median ± standard deviation or mean ± standard error of 
the mean as appropriate and were compared using a two-sample t-test. Categorical 
variables were compared using a chi-squared test, w ith Fishers exact test used where 
appropriate. Survival probabilities fo r clinical, pathological, and treatment variables 
were estimated by the Kaplan-Meier method350 and pairwise comparisons were made 
using a log-rank test. The effect, in patients over the age of 70 years, of extent of 
pathological response to neoadjuvant chemotherapy and 3D-conformal external-beam 
radiation therapy (either followed by surgical resection or surveillance), tumour 
histology, nodal status, tum our length and AJCC stage on overall survival were 
examined using logistic regression, and optimal cut-offs were determined using the
16.4 .4  SURVEILLANCE
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maximal chi-squared method. Significant univariate factors were included in a Cox 
proportional hazards regression model to  establish independent predictors of survival. 
Further substratification analysis was performed where necessary using the Mantel- 
Haenszel test351. P values of less than 0.05 were considered statistically significant.
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6.5.1 PATIENT CHARACTERISTICS
Records from Connolly Hospital Oesophageal Cancer Database were extracted for a 90- 
month period between January 2000 and July 2007. One hundred and twenty-nine 
patients over the age of 70 presented during this period. Following multidisciplinary 
discussion, 66 patients were considered to have disease too advanced (n=41) or were 
too unfit fo r curative intent (n=25) and were treated with palliative measures. Sixty- 
three patients were treated with curative intent, seven of whom underwent surgery 
alone.
Fifty-six patients completed neoadjuvant chemoradiotherapy for locoregionally 
advanced AC or SCC of the oesophagus and fulfilled the selection criteria. These 56 
patients formed the current study cohort.
All 56 patients were 70 years or older, 25 patients (45%) were aged 75 years or older 
and 10 patients (18%) were 80 years or older. The mean age was 75 years, ranging 
from 70 to 83 years. Thirty-five patients (62%) were male, with a male to female ratio 
of 1.7:1.
6.5 RESULTS
149
Of the 56 patients, 33 (59%) had AC and 23 (41%) had SCC. Three tumours were well 
differentiated (5%), 28 were moderately differentiated (50%) and 25 were poorly 
differentiated (45%).
| 6.5.3 RESPONSE TO CHEMORADIOTHERAPY
Thirty-one of the 56 patients (55%) had residual disease on endoscopy post- 
chemoradiotherapy. Twenty-five (45%) had a CCR: 36% of ACs (n=12) and 54% of SCCs 
(n=13). Of the 25 CCRs, 6 chose immediate resection while 8 declined and 11 were 
deemed unsuitable for surgery and all were placed on intensive surveillance.
Three patients who initially had a CCR had re-emergence of tumour and underwent an 
interval oesophagectomy following detection of recurrence at 11 months in two 
patients and at 12 months in one patient. The remaining 16 patients continued to be 
followed-up clinically.
16.5.4 FOLLOW-UP
Follow-up ranged between 2 and 116 months from date of diagnosis with no patients 
lost to follow-up. The overall mean survival for the entire cohort was 28 months with a 
median of 14 +/-1-8 months.
6.5.2  TUMOUR CHARACTERISTICS
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j 6.5.5 COMPLETE CLINICAL RESPONSE
Twenty-five patients had a complete clinical response. The mean overall survival of this 
cohort was 47 months with a median survival of 35 +/- 28.8 (95% confidence interval 
(Cl) 0-91 months). Overall, patients with a CCR had a survival advantage over those 
who had an incomplete clinical response (ICR) (p < 0.001) (Figure 20).
Figure 20: Kaplan-Meier Plot Of Overall Survival Of Patients With Oesophageal Cancer With 
Complete Clinical Response Versus Incomplete Clinical Response.
| 6.5.5.1 COMPLETE CLINICAL RESPONSE AND IMMEDIATE RESECTION 
Of the six patients with a CCR who underwent immediate resection, four (67%) also had 
a complete pathological response (CPR) while one had stage 2a and one had stage 2b 
disease. One of these latter patients died at 12 months of recurrence and one is alive
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at 111 months at completion of this study. Of the four patients with a CPR, one died at 
86 months without autopsy, one died at 35 months from an unknown cause and a third 
died at 8 months of metastatic disease. The remaining patient was alive at 112 months 
at completion of this study. The mean survival of this subgroup was 61 months with a 
median survival of 35 +/-10 months.
| 6.5.5.2 COMPLETE CLINICAL RESPONSE AND INTERVAL SURGERY 
Three patients who had a CCR had an interval oesophagectomy following detection of 
recurrent disease on surveillance. Mean survival of these patients was 29 months. One 
of these patients was alive at 47 months at completion of this study, whilst two died of 
metastatic disease at 28 and 12 months.
| 6.5.5.3 COMPLETE CLINICAL RESPONSE AND NON-OPERATIVE MANAGEMENT 
Sixteen patients with a CCR did not have surgery and had a mean survival 46 months 
(range 6-116) and a median survival of 24 +/- 36 months. The 1, 2, 3 and 5 year survival 
of this patient cohort was 88% (n=14), 56% (n=9), 50% (n=8), 44% (n=7). Seven patients 
died from recurrence or metastases, three died secondary to pneumonia, one from 
multi-organ failure and one from thoracic empyema366. Four patients (25%) were alive 
at completion of this study at 39, 64 and two at 88 months.
Patients with CCR who did not undergo surgery had a similar overall survival to those 
who underwent surgery (median 55.1 +/- 11 months) when compared to those 
undergoing oesophagectomy (median 56.4 +/-14 months; p=0.861) (Figure 21).
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Figure 21: Kaplan-Meier Plot of Survival of Patients With Oesophageal Cancer With Complete 
Clinical Response To Chemoradiotherapy Managed Operatively Versus Non-Operatively.
6.5.6 INCOMPLETE CLINICAL RESPONSE
I 6.5.6.1 INCOMPLETE CLINICAL RESPONSE UNDERGOING RESECTION 
Thirty-one patients had residual disease on endoscopy post-chemoradiotherapy. Of 
these, 8 underwent surgery with AJCC stage 1 in one patient, stage 2a in three patients, 
stage 2b in one patient and stage 3 in three patients. Fifty percent of patients had 
positive lymph nodes. Five of these eight died from metastases at 7, 10,12,16 and 17 
months and three were alive at 36, 45 and 76 months at completion of this study.
6.5.6.2 INCOMPLETE RESPONSE AND NON-OPERATIVE MANAGEMENT 
Twenty-three patients with an incomplete response did not undergo surgery. Of these, 
two died of pneumonia and two of myocardial infarctions before surgery could be 
considered. Five patients refused surgery due to advancing years (aged 78-81). A 
further five patients had progressive disease on treatment and eight had 
cardiorespiratory conditions with deterioration of performance status which precluded 
surgery. One final patient died of an upper gastrointestinal bleed at 13 months and had 
declined surgery due to age (aged 81). The mean survival of this cohort was 8 months 
(range 2-17 months) with a one-year survival of 30% (n=7) and a median survival of 6 
+/-11 months (95% Cl = 3.6 - 8.3 months).
Of patients who had an incomplete response, those who had completion 
oesophagectomy had a statistically-significant overall survival advantage (median 36.2 
+/- 10 months) compared with those who underwent surveillance (median 7.9 +/- 1 
month, p = 0.006) (Figure 22).
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Figure 22: Kaplan-Meier Plot Of Survival Of Patients With Oesophageal Cancer With 
Incomplete Clinical Response To Chemoradiotherapy Managed Operatively Versus Non-
Operatively.
| 6.5.7 LYMPH NODE STATUS
Sixty-four percent of those who underwent immediate surgery following 
chemoradiotherapy (9/14) were lymph node negative. Eighty-three percent of those 
who had a CCR and who had surgery (5/6) went on to have lymph node negative 
disease. Two of the three patients who had an interval oesophagectomy were also 
lymph node negative. Those who were lymph node negative had a mean survival of 44 
months (range 8-112 months) and those with node positive disease had a mean 
survival of 31 months (range 7-111 months) (p=0.03).
155
| 6.5.8 HOSPITAL MORTALITY
There was one (6%) in-hospital mortality following surgery in this series. This occurred 
in a patient with a 50-pack year smoking history and was due to respiratory 
complications.
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In the past, the majority of older patients diagnosed with oesophageal cancer were 
treated palliatively due to the combination of poor prognosis, shorter life expectancy 
and co-existent co-morbid conditions. With the rapidly aging global population314 we 
are now more frequently encountering older patients with oesophageal carcinoma4 for 
whom it is difficult to decide on best treatment, not least due to the exclusion of these 
patients in most randomised trials of gastrointestinal cancers392'393, despite the fact 
that the majority of cancers occur in this age cohort391.
It has long been insisted upon that the best hope of cure for oesophageal cancer is 
surgery, alone or following neoadjuvant therapy. While this may hold for younger, 
fitter patients, it may not prove true for the elderly or for patients with significant 
comorbidity. While several series have shown oesophagectomy to be tolerable in 
elderly patients394, 398, 3", including following chemoradiotherapy400, there is 
considerable patient selection as only a small minority of elderly patients diagnosed 
with oesophageal cancer are referred for oesophagectomy398,3". Many studies quote 
high co-morbidity rates of up to 86%401'404, lower resection eligibility rates394,395, higher 
post-operative complication rates394' 395 and mortality rates394'396, 405 following 
oesophagectomy being increased up to two-fold in those over the age of 80122. Thus 
the role of surgery in patients older than 70 years is still unclear but appears 
appropriate only for a minority.
6.6 DISCUSSION
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Several che mo radiotherapy regimes have been shown to be tolerable in the older age 
groups402,406-408 so patients should not be excluded from potentially curative treatment 
based on age alone402, 403, 409, 410 The advantages of providing neoadjuvant 
chemoradiotherapy include that as the majority of patients with "curable" disease have 
systemic micrometastases119,266,371,372 and the systemic component of the treatment 
will address the systemic component of the disease, enhancing survival over surgery 
alone218'220. Of greater importance is the fact that over one third of patients 
undergoing neoadjuvant chemoradiotherapy will have a CPR and should not require 
resection. Not only can they not benefit from surgery but are unnecessarily exposed to 
the considerable risk of mortality, severe morbidity and lifelong negative impact on 
quality of life123 134. The majority of patients treated with neoadjuvant 
chemoradiotherapy will have a CCR403 with median survival of up to 35 months402. We 
have previously shown that the majority of patients with a CCR have a CPR373. In recent 
years the CPR rate from chemoradiotherapy has increased dramatically with rates of up 
43% for advanced locoregional disease and up to 82.5% for early disease now being 
reported191,213.
While it is obvious that those with residual disease may benefit from surgery, the 
benefit to those with a CCR until now has been less clear. In this study, we have shown 
that patients who had chemoradiotherapy followed by surgery had no statistically 
significant survival advantage over those who had a CCR to chemoradiotherapy but 
who did not have surgery (p=0.861) with a 1, 2, 3 and 5-year survival of 83, 67, 67 and 
50% compared with 88, 56, 50 and 44% respectively. Others have shown that the 
combination of chemotherapy and concurrent radiotherapy alone can lead to similar 
long-term survival to surgical monotherapy and surgery following neoadjuvant
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treatment179, 183, 41\ There is only one randomised controlled trial of 80 patients 
comparing definitive chemoradiotherapy alone and surgery alone412. This study by 
Chiu et al, however, did not include patients with adenocarcinoma, had a mean age of 
only 62 and excluded patients over the age of 75 and those with significant co- 
morbidity412. Standard oesophagectomy or chemoradiotherapy seemed to offer similar 
early clinical outcome and survival. Similar results were noted in a Japanese non­
randomised retrospective comparison of definitive chemoradiotherapy and radical 
surgery in patients with resectable squamous cell carcinoma186 with overall survival and 
disease-free survival rates at 3-years were 48% and 44% in the chemoradiotherapy 
group and 65% and 59% in the surgery group, respectively. Again patients in the 70-79 
age-group were excluded. Thus chemoradiotherapy results in survival comparable with 
conventional surgery.
Salvage oesophagectomy may be offered those with an incomplete response to 
chemoradiotherapy or recurrent disease. It is accepted, however, that salvage surgery 
for re-emergent disease will not be as successful as immediate surgery, since tumour 
detected in the lumen on surveillance endoscopy may not represent early disease, but 
instead may represent "the tip of the iceberg" of a recurrence from without the 
oesophageal lumen. The patients who had salvage oesophagectomy in our study had a 
mean survival of 29 months and five-year survival rates of up to 25-35 per cent can be 
achieved in selected patients after local failure of chemoradiotherapy246 with most 
series, however, reporting on younger cohorts246.
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In conclusion, we identified a number of trends in this study. Almost half of all older 
patients completing treatment had a CCR. Two-thirds of those with a CCR and who 
underwent resection had a CPR, which is similar to that previously reported for all 
patients373. Furthermore, those managed non-operatively had comparable survival to 
those managed with additional radical surgery. Several studies, including ours, have 
shown that chemoradiotherapy may provide a CPR in one third of patients obviating 
the need for surgery in this cohort with its attendant risks and negative impact on 
quality of life. The 3-year survival of 50% in this cohort compares with the best results 
of more selective series of younger patients and is an attractive option to both patients 
and clinicians. Larger-scale randomised trials inclusive of older patients which compare 
radical chemoradiotherapy with surgery alone in both adenocarcinoma and squamous 
cell carcinoma are necessary but may pose difficulties in recruitment of patients and 
treating clinicians alike. In their absence, it would appear reasonable to consider 
treating all potentially curable patients with neoadjuvant therapy and electing to 
observe patients achieving a complete clinical response.
6.7 CONCLUSION
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CHAPTER V II:  STUDY 5
THE PREDICTIVE VALUE OF MOLECULAR MARKERS P53, VEGF AND 
METALLOTHIONEIN IN MULTIMODALLY TREATED OESOPHAGEAL 
CARCINOMA.
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Background. While neoadjuvant chemoradiotherapy allows improved survival over 
surgery alone for resectable oesophageal cancer, unresponsive patients are exposed to 
the negative-effects of therapy with little benefit. It would be advantageous to identify 
responsive patients. Because of their role in apoptosis and thus suspected involvement 
in treatment resistance, the molecular markers p53, metallothionein and VE6F have 
been examined as prognostic indicators in oesophageal cancer with variations in results 
largely due to study heterogeneity.
Aims. To determine whether the expression of the molecular markers p53, 
metallothionein and VEGF, alone or in combination can predict response and survival 
following neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
Methods. Immunohistochemical analysis was performed on pre- and post­
neoadjuvant chemoradiotherapy oesophageal tumour samples from 76 patients for 
expression of p53, VEGF and metallothionein and correlated with response and 
outcome.
Results: Pre-treatment negative expression of p53 was an independent predictor of 
survival (p<0.001). While pre-treatment tumours positive for metallothionein 
expression and post-treatment p53 and VEGF negativity showed a trend towards 
improved survival, this was not statistically significant. On combining factors, a survival 
advantage was identified with the association of pre-treatment tumours negative for 
p53 and VEGF and positive for metaJJothionein expression compared with all other 
combinations (p<0.001). None of the markers predicted response to treatment.
7.1 ABSTRACT
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C o n c lu s io n . W h i le  th e s e  re s u lts  s h o w  p o te n t ia l  f o r  c lin ic a l a p p lic a t io n , t h e r e  is an  
o b v io u s  n e e d  f o r  c o n f irm a t io n  o f  th e s e  o b s e rv a tio n s  in  a p ro s p e c t iv e  s tu d y  w ith  
s ta n d a rd is e d  te c h n iq u e s  in  w e l l -d e f in e d  p a t ie n t  c o h o rts  a n d  s h o u ld  b e  th e  s u b je c t o f  
fu tu r e  re s e a rc h . It  is lik e ly  t h a t  a c o m b in a t io n  o f  m a rk e rs  w il l  y ie ld  t h e  m o s t p ro m is in g  
re s u lts .
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N e o a d ju v a n t  c h e m o ra d io th e r a p y  p ro v id e s  a s u rv iv a l a d v a n ta g e  o v e r  s u rg e ry  a lo n e  fo r  
r e s e c ta b le  o e s o p h a g e a l c a n c e r182' 215222 w ith  th e  g re a te s t  b e n e f i t  in th o s e  w ith  a 
c o m p le te  re s p o n s e 203,209, Z10,212,360’365. T h o s e  w h o  d o  n o t re s p o n d  a re  u n lik e ly  to  d e r iv e  
b e n e f i t  b u t a re  e x p o s e d  to  its s id e -e f fe c ts  a n d  s o m e  h a v e  d is e a s e  p ro g re s s io n  d u r in g  
t r e a t m e n t 182,184,413. A ll in c u r  c o n s id e ra b le  c o s t, w h ic h  is a m a jo r  c o n s id e ra t io n  in a t im e  
o f  e c o n o m ic  d if f ic u lty . T h e  c h ie f  s h o r tc o m in g  o f  n e o a d ju v a n t  c h e m o ra d io th e r a p y  it 
t h a t  is s till n o t  p o s s ib le  t o  k n o w , in a d v a n c e  o f  t r e a t m e n t ,  w h ic h  p a t ie n ts  w il l  re s p o n d  
a n d  w h ic h  p a t ie n ts  w ill n o t b e n e f i t  o r  in d e e d  a r e  h a rm e d  by t r e a t m e n t 143.
M u c h  e f f o r t  has b e e n  e x p e n d e d  o n  te c h n iq u e s  to  p re d ic t  o u tc o m e  a n d  re s p o n s e  to  
t r e a t m e n t  in o e s o p h a g e a l c a n c e r . M e th o d s  su ch  as h is to lo g ic a l in d ic e s , c lin ic a l 
p a r a m e te r s ,  ra d io lo g ic a l im a g in g , a n d  a w id e  ra n g e  o f  s e ru m  a n d  tis s u e  m a rk e rs 270 
h a v e  b e e n  e x p lo re d  a n d  w h ils t  m a n y  s h o w  p o te n t ia l  f o r  c lin ic a l a p p lic a t io n , to  d a te  no  
o n e  te c h n iq u e  has e m e r g e d  in r o u t in e  c lin ic a l p ra c tic e .
R e s p o n s e  a n d  re s is ta n c e  o f  c a n c e r  cells  to  c h e m o th e r a p y  a n d /o r  ra d io th e ra p y  m a y  b e  
in f lu e n c e d  by t h e ir  p ro p e n s ity  t o  u n d e rg o  a p o p to s is  w h ic h , w h e n  in d u c e d  b y  
c h e m o ra d io th e r a p y ,  in v o lv e s  v a r io u s  b io lo g ic a l p ro c e s s e s  su ch  as D N A  re p a ir , a lte r e d  
d ru g  m e ta b o lis m , in f la m m a t io n  a n d  a lte r a t io n  o f  th e  ce ll c y c le 287,288. T h e  m o le c u la r  
m a rk e rs  p 5 3 , m e ta l lo th io n e in  a n d  v a s c u la r  e n d o th e l ia l  g r o w th  fa c to r  (V E G F ) a ll p la y  a 
c e n tra l ro le  in th is  p ro c e s s  a n d  m a y  b e  d e te c te d  by im m u n o h is to c h e m ic a l m e a n s  in 
tu m o u r s .
7.2 INTRODUCTION
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T h u s  p 5 3 271'286 , m e t a l lo th io n e in 308 310,316,317 a n d  V E G F 334' 336,337 h a v e  a ll b e e n  s tu d ie d  
in d iv id u a lly  o r  c o m b in e d  w ith  o t h e r  m a rk e rs  to  a v a ry in g  d e g re e  in o e s o p h a g e a l a d e n o -  
a n d  s q u a m o u s  ce ll c a rc in o m a , w ith  p ro m is in g  re s u lts . T o  d a te , h o w e v e r , th e y  h a v e  n o t  
b e e n  s h o w n  to  b e  s u f f ic ie n tly  a c c u ra te  o n  t h e ir  o w n , a n d  s tu d y  c o m p a ris o n  is d iff ic u lt  
d u e  in p a r t  to  d if fe r in g  te c h n iq u e s  a n d  tu m o u r  ty p e s  a n d  v a r ia b il i ty  o f  re s u lts . N o r  
h a v e  th e s e  m a rk e rs  b e e n  s tu d ie d  to g e th e r  t o  assess p ro g n o s is  a n d  re s p o n s e  to  
n e o a d ju v a n t  c h e m o ra d io th e r a p y . U s in g  im m u n o h is to c h e m is t ry , a p ro cess  a c h ie v a b le  in 
m o s t la b o ra to r ie s , th e s e  th r e e  t is s u e  m a rk e rs  in c o m b in a t io n  m a y  o f fe r  v a lu a b le  
p re d ic t iv e  in fo rm a t io n .
T h e  a im  o f  th is  s tu d y , th e r e f o r e ,  w a s  to  d e t e r m in e  w h e t h e r  th e  e x p re s s io n  o f  th e  
m o le c u la r  m a rk e rs  p 5 3 , m e ta l lo th io n e in  a n d  V E G F , c o r re la te s  w ith  re s p o n s e  to  
t r e a t m e n t  a n d  s u rv iv a l in p a t ie n ts  w ith  a d e n o c a rc in o m a  a n d  s q u a m o u s  ce ll c a rc in o m a  
o f  th e  o e s o p h a g u s  w h o  u n d e rg o  n e o a d ju v a n t  c h e m o ra d io th e r a p y .
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7 . 3  A IM
T o  e x a m in e  th e  ro le  o f  p 5 3 , V EG F a n d  m e ta l lo th io n e in  as p re d ic tiv e  m a rk e rs  fo r  
re s p o n s e  to  n e o a d ju v a n t  c h e m o ra d io th e r a p y  a n d  o u tc o m e  in o e s o p h a g e a l c a n c e r  a n d  
t o  e s ta b lis h  if  th e ir  c o m b in a t io n  w o u ld  p ro v e  m o re  e f fe c t iv e  th a n  th e s e  in d iv id u a l 
m a rk e rs  o n  t h e ir  o w n .
7 . 4  P A T IE N T S  A N D  M E T H O D S
7 . 4 . 1  P A T IE N T S
F o llo w in g  C o n n o lly  H o s p ita l e th ic s  c o m m it te e  a p p ro v a l, 7 6  p a t ie n ts  w h o  h ad  
u n d e rg o n e  n e o a d ju v a n t  t r e a t m e n t  fo r  o e s o p h a g e a l c a rc in o m a  b e tw e e n  J a n u a ry  2 0 0 0  
a n d  D e c e m b e r  2 0 0 7  w e r e  id e n t if ie d  f r o m  th e  p ro s p e c t iv e ly -m a in ta in e d  C o n n o lly  
H o s p ita l O e s o p h a g e a l C a n c e r  D a ta b a s e . A ll p a t ie n ts  h a d  a h is to lo g ic a lly  p ro v e n  
d ia g n o s is  o f  p r im a ry  o e s o p h a g e a l a d e n o -  o r  s q u a m o u s  ce ll c a rc in o m a  f r o m  b io p s ie s  
o b ta in e d  a t o e s o p h a g o s c o p y . T h e s e  p a t ie n ts  h a d  p re -  o r  p o s t o r  p re -  a n d  p o s t­
t r e a t m e n t  p a th o lo g y  s p e c im e n s  id e n t if ie d  as r e tr ie v a b le  f r o m  th e  C o n n o lly  H o s p ita l 
p a th o lo g y  s p e c im e n  a rc h iv e .
| 7 . 4 . 2  N E O A D J U V A N T  C H E M O R A D IO T H E R A P Y
A ll p a t ie n ts  w e r e  t r e a te d  w ith  n e o a d ju v a n t  c h e m o ra d io th e r a p y  as d e s c r ib e d  
p re v io u s ly 182. In b r ie f , th is  c o n s is te d  o f  tw o  cyc les  o f  5 - f lu o r o u r a c il  a n d  c is p la tin  d u r in g  
w e e k s  o n e  a n d  six, w ith  c o n c u rre n t  ra d io th e ra p y  (4 0  G y) in 1 5  fra c tio n s . T h o s e  w h o  
u n d e r w e n t  o e s o p h a g e c to m y  h a d  s u rg e ry  o n  o r  a f t e r  w e e k  8 .
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I 7 . 4 . 3  P A T H O L O G IC A L  S T A G E
F o llo w in g  n e o a d ju v a n t  t r e a t m e n t ,  th o s e  w h o  u n d e r w e n t  s u rg ic a l re s e c tio n  h a d  tu m o u r  
s ta g in g  as d e f in e d  a c c o rd in g  to  th e  A m e r ic a n  J o in t C o m m it te e  o n  C a n c e r  
c la s s ific a tio n 414. A  c o m p le te  p a th o lo g ic a l re s p o n s e  (C PR ) w a s  d e f in e d  by th e  a b s e n c e  o f  
re s id u a l t u m o u r  in th e  re s e c te d  s p e c im e n  a n d  in th e  ly m p h  n o d e s .
17 . 4 . 4  I M M U N O H IS T O C H E M IS T R Y
F o rm a lin -f ix e d  p a r a f f in -e m b e d d e d  t is s u e  b lo c k s  o f  s p e c im e n s  w e r e  ro u t in e ly  p ro c e s s e d  
fo r  h is to p a th o lo g ic a l a s s e s s m e n t o f  tu m o u r  ty p e , g ra d e  a n d  v a s c u la r  in v a s io n  a n d  
s ta g in g . P a tie n ts  a n d  c o r re s p o n d in g  s p e c im e n s  o f  p r e -  a n d  p o s t - t r e a tm e n t  b io p s ies  
a n d  re s e c tio n  s p e c im e n s  w e r e  id e n t if ie d  f r o m  th e  p ro s p e c t iv e ly  m a in ta in e d  C o n n o lly  
H o s p ita l O e s o p h a g e a l C a n c e r  D a ta b a s e  a n d  tis s u e  b lo c k s  w e r e  r e tr ie v e d  f r o m  th e  
C o n n o lly  H o s p ita l p a th o lo g y  s p e c im e n  a rc h iv e . F o u r  m ic ro n  s e c tio n s  w e r e  c u t f r o m  
th e s e  b lo cks  a n d  m o u n te d  o n  Leica  M ic ro s y s te m s  "P lu s" s lid es .
T o  o v e rc o m e  s o m e  o f  th e  lim ita t io n s  a n d  v a r ia b il i ty  o f  im m u n o h is to c h e m ic a l s ta in in g , 
a ll tis s u e  s e c tio n s  w e r e  p ro c e s s e d  in th e  s a m e  m a n n e r  o n  a s in g le  a u to m a te d  s ta in in g  
s y s te m . Th is  w a s  p e r fo rm e d  w ith  th e  B o n d M a x  a u to m a te d  s ta in in g  s y s te m  f r o m  Leica  
M ic ro s y s te m s  (N e w c a s t le -U p o n -T y n e , U K ). B o n d M a x  s o f tw a r e  4 .0  w a s  th e n  u sed  to  
ru n  th e  o p t im a l p ro to c o l fo r  th e  s e le c te d  a n t ib o d y  m a r k e r  a n d  h e n c e  a n t ig e n  to  b e  
d e m o n s tr a te d .  L a b e lle d  s lid es  w e r e  lo a d e d  o n to  th e  in s tr u m e n t  a n d  d e p a ra ff in is a t io n  
w a s  c a r r ie d  o u t  u s in g  B o n d ™  D e w a x  s o lu t io n  (L e ica  M ic ro s y s te m s , N e w c a s t le -U p o n -  
T y n e , U K ). F o llo w in g  d e p a ra f f in is a t io n , a n t ig e n  r e tr ie v a l w a s  p e r fo rm e d  w ith  h e a t -  
in d u c e d  e p i to p e - r e t r ie v a l  us in g  B o n d ™  E p ito p e  R e tr ie v a l s o lu t io n  (L e ic a  M ic ro s y s te m s ,
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N e w c a s t le -U p o n -T y n e , U K ) fo r  2 0  m in u te s . F o llo w in g  th is  t h e  p r im a r y  a n t ib o d y  w a s  
a p p lie d  ( i.e . e i th e r  a n t i-V E G F , a n t i-p 5 3  o r  a n t i - m e ta l lo th io n e in ) .  A  s e c o n d a ry  a n t ib o d y  
fo llo w e d  by a p o ly m e r  c o n ta in in g  h o rs e ra d is h  p e ro x id a s e  w h ic h  b in d  to  t h e  p r im a ry  
a n t ib o d y  w e r e  n e x t  a p p lie d . F in a lly  3 ,3 '  d ia m m o b e n z in e tr a h y d ro c h lo r id e  (D A B ), a 
c h ro m o g e n  w h ic h  p ro d u c e s  a b ro w n  e n d  p r o d u c t  a n d  w h ic h  is h ig h ly  in s o lu b le  in 
a lc o h o l a n d  o t h e r  o rg a n ic  s o lv e n ts , w a s  a p p lie d . A n y  a n t ig e n ic  s ites  p re s e n t  in th e  
t is s u e  to  w h ic h  t h e  p r im a ry  a n t ib o d y  b in d s , w e r e  th u s  s ta in e d  a n  in te n s e  b ro w n  c o lo u r. 
T h e  re a g e n ts  e m p lo y e d  in th is  in s ta n c e  w e r e  th e  c o m m e rc ia lly  a v a ila b le  M o n o c lo n a l  
M o u s e  A n t i-H u m a n  A n t ib o d ie s  p 5 3  (D O -7 )  a n d  V a s c u la r  E n d o th e lia l G r o w th  F a c to r  
(V G 1 ) a n d  M o n o c lo n a l M o u s e  A n t i-M e ta l lo th io n e in  C lo n e  (E 9 ), D a k o . E x a m p le s  
tu m o u rs  w ith  p o s it iv e  e x p re s s io n  o f  p 5 3 , M e ta l lo th io n e in  a n d  V EG F a re  s h o w n  in 
F ig u re  2 3  A , B a n d  C .
O n c e  th e  s lides w e r e  lo a d e d , t h e  p ro cess  w a s  a llo w e d  t o  c o n t in u e  to  c o m p le t io n  w h e r e  
fu lly  s ta in e d  s lid es  w e r e  c o v e r -s lip p e d . S p e c im e n s  o f  n o rm a l o e s o p h a g e a l m u co s a  
w e r e  used  as a p o s it iv e  c o n tro l.  T h e  p r im a ry  a n t ib o d y  w a s  o m it te d  a n d  s ta in in g  
r e p e a te d  as a n e g a t iv e  c o n tro l.
A n a ly s is  o f  th e  im m u n o h is to c h e m ic a lly  s ta in e d  s lid es  w a s  p e r fo r m e d  b y  a s in g le  
P a th o lo g is t. S ta in in g  w a s  c o n s id e re d  p o s it iv e  fo r  p 5 3  w h e n  m o re  th a n  1 0 %  o f  th e  ce lls ' 
n u c le i w e r e  s tro n g ly  s ta in e d 337. T h e  s ta in in g  p a t te r n  o f  m e ta l lo th io n e in  a n d  V E G F  is 
c y to p la s m ic  a n d /o r  m e m b ra n o u s  a n d  s ta in in g  w a s  c o n s id e re d  p o s it iv e  w h e n  m o re  th a n  
1 0 %  o f  th e  tu m o u r  ce lls  w e r e  s tro n g ly  s ta in e d 279, 309, 337. E v a lu a tio n  o f  th e  
im m u n o r e a c t iv ity  o f  s p e c im e n s  w a s  p e r fo rm e d  w it h o u t  k n o w le d g e  o f  th e  p a t ie n ts '
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c lin ic o p a th o lo g ic a l s ta tu s  o r  o u tc o m e ; T h e  d e g re e  o f  e x p re s s io n  w a s  th e n  c o m p a re d  
w ith  a n u m b e r  o f  t u m o u r  a n d  p a t ie n t  v a r ia b le s  a n d  c o r r e la te d  w ith  o u tc o m e .
Figure 23: Exam ples o f slides d isp lay ing  high levels o f  expression o f p 53  in a d e n o carc in o m a  
(A ), m e ta llo th o n e in  in ad e n o c a rc in o m a  (B) and VEGF in sq uam ous cell carc in o m a (C).
7 . 4 . 5  F O L L O W - U P
F o r th e  p u rp o s e s  o f  th is  s tu d y , a ll p a t ie n ts  w e r e  fo llo w e d -u p  u n t il  th e  d a te  o f  d e a th  o r  
las t c lin ic a l in te ra c t io n . F o llo w -u p  a n d  c a u s e  o f  d e a th ,  if  a p p lic a b le , w a s  d e te r m in e d  by  
te le p h o n e  c o m m u n ic a t io n  w it h  t h e ir  G e n e ra l P ra c t it io n e r ,  r e v ie w  o f  p a t ie n t  re c o rd s  o r  
s e a rc h e s  in th e  A rc h iv e s  o f  th e  N a t io n a l D e a th  R e g is try  O ffic e s , D u b lin , Ire la n d .
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| 7 . 4 . 6  S T A T IS T IC A L  A N A L Y S IS
S ta tis tic a l a n a ly s e s  w e r e  p e r fo rm e d  w ith  P A S W  v e rs io n  1 8 .0  f o r  W in d o w s . C o n tin u o u s  
v a r ia b le s  w e r e  e x p re s s e d  as m e d ia n  ±  s ta n d a rd  d e v ia t io n  o r  m e a n  ±  s ta n d a rd  e r ro r  o f  
th e  m e a n  as a p p r o p r ia te  a n d  w e r e  c o m p a re d  u s in g  a tw o -s a m p le  t - te s t .  C a te g o r ic a l  
a n d  p a ire d  v a r ia b le s  w e r e  c o m p a re d  u s in g  a c h i-s q u a re d  te s t .  S u rv iv a l p ro b a b ilit ie s  fo r  
c lin ic a l, p a th o lo g ic a l, a n d  t r e a t m e n t  v a r ia b le s  w e r e  e s t im a te d  by th e  K a p la n - M e ie r  
m e t h o d 350 a n d  p a irw is e  c o m p a ris o n s  w e r e  m a d e  u s in g  a lo g - r a n k  te s t .  T h e  p re d ic tiv e  
v a lu e  o f  p r e -  a n d  p o s t - th e ra p y  o e s o p h a g e a l b io p s y  V E G F , p 5 3  a n d  m e ta l lo th io n e in  o f  
th e  e x te n t  o f  p a th o lo g ic a l re s p o n s e  to  n e o a d ju v a n t  c h e m o th e r a p y  a n d  3 D -c o n fo r m a l  
e x te r n a l-b e a m  ra d ia t io n  th e r a p y  ( e i t h e r  fo llo w e d  by s u rg ic a l re s e c tio n  o r  s u rv e illa n c e ),  
tu m o u r  h is to lo g y , n o d a l s ta tu s , tu m o u r  le n g th  a n d  AJCC s ta g e  o n  o v e ra ll s u rv iv a l w e r e  
e x a m in e d  us in g  lo g is tic  re g re s s io n , a n d  o p t im a l c u t -o ffs  w e r e  d e te r m in e d  u s in g  th e  
m a x im a l c h i-s q u a re d  m e th o d . S ig n ific a n t u n iv a r ia te  fa c to rs  .w e r e  in c lu d e d  in a C ox  
p ro p o r t io n a l  h a z a rd s  re g re s s io n  m o d e l to  e s ta b lis h  in d e p e n d e n t  p re d ic to rs  o f  s u rv iv a l. 
P v a lu e s  o f  less th a n  0 .0 5  w e r e  c o n s id e re d  s ta t is t ic a lly  s ig n if ic a n t.
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7 . 5  R E S U L T S
7 . 5 . 1  P A T IE N T  C H A R A C T E R IS T IC S
P a ra f f in -e m b e d d e d  tu m o u r  b lo cks  f r o m  7 6  p a t ie n ts  w ith  c a rc in o m a  o f  th e  o e s o p h a g u s  
w e r e  s tu d ie d . T h e  m e a n  a g e  w a s  6 4  y e a rs  (ra n g e  3 8 -8 3  y e a rs ). T h e  m a le  to  fe m a le  ra t io  
w a s  2 :1 . O v e ra ll s u rv iv a l ra n g e d  b e tw e e n  0 .5 - 1 1 1  m o n th s  f r o m  d a te  o f  d ia g n o s is  w ith  a 
m e a n  o f  2 3  m o n th s .
A ll w e r e  t r e a te d  w ith  n e o a d ju v a n t  c h e m o ra d io th e r a p y  a n d  a ll h a d  p re -a n d  p o s t­
t r e a t m e n t  e n d o s c o p y  a n d  b io p s y  (a t  le a s t 1 0  p e r  s ess io n ) a n d  3 7  w e n t  o n  to  s u rg ica l 
re s e c tio n . T h e  r e m a in d e r  d e c lin e d  o r  w e r e  n o t o f fe r e d  re s e c tio n  d u e  to  c o -m o r b id ity ,  
d e te r io r a t io n  in p e r fo rm a n c e  s ta tu s  o r  p ro g re s s iv e  d is e a s e .
7 . 5 . 2  T U M O U R  C H A R A C T E R IS T IC S
F o r ty -n in e  (6 4 % ) p a t ie n ts  h a d  a d e n o c a rc in o m a  a n d  2 7  (3 6 % ) p a t ie n ts  h a d  s q u a m o u s  
c e ll c a rc in o m a . F ive  tu m o u rs  (7 % ) w e r e  w e l l - d i f fe r e n t ia te d ,  4 1  (5 4 % ) w e r e  m o d e ra te ly -  
d if f e r e n t ia te d  a n d  th e  re m a in in g  3 0  (3 9 % ) w e r e  p o o r ly -d if fe r e n t ia te d .  T u m o u r  g ra d e  
w a s  p re d ic t iv e  o f  s u rv iv a l, w ith  m o d e r a te ly -  a n d  p o o r ly -d if fe r e n t ia te d  tu m o u rs  
c o n fe rr in g  a s ig n if ic a n t ly -s h o rte r  m e d ia n  s u rv iv a l t im e  ( 1 2 + / - 2 .7  a n d  1 2 .5 + /- 1 - 8  
m o n th s )  c o m p a re d  w ith  w e l l - d i f fe r e n t ia te d  tu m o u r s  (6 1 + / -4 0 m o n th s )  (p = 0 .0 3 9 ) .  T h e  
a v e ra g e  tu m o u r  le n g th , m e a s u re d  o n  in it ia l e n d o s c o p y , w a s  5 c m  (ra n g e  l - 1 2 c m ) .  In it ia l  
tu m o u r  le n g th  w a s  p o o r ly -p re d ic t iv e  o f  s u rv iv a l (p = 0 .3 2 5 ) .
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T h ir ty - fo u r  p a t ie n ts  u n d e r w e n t  re s e c tio n , o f  w h o m  5 (1 5 % ) h a d  a CPR, w h ile  2 9  (8 5 % )  
h a d  re s id u a l d is e a s e  in th e  re s e c te d  s p e c im e n . O v e ra ll,  8 %  p e rc e n t  o f  a ll 
a d e n o c a rc in o m a s  ( 2 /2 5 )  a n d  3 3 %  o f  s q u a m o u s  ce ll c a rc in o m a s  ( 3 /9 )  h a d  a CPR. T h e  
p o s t - t r e a tm e n t  AJCC d is e a s e  s ta g e  in th e s e  p a t ie n ts  w ith  re s id u a l d is e a s e  w a s  s ta g e  1 
in 1 p a t ie n t ,  2 a  in 7  p a t ie n ts , s ta g e  2 b  in 1 0  p a t ie n ts  a n d  s ta g e  3  in 1 0  p a t ie n ts  a n d  
s ta g e  4  w ith  p e r ito n e a l m e ta s ta s e s  in 1 p a t ie n t  1 4  o f  th e  3 4  p a t ie n ts  w e r e  ly m p h  n o d e  
n e g a t iv e  (4 1 % ).
| 7 . 5 . 3  D E T E C T IO N  O F  T U M O U R
O f  1 8 9  p r e - t r e a t m e n t  e n d o s c o p ic  b io p s y  o f  tu m o u r s  s a m p le d  fo r  th is  s tu d y , 3 1  d id  n o t  
d e m o n s tr a te  tu m o u r  (1 6 % ), a lth o u g h  tu m o u r  w a s  d e te c te d  in th e s e  p a t ie n ts  o n  fo rm a l  
p r e - t r e a t m e n t  h is to -p a th o lo g ic a l a s s e s s m e n t. O n e -h u n d r e d  a n d  n in e  p o s t - t r e a tm e n t  
s a m p le s  w e r e  a n a ly s e d , 1 5  o f  w h ic h  w e r e  f r o m  p a t ie n ts  w ith  a c o m p le te  p a th o lo g ic a l  
re s p o n s e  a n d  d id  n o t  d e m o n s tr a te  tu m o u r .  O f  th e  r e m a in d e r  9 4  p o s t - t r e a tm e n t  
s a m p le s  f r o m  p a t ie n ts  w ith  re s id u a l d is e a s e , 2 9  (3 1 % ) s a m p le s  fo r  th is  s tu d y  fa ile d  to  
d e m o n s tr a te  tu m o u r ,  a lth o u g h  tu m o u r  w a s  d e te c te d  o n  fo r m a l h is to -p a th o lo g ic a l  
a s s e s s m e n t w ith  m u lt ip le  s a m p lin g .
| 7.5.3 PATHOLOGICAL RESPONSE AND PROGNOSIS
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I 7 . 4 . 5 . 1  P 5 3  E X P R E S S IO N  P R E -T R E A T M E N T  A N D  T U M O U R  C H A R A C T E R IS T IC S  
A  to ta l  o f  5 9  s a m p le s  f r o m  5 9  p a t ie n ts  w e r e  s ta in e d  fo r  p 5 3 ; 3 8  a d e n o c a rc in o m a s  a n d  
2 1  s q u a m o u s  ce ll c a rc in o m a s . p 5 3  p o s it iv e  s ta in in g  w a s  fo u n d  in 6 6 %  (n = 3 9 )  a n d  3 4 %  
s ta in e d  n e g a t iv e  (n = 2 0 ) .  A  fu r t h e r  4  s a m p le s  d id  n o t  d e m o n s tr a te  tu m o u r  a n d  w e r e  
th u s  e x c lu d e d  f r o m  th e  a n a lys is .
T h e  a v e ra g e  le n g th  o f  tu m o u r  in t h e  tw o  g ro u p s  d id  n o t d i f f e r  s ig n if ic a n tly  w ith  th e  
a v e ra g e  le n g th  in t h e  n e g a t iv e  a n d  p o s it iv e  g ro u p s  o f  5 .7  a n d  5 c m  re s p e c tiv e ly  (ra n g e  
l - 1 2 c m )  (p = 0 .6 8 9 ) .
In  th e  p 5 3  n e g a t iv e  g ro u p , 2 tu m o u r s  w e r e  w e l l - d i f fe r e n t ia te d  (1 0 % ), 1 0  w e r e  
m o d e r a t e ly -d i f f e r e n t ia te d  (5 0 % ) a n d  8  w e r e  p o o r ly -d if fe r e n t ia te d  (4 0 % ) . T h is  
c o m p a re s  w ith  3 (5 % ), 2 4  (6 2 % ) a n d  1 3  (3 3 % ) re s p e c tiv e ly  in t h e  p o s it iv e  g ro u p . P re ­
t r e a t m e n t  p 5 3  s ta tu s  d id  n o t c o r r e la te  w ith  w o rs e  t u m o u r  g ra d e  (p = 0 .6 4 8 ) .
O v e ra ll 2 9 %  o f  a d e n o c a rc in o m a s  ( 1 1 /3 8 )  a n d  4 3 %  o f  s q u a m o u s  ce ll c a rc in o m a s  ( 9 /2 1 )  
d e m o n s tr a te d  n e g a t iv e  e x p re s s io n  o f  p 5 3 . F if ty - f iv e  p e r c e n t  o f  n e g a t iv e  tu m o u r s  w e r e  
a d e n o c a rc in o m a s  ( 1 1 /2 0 )  a n d  4 5 %  w e r e  s q u a m o u s  ce ll c a rc in o m a s  ( 9 /2 0 ) .
| 7.5.4 P53 EXPRESSION PRE-TREATMENT
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I 7 . 4 , 5 . 2  P 5 3  E X P R E S S IO N  A N D  R E S P O N S E  T O  N E O A D J U V A N T  
C H E M O R A D IO T H E R A P V
T w e n ty  p a t ie n ts  in th is  g ro u p  u n d e r w e n t  re s e c tio n , w ith  t h e  AJCC tu m o u r  s ta g e  
o u t l in e d  in T a b le  1 0 . F o r ty - fo u r  p e r c e n t  o f  p 5 3  n e g a t iv e  ( 4 /9 )  a n d  6 4 %  o f  p 5 3  p o s it iv e  
( 7 /1 1 )  s a m p le s  h a d  ly m p h  n o d e  m e ta s ta s is  (p = 0 .4 1 4 ) .  P o s t - t r e a tm e n t  p 5 3  o v e r ­
e x p re s s io n  d ire c t ly  c o r r e la te d  w it h  m o d e r a t e  d i f fe r e n t ia t io n  o f  th e  tu m o u r ,  w h ile  
n e g a t iv e  e x p re s s io n  w a s  o c c u rre d  in b o th  w e l l - d i f fe r e n t ia te d  tu m o u r s  a n d  p o o r ly -  
d if f e r e n t ia te d  tu m o u r s  (p = 0 .0 4 4 ) .
| 7 . 4 . 5 . 3  P 5 3  E X P R E S S IO N  P R E -T R E A T M E N T  A N D  S U R V IV A L  
In  th e  n e g a t iv e  g ro u p , t h e  1 , 2 , 3 a n d  5 -y e a r  s u rv iv a l w a s  8 0 %  (n = 1 6 ) ,  4 5 %  (n = 9 ) ,  3 0 %  
(n = 6 )  a n d  2 0 %  (n = 4 ) . T h is  c o m p a re s  w ith  4 4 %  (n = 1 7 ) ,  1 3 %  (n = 5 ) ,  3 %  ( n = l )  a n d  0 %  in 
t h e  p o s it iv e  g ro u p . T h e  o v e ra ll m e a n  s u rv iv a l f o r  p 5 3  n e g a t iv e  tu m o u r s  w a s  4 8  m o n th s  
(ra n g e  6 -1 0 2  m o n th s ) c o m p a re d  w ith  1 5  m o n th s  (ra n g e  0 .5 - 1 0 0  m o n th s )  fo r  p o s it iv e  
tu m o u r s  (p < 0 .0 0 1 )  (F ig u re  2 4 ) .
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Figure 24: K a p la n -M e ie r  Survival A nalysis C om parin g  Survival T im e  For p 53  Expression P re-
c h e m o ra d io th e ra p y .
! 7 . 4 . 5 . 4  P 5 3  E X P R E S S IO N  P O S T -T R E A T M E N T  A N D  S U R V IV A L  
T h ir ty -s ix  p o s t - t r e a tm e n t  s a m p le s  w e r e  s ta in e d  fo r  p 5 3  e x p re s s io n . T w e n ty  o f  th e s e  
d id  n o t  d e m o n s tr a te  tu m o u r  a n d  w e r e  e x c lu d e d  f r o m  a n a ly s is . O f  th e  r e m a in d e r , 1 3 %  
o f  s a m p le s  (n = 2 )  w e r e  n e g a t iv e  a n d  8 8 %  (n = 1 4 )  w e r e  p o s it iv e  fo r  p 5 3  e x p re s s io n .  
T h e r e  w a s  n o  s ig n if ic a n t d if fe r e n c e  o v e ra ll b e t w e e n  th o s e  w h o  w e r e  n e g a t iv e  fo r  p 5 3  
(m e a n  s u rv iv a l o f  2 1  m o n th s , ra n g e  6 - 3 6  m o n th s )  a n d  th o s e  p o s it iv e  fo r  p 5 3  e x p re s s io n  
p o s t - t r e a tm e n t  (m e a n  s u rv iv a l 2 2  m o n th s , ra n g e  4 -7 2 )  (p = 0 .2 3 5 ) .  H o w e v e r ,  w h ils t  th e  
K a p la n -M e ie r  c u rv e  s h o w s  n o  d if fe r e n c e  in e a r ly  s u rv iv a l w ith  th e  lin es  o v e r la p p in g  a t
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a b o u t  2 0  m o n th s  le a d in g  to  t h e  n o n -s ig n if ic a n t o v e ra ll p -v a lu e , a m a rk e d  d iv e rg e n c e  in  
lo n g - te rm  s u rv iv a l is s e e n , w ith  p 5 3  n e g a t iv e  tu m o u rs  d o in g  b e t te r  th a n  p o s it iv e  o n e s  
(F ig u re  2 5 ) .
Time from first presentation (months)
Figure 25: K a p la n -M e ie r  Survival A nalysis C om parin g  Survival T im e  For p 53  Expression Post-
c h e m o ra d io th e ra p y .
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| 7 . 5 . 6 . 1  M E T A L L O T H IO N E IN  P R E -T R E A T M E N T  E X P R E S S IO N  A N D  T U M O U R  
C H A R A C T E R IS T IC S
M e ta l lo th io n e in  c o u ld  b e  d e m o n s tr a te d  in t h e  c y to p la s m , n u c le u s  o r  b o th  in n o rm a l  
a n d  m a lig n a n t  cells  b u t f o r  t h e  p u rp o s e  o f  th is  s tu d y , o n ly  in v a s iv e  m a lig n a n c y  w a s  
e x a m in e d . A  to ta l  o f  4 5  s a m p le s  f r o m  4 5  p a t ie n ts  w e r e  s ta in e d  f o r  m e ta l lo th io n e in  
e x p re s s io n ; 3 1  a d e n o c a rc in o m a s  a n d  1 4  s q u a m o u s  c e ll c a rc in o m a s . M e ta l lo th io n e in  
p o s it iv e  s ta in in g  w a s  fo u n d  in 6 4 %  (n = 1 6 )  a n d  3 6 %  s ta in e d  n e g a t iv e  (n = 2 9 ) .  A  fu r t h e r  
1 8  s a m p le s  d id  n o t d e m o n s tr a te  tu m o u r  a n d  w e r e  th u s  e x c lu d e d  f r o m  th e  ana lys is .
T h e  a v e ra g e  le n g th  o f  tu m o u r  in t h e  tw o  g ro u p s  d id  n o t  d i f f e r  s ig n if ic a n tly  w ith  th e  
a v e ra g e  le n g th  in th e  n e g a t iv e  a n d  p o s it iv e  g ro u p s  5 .4  o f  a n d  5 c m  re s p e c tiv e ly  (ra n g e
l - 1 2 c m )  (p = 0 .6 9 2 ) .
In  th e  n e g a t iv e  g ro u p , n o  tu m o u r s  w e r e  w e ll  d i f f e r e n t ia te d ,  1 2  w e r e  m o d e ra te ly  
d if f e r e n t ia te d  (7 5 % ) a n d  4  w e r e  p o o r ly  d if f e r e n t ia te d  (2 5 % ) . T h is  c o m p a re s  w ith  3  
(1 0 % ), 1 6  (5 5 % ) a n d  1 0  (3 4 % ) in th e  p o s it iv e  g ro u p . P r e - t r e a tm e n t  b io p s y  
m e ta l lo th io n e in  s ta tu s  d id  n o t  c o r r e la te  w it h  w o rs e  t u m o u r  g ra d e  (p = 0 .4 8 5 ) .
O v e ra ll ,  3 9 %  o f  a d e n o c a rc in o m a s  ( 1 2 /3 1 )  a n d  2 9 %  o f  s q u a m o u s  ce ll c a rc in o m a s  ( 4 /1 4 )  
d e m o n s tr a te d  n e g a t iv e  e x p re s s io n  o f  m e ta l lo th io n e in .  S e v e n ty -f iv e  p e r c e n t  o f  
m e ta l lo th io n e in  n e g a t iv e  tu m o u r s  w e r e  a d e n o c a rc in o m a s  ( 1 2 /1 6 )  a n d  2 5 %  w e r e  
s q u a m o u s  ce ll c a rc in o m a s  ( 4 /1 6 ) .
| 7.5.5 METALLOTHIONEIN EXPRESSION PRE-TREATMENT
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7 . 5 . 6 . 2  M E T A L L O T H IO N E IN  E X P R E S S IO N  A N D  R E S P O N S E  T O  N E O A D J U V A N T  
C H E M O R A D IO T H E R A P Y
T h ir te e n  p a t ie n ts  in th is  g ro u p  u n d e r w e n t  re s e c tio n , w i t h  th e  AJCC t u m o u r  s ta g e
o u t l in e d  in  T a b le  1 1 . E ig h ty  p e r c e n t  o f  m e ta l lo th io n e in  n e g a t iv e  ( 4 /5 )  a n d  5 0 %  o f
p o s it iv e  ( 4 /8 )  s a m p le s  h a d  ly m p h  n o d e  p o s it iv e  d is e a s e  (p = 0 .2 7 9 ) .  P o s t - t r e a tm e n t
m e ta l lo th io n e in  o v e r -e x p re s s io n  d ire c tly  c o r re la te d  w it h  m o d e r a te  a n d  p o o r
d if f e r e n t ia t io n  o f  t h e  tu m o u r ,  w h ile  e x p re s s io n  w a s  a b s e n t in w e l l - d i f fe r e n t ia te d
tu m o u r s  (p = 0 .0 2 3 ) .
7 . 5 . 6 . 3  M E T A L L O T H IO N E IN  E X P R E S S IO N  P R E -T R E A T M E N T  A N D  S U R V IV A L
In th e  n e g a t iv e  g ro u p , th e  1, 2 , 3  a n d  5 -y e a r  s u rv iv a l w a s  5 6 %  (n = 9 ) ,  6 %  ( n = l ) ,  0 %  a n d  
0 % . T h is  c o m p a re s  w it h  5 9 %  (n = 1 7 ) ,  2 8 %  (n = 8 ) ,  1 0 %  (n = 3 )  a n d  0 %  re s p e c tiv e ly  in  t h e  
p o s it iv e  g ro u p . T h e  m e ta l lo th io n e in  n e g a t iv e  tu m o u r s  te n d e d  to w a r d s  a n  d e c re a s e d  
o v e ra ll s u rv iv a l w ith  a m e a n  o f  12  m o n th s  (ra n g e  0 .5 - 2 9  m o n th s )  c o m p a re d  w ith  2 1  
m o n th s  (ra n g e  2 -1 0 2  m o n th s )  fo r  p o s it iv e  tu m o u rs , b u t  th is  w a s  n o t fo u n d  to  b e  
s ta t is t ic a lly  s ig n if ic a n t (p = 0 .2 9 6 ) .
7 . 5 . 6 . 4  M E T A L L O T H IO N E IN  E X P R E S S IO N  P O S T -T R E A T M E N T  A N D  S U R V IV A L  
T h ir ty -s e v e n  p o s t - t r e a tm e n t  s a m p le s  w e r e  s ta in e d  f o r  m e ta l lo th io n e in  e x p re s s io n . 
E ig h te e n  o f  th e s e  d id  n o t  d e m o n s tr a te  tu m o u r  a n d  w e r e  e x c lu d e d  f r o m  a n a ly s is . O f  
th e  r e m a in d e r ,  3 2 %  o f  s a m p le s  (n = 6 )  w e r e  n e g a t iv e  fo r  m e ta l lo th io n e in  e x p re s s io n  a n d  
6 8 %  (n = 1 3 )  w e r e  p o s it iv e . T h e  m e a n  s u rv iv a l w a s  2 5  m o n th s  f o r  th e  n e g a t iv e  g ro u p  
(ra n g e  7 -1 1 1 )  a n d  2 4  m o n th s  f o r  th e  p o s it iv e  g ro u p  (ra n g e  4 - 8 1 )  (p = 0 .2 1 3 ) .
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[ 7 . 5 . 7 . 1  P R E -T R E A T M E N T  V E G F  E X P R E S S IO N  A N D  T U M O U R  C H A R A C T E R IS T IC S  
A  to ta l  o f  5 4  s a m p le s  f r o m  5 4  p a t ie n ts  w e r e  s ta in e d  f o r  V E G F  e x p re s s io n ; 3 5  
a d e n o c a rc in o m a s  a n d  1 9  s q u a m o u s  ce ll c a rc in o m a s . V E G F  p o s it iv e  s ta in in g  w a s  fo u n d  
in  1 7 %  (n = 9 )  a n d  8 3 %  s ta in e d  n e g a t iv e  (n = 4 5 ) .  A  fu r t h e r  9  s a m p le s  d id  n o t  
d e m o n s tr a te  tu m o u r  a n d  w e r e  th u s  e x c lu d e d  fro m  th e  a n a ly s is .
T h e  a v e ra g e  le n g th  o f  t u m o u r  in  th e  tw o  g ro u p s  d id  n o t  d i f f e r  s ig n if ic a n tly  w ith  th e  
a v e ra g e  le n g th  in th e  n e g a t iv e  a n d  p o s it iv e  g ro u p s  o f  6 .8  (ra n g e  1 -1 2 )  a n d  5 .3 c m  (ra n g e
2 -1 0 )  re s p e c tiv e ly  (p = 0 .9 4 9 ) .
In  th e  n e g a t iv e  g ro u p , 3 tu m o u r s  w e r e  w e ll  d i f f e r e n t ia te d  (7 % ), 2 9  w e r e  m o d e ra te ly  
d if f e r e n t ia te d  (6 4 % ) a n d  13  w e r e  p o o r ly  d i f f e r e n t ia te d  (2 9 % ). T h is  c o m p a re s  w ith  0 , 4  
(4 4 % ) a n d  5 (5 6 % ) in th e  p o s it iv e  g ro u p . P r e - t r e a tm e n t  V E G F  s ta tu s  d id  n o t c o r r e la te  
w ith  w o rs e  tu m o u r  g ra d e  (p = 0 .6 5 3 ) .
S ix ty -n in e  p e r c e n t  o f  n e g a t iv e  tu m o u r s  w e r e  a d e n o c a rc in o m a s  ( 3 1 /4 5 )  a n d  3 1 %  w e r e  
s q u a m o u s  ce ll c a rc in o m a s  ( 1 4 /4 5 ) .  O v e ra ll 8 9 %  o f  a d e n o c a rc in o m a s  ( 3 1 /3 5 )  a n d  3 6 %  
o f  s q u a m o u s  ce ll c a rc in o m a s  ( 5 /1 4 )  d e m o n s tr a te d  n e g a t iv e  e x p re s s io n  o f  V E G F .
| 7.5.7 VEGF EXPRESSION PRE-TREATMENT
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7 . 5 . 7 . 2  V E G F  E X P R E S S IO N  A N D  R E S P O N S E  T O  N E O A D J U V A N T  
C H E  M O  R A D IO T H E R A P Y
T w e n ty  p a t ie n ts  in th is  g ro u p  u n d e r w e n t  re s e c tio n , w ith  t h e  AJCC tu m o u r  s ta g e  
o u t l in e d  in T a b le  1 1 . F o u r ty - th re e  p e rc e n t  o f  n e g a t iv e  ( 6 /8 )  a n d  1 0 0 %  o f  p o s it iv e  ( 3 /3 )  
s a m p le s  h a d  ly m p h  n o d e  d is e a s e  (p = 0 .0 7 5 ) .  P o s t - t r e a t m e n t  V E G F  d id  n o t c o r r e la te  
w ith  w o rs e  tu m o u r  g ra d e  (p = 0 .6 0 8 ) .
T ab le  11: AJCC S tage In P a tien ts  U n d erg o in g  Surgery Fo llo w in g  N e o a d ju v a n t  
C h e m o ra d io th e ra p y  Based O n Expression O f p 5 3 , M e ta llo th io n e in  A nd  VEGF.
p53 Expression Metallothionein
Expression
VEGF Expression
AJCC Stage“ Negative Positive Negative Positive Negative Positive0 1 1 0 1 2 0
1 1 0 0 0 1 0
2a 2 3 1 2 4 0
2b 3 3 2 2 3 2
3 2 4 2 3 3 1
4 0 0 0 0 0 0
I 7 . 5 . 7 . 3  V E G F  E X P R E S S IO N  P R E -T R E A T M E N T  A N D  S U R V IV A L
:
In  th e  V EG F n e g a t iv e  g ro u p , th e  1 , 2 , 3  a n d  5 -y e a r  s u rv iv a l w a s  5 8 %  (n = 2 6 ) ,  2 2 %  (n = 1 0 ) ,  
9 %  (n = 4 )  a n d  4 %  (n = 2 ) .  Th is  c o m p a re s  w it h  4 4 %  (n = 4 ) ,  2 2 %  (n = 2 ) ,  0 %  a n d  0 %  in  th e  
p o s it iv e  g ro u p . T h e  o v e ra ll m e a n  s u rv iv a l fo r  V E G F  n e g a t iv e  tu m o u r s  w a s  1 9  m o n th s  
(ra n g e  0 .5 -6 1  m o n th s )  c o m p a re d  w ith  13  m o n th s  (ra n g e  2 .5 -2 9  m o n th s )  fo r  p o s it iv e  
tu m o u r s  (p = 0 .4 2 4 ) .
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| 7 . 5 . 7 . 4  V E G F  E X P R E S S IO N  P O S T -T R E A T M E N T  A N D  S U R V IV A L  
T h ir ty -s ix  p o s t - t r e a tm e n t  s a m p le s  w e r e  s ta in e d  f o r  e x p re s s io n . S ix te e n  o f  th e s e  d id  n o t  
d e m o n s tr a te  tu m o u r  a n d  w e r e  e x c lu d e d  f r o m  a n a ly s is . O f  th e  r e m a in d e r , 6 5 %  o f  
s a m p le s  (n = 1 3 )  w e r e  n e g a t iv e  f o r  e x p re s s io n  a n d  3 5 %  (n = 7 )  w e r e  p o s it iv e  fo r  
e x p re s s io n . T h o s e  w h o  w e r e  n e g a t iv e  fo r  V E G F  te n d e d  to w a r d s  im p ro v e d  s u rv iv a l w ith  
a m e a n  o f  4 3  m o n th s  (ra n g e  2 1 -6 5  m o n th s )  v e rs u s  o n ly  2 4  m o n th s  in t h e  p o s it iv e  g ro u p  
(ra n g e  4 -4 3 )  (p = 0 .1 9 ) .
7 . 5 . 8  M U L T IV A R IA T E  A N A L Y S IS  P 5 3 ,  M E T A L L O T H IO N E IN  A N D  V E G F  
E X P R E S S IO N
T h e  f re q u e n c y  o f  p 5 3 , m e ta l lo th io n e in  a n d  V EG F e x p re s s io n  in c o m b in a t io n  (a ll 
p a t ie n ts , a ll h is to lo g ie s ) is d is p la y e d  in F ig u re  2 6 . S e p a ra t io n  in to  a d e n o c a rc in o m a  a n d  
s q u a m o u s  ce ll c a rc in o m a  s h o w e d  s im ila r  t re n d s , b u t d id  n o t  a c h ie v e  s ta t is t ic a l  
s ig n if ic a n c e , lik e ly  d u e  to  th e  s m a ll n u m b e rs  in th is  se rie s .
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Markers in Combination (sorted by decreasing incidence)
Figure 26: Frequen cy o f p 5 3 , M e ta llo th io n e in  A nd  VEGF Expression In C o m b in a tio n
j 7 . 5 . 8 . 1 .  M U L T IV A R IA T E  A N A L Y S IS : P 5 3 ,  M E T A L L O T H IO N E IN  A N D  V E G F  
E X P R E S S IO N  A N D  S U R V IV A L
M u lt iv a r ia te  a n a ly s is  o f  a d e n o -  a n d  s q u a m o u s  ce ll c a rc in o m a  c o m b in e d  s h o w e d  t h a t
p 5 3 , V E G F  a n d  m e ta l lo th io n e in  to g e th e r  h a v e  p ro g n o s tic  s ig n if ic a n c e . T u m o u rs  w h ic h
w e r e  p 5 3  a n d  V E G F  n e g a t iv e  a n d  m e ta l lo th io n e in  p o s it iv e  (p 5 3 - /V E G F - /M e t + )  h a d  a
s tro n g ly  s ta t is t ic a lly  im p ro v e d  o u tc o m e  c o m p a re d  w ith  th o s e  w h o  w e r e  p 5 3 , V E G F  a n d
m e ta l lo th io n e in  n e g a t iv e  ( p 5 3 - /V E G F - /M e t - )  a n d  all o t h e r  c o m b in a t io n s  (p < 0 .0 0 1 )
(F ig u re  2 7 ) .  M e a n  s u rv iv a l fo r  th e  p 5 3 - /V E G F - /M e t +  w a s  8 8  + / - 1 3  m o n th s  (9 5 % C I 6 2 -
1 1 3  m o n th s )  c o m p a re d  w ith  4 1  + / -  9  m o n th s  (9 5 %  Cl 2 3 -5 9  m o n th s )  in th e  p 5 3 - /V E G F -
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/ M e t -  g ro u p . T h is  c o m p a re d  w ith  a m e a n  s u rv iv a l o f  2 0  m o n th s  a n d  3 0  m o n th s  fo r  a ll 
o t h e r  c o m b in a t io n s  a n d  o v e ra ll re s p e c tiv e ly .
Time from first presentation (months)
Figure 27: K a p la n -M e ie r  S urv iva l A nalysis C o m p arin g  Survival T im e  For VEGF, p 5 3  A nd  
M e ta llo th io n e in  In C o m b in a tio n  P re -C h e m o ra d io th e ra p y .
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N e o a d ju v a n t  c h e m o ra d io th e r a p y  fo llo w e d  by s u rg e ry  c u r r e n t ly  p ro v id e s  t h e  b e s t h o p e  
f o r  c u re  fo r  o e s o p h a g e a l c a n c e r . A  re c e n t  m e ta -a n a ly s is  id e n t i f ie d  a n  8 .7 %  s u rv iv a l 
a d v a n ta g e  across  a ll ra n d o m is e d  tr ia ls 222. U p  t o  4 0 %  o f  p a t ie n ts  w ith  lo c a lly  a d v a n c e d  
d is e a s e  h a v e  a c o m p le te  p a th o lo g ic a l re s p o n s e  to  th e  m o s t e f fe c t iv e  re g im e n s 182,213' 215, 
221 w h ile  8 7 .5 %  o f  p a t ie n ts  w ith  e a r ly  tu m o u r s 191 m a y  h a v e  a c o m p le te  re s p o n s e  b u t  
n o t  a ll re g im e n s  a re  e q u a lly  e f fe c t iv e  a n d  n o t  a ll tu m o u r s  a re  e q u a lly  re s p o n s iv e . 
F u r th e r m o r e ,  n o n -re s p o n d e rs  c a n n o t b e n e f i t  f r o m  c h e m o ra d io th e r a p y  b u t  c o n t in u e  to  
e n d u re  th e  s id e  e ffe c ts  o f  t r e a t m e n t ,  a n d  th e  d is e a s e  m a y  p ro g re s s  o n  t r e a t m e n t  
re p re s e n tin g  a lo s t o p p o r tu n ity  fo r  c u re .
W it h  th e  c u r r e n t  p r e v a le n t  u s e  o f  n e o a d ju v a n t  th e r a p y  t h e r e  is an  u r g e n t  n e e d ,  
th e r e f o r e ,  fo r  a m a r k e r  o r  m a rk e rs  o f  re s p o n s e  to  t r e a t m e n t  to  g u id e  p a t ie n t  
m a n a g e m e n t .  T h e s e  c o u ld  o f fe r  p a t ie n ts  b o th  p ro g n o s tic  in fo rm a t io n  a n d  p re d ic t  
re s p o n s e  to  t r e a t m e n t .  P a tie n ts  d e e m e d  to  h a v e  tu m o u rs  re s p o n s iv e  to  
c h e m o ra d io th e r a p y  c o u ld  b e  id e n t i f ie d  p ro s p e c t iv e ly  a n d  b e  c o n s id e re d  fo r  
n e o a d ju v a n t  t r e a t m e n t  w ith  o r  w it h o u t  s u rg ic a l in te r v e n t io n .  T h o s e  p a t ie n ts  p re d ic te d  
to  re s p o n d  p o o r ly  c o u ld  be s p a re d  th e  p o te n t ia l  m o rb id ity ,  in c o n v e n ie n c e , t im e  a n d  
f in a n c ia l b u rd e n  o f  u n d e rg o in g  su ch  t r e a t m e n t ,  a n d  m a y  o p t  f o r  a l te r n a t iv e  t r e a t m e n t  
re g im e s  o r  p a llia t iv e  m e a s u re s  a lo n e .
B e c a u s e  o f  t h e ir  k n o w n  ro le  in  a p o p to s is  a n d  th u s  t r e a t m e n t  re s is ta n c e , th e  c lin ic a l 
s ig n if ic a n c e  o f  p 5 3 , V EG F a n d  m e ta l lo th io n e in  e x p re s s io n  in p re -  a n d  p o s t - t r e a tm e n t
7.6 DISCUSSION
184
b io p s y  a n d  re s e c tio n  s p e c im e n s  w a s  e x a m in e d  in p a t ie n ts  w ith  b o th  o e s o p h a g e a l  
a d e n o c a rc in o m a  a n d  s q u a m o u s  c e ll c a rc in o m a . T h e s e  m a rk e rs  h a v e  b e e n  a n a ly s e d  to  
a v a ry in g  d e g re e  in t h e  l i te r a tu r e  w it h  w id e -r a n g in g  re s u lts , b u t  t h e r e  a re  m a n y  l im it in g  
fa c to rs  w h e n  t ry in g  t o  c o m p a re  re s u lts  su ch  as th e  u se  o f  d i f f e r e n t  a n t ib o d ie s , v a r ia t io n  
in ¡m m u n o h is to c h e m ic a l, p a t ie n t  a n d  tu m o u r  c h a ra c te r is tic s , v a r ia b le  u se  o f  
n e o a d ju v a n t  th e ra p y ,  v a r ia t io n  in o p e r a t iv e  te c h n iq u e s  a n d  p o s t -o p e r a t iv e  c a re , lack  o f  
a c c u ra te  t u m o u r  s ta g in g , a n d  th e  v a r ia t io n  in s tu d y  d e s ig n  a n d  a n a ly t ic a l m e th o d s . O u r  
a im  w a s  to  in v e s tig a te  in a s in g le  s tu d y  if  th e s e  m a rk e rs  m a y  b e  u t ilis e d , a lo n e  o r  
c o m b in e d , as p re d ic t iv e  m a rk e rs  fo r  re s p o n s e  to  n e o a d ju v a n t  c h e m o ra d io th e r a p y  a n d  
o u tc o m e  in o e s o p h a g e a l c a n c e r .
M o r e  th a n  5 0  p e r c e n t  o f  a ll h u m a n  tu m o u r s 291 c o n ta in  a m u ta t io n  o r  d e le t io n  o f  th e  
p 5 3  g e n e . D u e  to  its m a n y  a n t i-c a n c e r  m e c h a n is m s  su ch  as D N A  re p a ir , g e n e t ic  
s ta b ilis a t io n , in h ib it io n  o f  a n g io g e n e s is  a n d  in it ia t io n  o f  a p o p to s is 289, p 5 3  is o f te n  
re fe r r e d  to  as th e  " g u a rd ia n  o f  th e  g e n o m e " 290. A  p 5 3  a b n o rm a li ty  is o b s e rv e d  in o v e r  
7 0  p e rc e n t  o f  o e s o p h a g e a l c a n c e rs 272 b u t  s tu d ie s  e v a lu a t in g  t h e  p ro g n o s tic  s ig n if ic a n c e  
o f  p 5 3  e x p re s s io n  h a v e  fo c u s e d  p r im a r ily  in  o e s o p h a g e a l s q u a m o u s  ce ll c a rc in o m a 271'279 
a n d  to  a le s s e r e x te n t  a d e n o c a rc in o m a 280*283 a n d  e v e n  fe w e r  in c lu d e d  b o th  tu m o u r  
ty p e s 284,285. T h e  re s u lts  f r o m  th e s e  s tu d ie s  h a v e  b e e n  c o n f lic t in g 271*286. S o m e  h a v e  
fo u n d  p 5 3  t o  b e  a g o o d  p ro g n o s tic  in d ic a to r  fo r  tu m o u r  in v a s iv e n e s s  a n d  p ro p e n s ity  to  
m e ta s ta s is e  o r  r e c u r274, 275, 286, s u rv iv a l271, 273*275, 277, 278, 282, 285, 286 a n d  re s p o n s e  to  
th e r a p y 277,280,283 a n d  s o m e  h a v e  fo u n d  it  n o t  t o  b e  u s e fu l272,276,280,284 u n less  a s s o c ia te d  
w ith  o t h e r  m a rk e rs 279.
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C o n s is te n t w ith  th e  m a jo r ity  o f  th e s e  re s u lts , o u r  s tu d y  s h o w e d  t h a t  p 5 3  n e g a t iv ity  
c o n fe r re d  s ig n if ic a n tly  im p ro v e d  s u rv iv a l w h ile  p 5 3  p o s it iv e  p a t ie n ts  te n d e d  to w a rd s  
la te r  d is e a s e  s ta g e s  fo llo w in g  c h e m o ra d io th e r a p y .  N in e ty -o n e  p e rc e n t  o f  p 5 3  p o s it iv e  
tu m o u rs  h a d  s ta g e  2 o r  3 d is e a s e  a n d  6 4 %  h a d  ly m p h  n o d e  p o s it iv ity  c o m p a re d  w ith  
7 8 %  a n d  4 4 %  re s p e c tiv e ly  in t h e  p 5 3  n e g a t iv e  g ro u p , b u t  th e s e  d id  n o t  a c h ie v e  
s ta t is t ic a l s ig n if ic a n c e . R esu lts  o f  p o s t -c h e m o ra d io th e r a p y  p 5 3  e x p re s s io n  s ta tu s  a lso  
fa i le d  to  re a c h  s ta t is t ic a l s ig n if ic a n c e , b u t it  a p p e a r e d  t h a t  w h ile  th e r e  w a s  n o  
d if fe r e n c e  in e a r ly  s u rv iv a l, p 5 3  n e g a t iv ity  w a s  a s s o c ia te d  w ith  a lo n g -te rm  s u rv iv a l 
a d v a n ta g e .
S q u a m o u s  ce ll c a rc in o m a s  h a d  a h ig h e r  p e rc e n ta g e  o f  p 5 3  n e g a t iv ity  c o m p a re d  w ith  
a d e n o c a rc in o m a s  (4 3 %  a n d  2 9 % ). Th is  m a y  b e  o n e  e x p la n a t io n  f o r  th e  fa c t  th a t  
s q u a m o u s  c e ll c a rc in o m a s  te n d  to  b e  m o re  s e n s itiv e  t o  c h e m o ra d io th e r a p y  a n d  h a v e  
h ig h e r  c o m p le te  p a th o lo g ic a l re s p o n s e  ra te s .
M e ta l lo th io n e in  is a lo w  m o le c u la r  w e ig h t ,  c y s te in e -r ic h  p r o te in , w h ic h  has a h igh  
a f f in ity  fo r  m e ta l  io n s 298. I t  is in v o lv e d  in m a n y  p a th o p h y s io lo g ic a l p ro c e s s e s , in c lu d in g  
m e ta l io n  h o m o e o s ta s is , p r o te c t io n  a g a in s t o x id a t iv e  d a m a g e  a n d  ce ll p r o life r a t io n  a n d  
a p o p to s is 299, 30°. Its a b ility  to  in h ib it  a p o p to s is 311 a n d  its f r e e  ra d ic a l s c a v e n g in g  
p r o p e r t y 299 p r o te c t  t h e  ce lls  f r o m  ra d ia t io n  a n d  c h e m o th e r a p e u t ic  a g e n ts . O v e r ­
e x p re s s io n  o f  m e ta l lo th io n e in  c o r re la te s  s ig n if ic a n tly  w it h  a p o o re r  p ro g n o s is  in s e v e ra l 
t u m o u r  ty p e s 303'307 a n d  m e ta s ta t ic  tu m o u r  a c t iv ity  a n d  p r o l i fe r a t iv e  p o t e n t ia l308 in  
o e s o p h a g e a l s q u a m o u s  ce ll c a rc in o m a .
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E x p re s s io n  o f  m e ta l lo th io n e in  in tu m o u r s  f r o m  p a t ie n ts  w ith  o e s o p h a g e a l c a n c e r  
t r e a t e d  w ith  n e o a d ju v a n t  c h e m o ra d io th e r a p y  has b e e n  a s s o c ia te d  w ith  a w o rs e  
p ro g n o s is 309, b u t re s u lts  f r o m  o t h e r  s tu d ie s  h a v e  s h o w n  n o  su ch  a s s o c ia t io n 309,310. W e  
fo u n d  t h a t  tu m o u rs  w ith  p o s it iv e  e x p re s s io n  f o r  m e ta l lo th io n e in  p r e - t r e a t m e n t  te n d e d  
to w a r d s  an  im p ro v e d  o v e ra ll s u rv iv a l w ith  a m e a n  s u rv iv a l a lm o s t  d o u b le  th a t  o f  
n e g a t iv e  o n e s , b u t th is  fa i le d  to  re a c h  s ta t is t ic a l s ig n if ic a n c e .
M e ta l lo th io n e in  o v e r -e x p re s s io n  has b e e n  im p lic a te d  in re s is ta n c e  to  c is p la tin  in m a n y  
tu m o u r  ty p e s 312'315, in c lu d in g  o e s o p h a g e a l s q u a m o u s  ce ll c a rc in o m a 309, 316, 317 a n d  
c is p la tin  fo rm s  t h e  c o rn e rs to n e  o f  th e  m o s t successsfu l o e s o p h a g e a l c a n c e r  t r e a t m e n t  
re g im e n s 182, 21S. W h ile  p o s t - t r e a tm e n t  m e ta l lo th io n e in  o v e r -e x p re s s io n  d ire c t ly  
c o r r e la te d  w ith  m o d e r a te  a n d  p o o r  d i f fe r e n t ia t io n  o f  tu m o u r s  in o u r  s tu d y , it d id  n o t  
c o r r e la te  w ith  re s p o n s e  to  t r e a t m e n t  o r  o u tc o m e . W h ile  c o n s is te n t w ith  th e s e  fin d in g s  
r e p o r te d  in th e  l i te r a tu r e ,  o u r  re s u lts  m a y  b e  c o n fo u n d e d  by s m a ll n u m b e rs , c o m b in in g  
o f  tu m o u r  ty p e s  a n d  th e  fa c t  t h a t  a lm o s t  3 0 %  o f  s a m p le s  e v a lu a te d  d id  n o t c o n ta in  
tu m o u r  a n d  t h e r e f o r e  c o u ld  n o t  b e  e v a lu a te d .
A n g io g e n e s is  p lays  a k e y  ro le  in g r o w th  a n d  m e ta s ta s is  o f  s o lid  tu m o u r s 415,416. V EG F is 
o n e  o f  th e  m o s t p o w e r fu l a n d  s p e c ific  in d u c e rs  o f  n e o v a s c u la r is a tio n  in m a lig n a n t  
n e o p la s m s  a n d  p lays  a v ita l  ro le  in in h ib it in g  tu m o u r  ce ll a p o p to s is 320. V E G F  e x p re s s io n  
has b e e n  s h o w n  to  c o r r e la te  w ith  p o o r  p ro g n o s is  in m a n y  c a n c e rs 323'327 b u t t h e  d a ta  in 
o e s o p h a g e a l c a n c e r  m a in ly  re fe rs  to  s q u a m o u s  ce ll c a rc in o m a , w h e r e  th e r e  is a p o s it iv e  
c o r r e la t io n  b e tw e e n  V E G F  e x p re s s io n , d e p th  o f  tu m o u r  in v a s io n  a n d  lo c o re g io n a l a n d  
d is ta n t  m e ta s ta s is 328'331,333. L o w  le v e ls  o f  V E G F  a re  a s s o c ia te d  w ith  a b e t te r  lo n g -te rm  
s u rv iv a l334. T h e s e  fin d in g s , h o w e v e r ,  w e r e  n o t s u p p o r te d  b y  o u r  s tu d y .
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T u m o u r  m ic ro c irc u la t io n  a n d  v e s s e l p e r m e a b il i ty  a r e  im p o r t a n t  fa c to rs  in tis s u e  
o x y g e n a t io n , d ru g  d e liv e ry  a n d  ra d io -s e n s it is a tio n  o f  m a lig n a n t ce lls 335. T h u s  V EG F  
e x p re s s io n  in o e s o p h a g e a l c a n c e r  has b e e n  e x p lo re d  as a m e a n s  o f  p re d ic t in g  re s p o n s e  
to  c h e m o ra d io th e r a p y  w ith  s ig n if ic a n tly  h ig h e r  le v e ls  o f  V E G F  in p r e - t r e a t m e n t  b io p s ies  
in n o n -re s p o n d e rs  th a n  in th o s e  w h o  re s p o n d  to  c h e m o r a d io th e r a p y 336' 337. S im ila r ly , 
w e a k  V EG F im m u n o r e a c t iv ity  in p r e - t r e a t m e n t  b io p s ie s  is a s s o c ia te d  w ith  a h ig h e r  
in c id e n c e  o f  c o m p le te  tu m o u r  re g re s s io n  a n d  im p ro v e d  lo n g -te r m  s u rv iv a l a f t e r  
n e o a d ju v a n t  c h e m o ra d io th e r a p y 334. In  o u r  s tu d y , th o s e  n e g a t iv e  fo r  V EG F e x p re s s io n  
p o s t - t r e a tm e n t  h a d  a lm o s t d o u b le  m e a n  s u rv iv a l t im e  c o m p a re d  to  th o s e  w ith  
p o s t it iv e  e x p re s s io n , b u t th is  fa i le d  t o  re a c h  s ig n if ic a n c e , lik e ly  c o n fo u n d e d  by 4 4 %  o f  
s a m p le s  n o t  d e m o n s tra t in g  t u m o u r
D e te c t io n  ra te s  o f  p 5 3 272,273,280,284,286, m e t a l lo th io n e in 309,316 a n d  V E G F 334 p o s t it iv ity  in 
th is  s tu d y  w e r e  s im ila r  t o  p re v io u s  re p o r ts  a lth o u g h  V E G F  p o s it iv ity  ra te s  v a ry  in  th e  
l i t e r a tu r e  a n d  o u r  le v e l w a s  lo w e r  th a n  m a n y 330,331' 333,337. T h is  h ig h lig h ts  th e  n e e d  fo r  
s ta n d a rd is a t io n  o f  te c h n iq u e s  to  a l lo w  a c c u ra te  c o m p a ris o n  acro ss  th e  l i te r a tu r e .  In  
o u r  s e rie s , 1 6 %  p re - a n d  3 1 %  p o s t - t r e a tm e n t  s a m p le s  d id  n o t  id e n t ify  tu m o u r  a lth o u g h  
tu m o u r  w a s  d e te c te d  o n  fo rm a l h is to -p a th o lo g ic a l a s s e s m e n t p re -a n d  p o s t - t r e a tm e n t .  
H ig h e r  d e te c t io n  ra te s  w o u ld  m o re  lik e ly  h a v e  o c c u rre d  h a d  w e  e v a lu a te d  m u lt ip le  
tis s u e  s e c tio n s  a n d  th u s  id e n t if ie d  tu m o u r  in  m o re  s e c tio n s . T h e s e  fin d in g s  h o w e v e r  
u n d e r lin e  a n d  s u p p o r t  o u r  p o lic y  o f  ta k in g  a t  le a s t 1 0  b io p s ie s  fo r  h is to lo g ic a l a n a ly s is , 
e s p e c ia lly  p o s t -n e o a d ju v a n t t r e a t m e n t  w h e r e  re s id u a l tu m o u r  m a y  n o t b e  
m a c ro s c o p ic a lly  v is a b le  a t  e n d o s c o p ic  a s s e s s m e n t, in o r d e r  to  re lia b ly  assess fo r  
p re s e n c e  o r  a b s e n c e  o f  tu m o u r .
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O n  in d iv id u a l a n a ly s is , o u r  re s u lts  in d ic a te d  t h a t  p 5 3  b u t  n o t m e ta l lo th io n e in  o r  V E G F  
e x p re s s io n  p r e - t r e a t m e n t  w a s  a n  in d e p e n d e n t  p r e d ic to r  o f  s u rv iv a l. W h ile  th e r e  w a s  a 
fa i lu r e  t o  f in d  a s ig n if ic a n tly  s h o r te r  d is e a s e  f r e e  s u rv iv a l in p 5 3 , V E G F  a n d  
m e ta l lo th io n e in  p o s it iv e  tu m o u r s  p o s t - t r e a tm e n t ,  it  is p o s s ib le  t h a t  th is  m a y  a c tu a lly  
r e f le c t  th e  a b il i ty  o f  n e o a d ju v a n t  c h e m o ra d io th e r a p y  t o  im p ro v e  o u tc o m e . W h e n  th e  
m a rk e rs  w e r e  c o m b in e d , h o w e v e r , t h e ir  p re d ic t iv e  c a p a c ity  w a s  im p ro v e d  s ig n if ic a n tly  
w ith  th o s e  p a t ie n ts  w ith  p r e - t r e a t m e n t  tu m o u r s  n e g a t iv e  f o r  p 5 3  a n d  V EG F a n d  
p o s it iv e  fo r  m e ta l lo th io n e in  e x p re s s io n  h a v in g  th e  b e s t o u tc o m e .
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T h e  m u lt i tu d e  o f  v a r ia b le s  a n d  h e te r o g e n e ity  o f  s tu d ie s  in  t h e  l i te r a tu r e  m a k e s  
a c c u ra te  c o m p a ris o n  d iff ic u lt . W h ile  re s u lts  f r o m  o u r  s tu d y  a n d  o th e rs  s h o w  p o te n t ia l  
f o r  c lin ic a l a p p lic a t io n  o f  m o le c u la r  m a rk e rs  su ch  as p 5 3 , m e ta l lo th io n e in ,  V EG F a n d  
o th e rs , th e r e  is a n e e d  to  c o n f irm  th e s e  o b s e rv a tio n s  in a p ro s p e c t iv e  s tu d y  w ith  
s ta n d a rd is e d  te c h n iq u e s  in w e ll -d e f in e d  p a t ie n t  c o h o rts  a n d  s h o u ld  b e  th e  s u b je c t o f  
f u tu r e  re s e a rc h . It  is lik e ly  th a t  a c o m b in a t io n  o f  m a rk e rs  w ill  y ie ld  th e  m o s t p ro m is in g  
re s u lts .
7.7 CONCLUSION
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CHAPTER VIII: GENERAL DISCUSSION AND CONCLUSIONS
O e s o p h a g e a l c a n c e r  is th e  e ig h th  m o s t c o m m o n  c a n c e r  a n d  s ix th  m o s t c o m m o n  c a u s e  
o f  d e a th  f r o m  c a n c e r  w o r ld w id e 1 b u t th e  o v e ra ll p ro g n o s is  re m a in s  p o o r, h a v in g  
im p ro v e d  m in im a lly  s in c e  th e  1 9 7 0 s 3' 4 5. O n e  o f  th e  p r im a ry  re a s o n s  fo r  th e  p o o r  
p ro g n o s is  is th e  a d v a n c e d  s ta g e  o f  d is e a s e  a t  d ia g n o s is  in m o s t p a t ie n ts 80 w ith  o n e  
th ir d  o f  p a t ie n ts  h a v in g  m e ta s ta t ic  d is e a s e  a t  p r e s e n ta t io n 78. E x p la n a tio n s  fo r  th is  
in c lu d e  th e  a g g re s s iv e  b io lo g ic a l n a tu r e  o f  th is  d is e a s e , re s u lt in g  in ra p id  d is s e m in a tio n .  
A lth o u g h  s c re e n in g  p ro g ra m m e s  fo r  p a t ie n ts  w ith  B a r re tt 's  o e s o p h a g u s  e x is t to  d e te c t  
e a r ly  d is e a s e , th e y  a re  c o s tly  a n d  h a v e  y e t  to  s h o w  a n y  e f fe c t  o n  s u rv iv a l50' 6367 
e s p e c ia lly  s in ce  th e  a c tu a l p ro g re s s io n  ra te s  to  c a n c e r  a re  lo w 49'51. In fa c t , m o s t  
p a t ie n ts  w ith  B a r re tt 's  d ie  d u e  to  cau ses  o t h e r  th a n  o e s o p h a g e a l a d e n o c a rc in o m a 50. 
A n o th e r ,  a n d  m o re  m o d if ia b le  re a s o n , is th e  lack o f  a w a re n e s s , e s p e c ia lly  a m o n g  th e  
p u b lic , o f  th e  s y m p to m s  o f  o e s o p h a g e a l c a n c e r81'83. E ffo rts  s p e n t  o n  B a r re tt 's  
s u rv e illa n c e  m a y  b e  m o re  a p p r o p r ia te ly  p la c e d  in life s ty le  m o d if ic a t io n  a n d  h e a lth  
e d u c a t io n  p ro g ra m m e s  a n d  a w a re n e s s  c a m p a ig n s  to  p r e v e n t  d is e a s e  o r  fa c i l i ta te  e a r ly  
re c o g n it io n  o f  s y m p to m s  by d o c to rs  a n d  p a t ie n ts .
A lth o u g h  s q u a m o u s  ce ll c a rc in o m a  is th e  m o s t p r e v a le n t  h is to lo g ic a l ty p e  w o r ld w id e ,  
a d e n o c a rc in o m a  is b e c o m in g  th e  d o m in a n t  h is to lo g y  in d e v e lo p e d  c o u n tr ie s 7 1 0 ,1 7 ,18 
a n d  th e  p a t ie n t  d e m o g ra p h ic s  a re  c h a n g in g  a lo n g  w ith  th is  t r e n d . T h e  p a t ie n ts  a re  n o w  
o ld e r 4 ,13 a n d  m o re  o b e s e 68'70 w ith  s ig n ig ic a n t c o -m o r b id ity  a t ta c h e d  t o  b o th  c o h o rts . 
T h u s  th e  m a n a g e m e n t  o f  th is  d is e a s e  is b e c o m in g  e v e r m o r e  c h a lle n g in g .
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D e s p ite  th e  d is m a l s ta tis tic s , t h e r e  is h o p e . W e  h a v e  s h o w n  th a t  im p ro v e d  lo n g -te rm  
s u rv iv a l ra te s  can  b e  a c h ie v e d  w h e n  c h e m o ra d io th e r a p y  is a d m in is te r e d  a n d  t h a t  th o s e  
w it h  a c o m p le te  p a th o lo g ic a l re s p o n s e , o r  th o s e  w i t h  s ig n if ic a n t d o w n s ta g in g  h a v e  th e  
b e s t o u tc o m e s  (C h a p te rs  3  &  4 ).
T h e  c h ie f  f in d in g  o f  C h a p te r  3  is th a t  th e  s h o r t - te r m  s u rv iv a l a d v a n ta g e  f o r  n e o a d ju v a n t  
c h e m o ra d io th e r a p y  f o r  a d e n o c a rc in o m a  in t h e  p re v io u s ly  p u b lis h e d  ra n d o m is e d  t r ia l182 
is s u s ta in e d  u p  to  1 5  y e a rs . T h is  a v a lu a b le  a d d it io n  to  t h e  ra n d o m is e d  tr ia ls  r e p o r te d  
t o  d a te , w h e r e  th e  m e d ia n  fo llo w -u p  o n ly  ra n g e d  f r o m  2 to  8  y e a rs 123,143,182,211,213,215, 
221, 223, 224, 231,348 f j ncjjn g s  o f  o u r  lo n g -te rm  fo llo w -u p  a re  re a s s u r in g  a n d  s u g g es t 
t h a t  th e  s u rv iv a l b e n e f i t  is d u e  to  t h e  e l im in a t io n  o f  m ic ro m e ta s ta s e s  r a th e r  th a n  
m e r e ly  in d u c in g  d o r m a n c y 352 o r  a l lo w in g  re s is ta n t c lo n e s  to  re -e m e r g e ,  a n d  fo r  p a t ie n ts  
t o  s u c c u m b  to  re c u r re n t  d is e a s e 353.
A d e n o c a rc in o m a  a n d  s q u a m o u s  ce ll c a rc in o m a  a re  tw o  d i f f e r e n t  d is e a s e s  in te rm s  o f  
t h e ir  a e tio lo g y , p a t ie n t  p o p u la t io n , d is tr ib u t io n  in th e  o e s o p h a g u s  a n d  in c id e n c e  o f  
ly m p h  n o d e  m e ta s ta s e s . W e  t h e r e f o r e  c o u ld  n o t  a s s u m e  th a t  s q u a m o u s  ce ll c a rc in o m a  
w o u ld  h a v e  a s im ila r  re s p o n s e  as a d e n o c a rc in o m a  t o  th e  4 0 G y  ra d io th e ra p y  a n d  5 -F U  
a n d  c is p la tin  p ro to c o l, o r  t h a t  re s p o n s e  w o u ld  b e  s u s ta in e d . T h e  re s u lts  f r o m  C h a p te r  
3  has fu r t h e r  d e m o n s tr a te  t h a t  th e  s u rv iv a l b e n e f i t  a c h ie v e d  in  a d e n o c a rc in o m a ,  
e x te n d s  to  s q u a m o u s  ce ll c a rc in o m a , a n d  lo n g -te r m , as d id  th e  b e n e f its  o f  a s s o c ia te d  
d is e a s e  d o w n s ta g in g .
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F o r n o w , s u rg e ry  s till p lays  a k e y  ro le  as c o m p le te  re s p o n s e  ra te s  a re  s ig n if ic a n tly  less  
th a n  th e  id e a l 1 0 0 %  a n d  c o m p le te  re s p o n d e rs  a re  n o t re a d ily  id e n t if ia b le , b u t  it  s till 
c a rr ie s  a s ig n if ic a n t m o r t a l i t y 122. In d e e d  in o u r  s e r ie s , th e r e  w a s  a s ig n if ic a n t p o s t­
o p e r a t iv e  m o r ta lity ,  e s p e c ia lly  in  s q u a m o u s  ce ll c a rc in o m a  p a t ie n ts , w h ic h  w a s  
c r it ic is e d  in  th e  l i te r a tu r e .  T h e  h ig h  p o s t -o p e r a t iv e  m o r ta li t y  r a te  w a s  la rg e ly  d u e  to  
t h e  a g e  a n d  c o -m o r b id ity  o f  th e  p a t ie n t  c o h o r t ,  as s q u a m o u s  c e ll c a rc in o m a  is 
a s s o c ia te d  w ith  g r e a te r  c a rd io re s p ira to ry  risks, w i t h  b o th  d is e a s e s  b e in g  c lo s e ly  
a s s o c ia te d  w it h  s m o k in g  a n d  a lc o h o l. T h e  lo w  lo n g -te rm  s u rv iv a l fo r  th e  s u rg e ry  a lo n e  
c o h o rts  w a s  lik e ly  t o  b e  la rg e ly  r e la te d  to  th e  la c k  o f  s o p h is tic a tio n  o f  a v a ila b le  p r e ­
o p e r a t iv e  s ta g in g  m o d a lit ie s  a n d  th e  w id e  a g e -ra n g e  a n d  r e c r u itm e n t  c r ite r ia  s e t fo r  
th e  t r ia l .  W e  b e lie v e , h o w e v e r , t h a t  th is  w a s  u lt im a te ly  to  t h e  b e n e f i t  o f  th e  t r ia l ,  as it 
d e m o n s tr a te d  th e  b e n e f its  o f  n e o a d ju v a n t  th e ra p y  in a c o h o r t  m o re  re f le c t iv e  o f  th e  
t r u e  d is e a s e  p o p u la t io n . T o  " c h e r ry -p ic k "  o n ly  th o s e  w ith  th e  e a r lie s t  o f  d is e a s e  fo r  
in c lu s io n  in to  ra n d o m is e d  t r ia l ,  as so f r e q u e n t ly  o ccu rs  in t h e  l i te r a tu r e ,  d o e s  n o t  d o  
ju s t ic e  to  th e  m a jo r ity  w h o  p re s e n t  w ith  a d v a n c e d  lo c o -re g io n a l d is e a s e  o r  m e ta s ta t ic  
c a n c e r  a n d  can  h a v e  l i t t le  re le v a n c e  fo r  th e  d is e a s e -c o m m u n ity  as a w h o le .
By g iv in g  n e o a d ju v a n t  c h e m o ra d io th e r a p y  in a d v a n c e  o f  s u rg e ry , a u n iq u e  o p p o r tu n ity  
is p r e s e n te d  to  d o w n s ta g e  d is e a s e , p ro v id e  g r e a te r  R 0 re s e c tio n  ra te s , a n d  p e rh a p s  
m o s t im p o r ta n t ly ,  e r a d ic a te  th e  s y s te m ic  m a n ife s ta t io n  o f  th e  d is e a s e . In  a d d it io n ,  
th e s e  re g im e n s  can  b e  so e ffe c t iv e  as to  to ta l ly  e l im in a te  th e  d is e a s e  c a llin g  in to  
q u e s t io n  th e  b e n e f i t  o f  s u rg e ry  in th is  c o h o rt . In  th e  tw o  ra n d o m is e d  tr ia ls , 2 5 %  o f  
a d e n o c a rc in o m a s  a n d  3 0 %  o f  s q u a m o u s  ce ll c a rc in o m a s  h a d  a c o m p le te  p a th o lo g ic a l 
re s p o n s e  to  n e o a d ju v a n t  t r e a t m e n t ,  b u t 1 2 %  d ie d  fo llo w in g  a n  (u n n e c e s s a ry ) re s e c tio n  
a n d  t h e  re s t re m a in e d  e x p o s e d  to  th e  m o rb id ity  o f  th e  re s e c tio n  a n d  a l ife - lo n g
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n e g a t iv e  q u a lity  o f  life  im p a c t  o f  s u rg e ry . In  th e  e ra  o f  e v e r - in c re a s in g  c o m p le te  
p a th o lo g ic a l re s p o n s e  ra te s , it is e x c e e d in g ly  d if f ic u lt  t o  ju s t ify  th e  ro le  o f  s u rg e ry  
e s p e c ia lly  in th e  e a r l ie s t  d is e a s e  s ta g e s , a n d  th is  issue is b e c o m in g  e v e r m o r e  
c o n c e rn in g .
T h e  m a jo r  l im ita t io n  o f  n e o a d ju v a n t  th e ra p y  h o w e v e r , is t h a t  w e  c a n n o t c u r re n t ly  
re lia b ly  p re d ic t  w h o  w ill  re s p o n d  to  n e o a d ju v a n t  t r e a t m e n t  a n d  to  id e n t ify  th o s e  w h o  
c a n n o t b e n e f i t  f r o m  s u rg e ry , e i th e r  b e c a u s e  o f  th e  a b s e n c e  o f  v ia b le  d is e a s e  o r  d u e  to  
th e  p re s e n c e  o f  m ic r o m e ta s ta t ic  d is e a s e .
F o llo w in g  n e o a d ju v a n t  th e ra p y , w e  fo u n d  t h a t  t h e  s im p le  a p p ro a c h  o f  e n d o s c o p y  w ith  
m u lt ip le  tu m o u r  b e d  b io p s ie s , w ith  c a re fu l h is to lo g ic a l an a ly s is  a n d  c o m p u te r is e d  
to m o g r a p h y  id e n t if ie d  w ith  7 4 %  a c c u ra c y  a c o h o r t  o f  p a t ie n ts  w h o  h a d  a c o m p le te  
p a th o lo g ic a l re s p o n s e . U p  to  3 1 %  o f  s a m p le s  in o u r  s e rie s  a n a ly s in g  m o le c u la r  m a rk e rs  
d id  n o t  id e n t ify  tu m o u r ,  a lth o u g h  tu m o u r  w a s  d e te c te d  o n  fo r m a l  h is to -p a th o lo g ic a l 
a s s e s m e n t. T h e s e  fin d in g s  u n d e rs c o re  a n d  g iv e  s tre n g th  to  o u r  p o lic y  o f  ta k in g  a n d  
p e r fo rm in g  h is to lo g ic a l an a lys is  o f  a t  le a s t 1 0  b io p s ie s , e s p e c ia lly  p o s t -n e o a d ju v a n t  
t r e a t m e n t  w h e r e  re s id u a l tu m o u r  m a y  b e  e lu s iv e , in  o r d e r  to  re lia b ly  assess  
h is to lig ic a lly  fo r  t h e  p re s e n c e  o r  a b s e n c e  o f  tu m o u r ,  a p o lic y  w h ic h  a p p e a rs  n o t to  b e  
a d o p te d  in  o t h e r  in s t itu t io n s 103,104.
In  C h a p te r  5 , w e  fu r t h e r  s h o w e d  th a t  th e  a d d it io n  o f  m ic r o m e ta s ta t ic  d is e a s e  s ta tu s  
im p r o v e d  a c c u ra c y  o f  lu m in a l re s p o n s e  as a p ro g n o s tic  in d ic a to r . W e  h ig h lig h te d  th e  
fu n d a m e n t a l  im p o r ta n c e  t h a t  a s s e s s m e n t o f  re s p o n s e  s h o u ld  n o t  fo c u s  s o le ly  o n  lo c o -
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re g io n a l d is e a s e  re s p o n s e  b u t  r a th e r  t o  fo c u s  o n  th e  s y s te m ic  b u rd e n  as th is  u lt im a te ly  
d e c id e s  th e  o u tc o m e . T h e  lo c o re g io n a l re s p o n s e  m a y , h o w e v e r , p ro v e  t o  b e  im p o r ta n t  
as a s u r ro g a te  m a r k e r  fo r  s y s te m ic  re s p o n s e . W h ile  t h e  re s u lts  o f  th is  s tu d y  a re  
p ro m is in g , m o re  re lia b le  a n d  s ta n d a rd is e d  m e th o d s  n e e d  to  b e  d e v e lo p e d  b e fo re  
m ic r o m e ta s ta t ic  s ta tu s  can  in c o rp o ra te d  in r o u t in e  c lin ic a l s ta g in g .
A  m a jo r  c h a lle n g e  re m a in s  to  d e v e lo p  m in im a lly  in v a s iv e , a f fo r d a b le  a n d  re lia b le  
te c h n iq u e s  t o  id e n t ify ,  in a d v a n c e  o f  t r e a t m e n t ,  th o s e  w h o  a r e  m o s t lik e ly  to  re s p o n d ;  
a n d  fo llo w in g  t r e a t m e n t  th o s e  w h o  c a n n o r  b e n e f i t  f r o m  s u rg e ry . In  C h a p te r  7  w e  
e x a m in e d  p 5 3 , m e ta l lo th io n e in  a n d  V EG F as c a n d id a te s  f o r  such m a rk e rs . T h e s e  
m a rk e rs  h a v e  b e e n  a n a ly s e d  to  a v a ry in g  d e g re e  in th e  l i te r a tu r e  w ith  w id e -ra n g in g  a n d  
c o n f lic t in g  re s u lts 271'286' 308'310' 316' 317f 334' 336- 337 a n d  o n  a n a ly s is  o f  th e s e  s tu d ie s , m a n y  
l im ita t io n s  b e c o m e  a p p a r e n t ,  su ch  as th e  use o f  d i f f e r e n t  a n t ib o d ie s , v a r ia t io n  in 
p a t ie n t ,  tu m o u r  a n d  im m u n o h is to c h e m ic a l c h a ra c te r is tic s , v a r ia b le  use o f  d if fe r in g  
n e o a d ju v a n t  th e ra p ie s , v a r ia t io n  in s u rg ic a l te c h n iq u e s  a n d  p o s t -o p e r a t iv e  c a re , lack  o f  
a c c u ra te  t u m o u r  s ta g in g , a n d  th e  v a r ia t io n  in  s tu d y  d e s ig n  a n d  a n a ly tic a l m e th o d s . In  
o u r  s e rie s , w h ile  p 5 3  p o s it iv e  tu m o u r s  te n d e d  to w a r d s  la te r  d is e a s e  s tag es  a n d  h ig h e r  
ra te s  o f  ly m p h  n o d e  p o s it iv ity  p o s t - t r e a tm e n t ,  m e ta l lo th io n e in  a n d  V E G F  d id  n o t s h o w  
su ch  a s s o c ia tio n  a n d  c o u ld  n o t  p re d ic t  re s p o n s e  to  t r e a t m e n t .  W h ile  th e r e  w a s  a 
fa i lu r e  to  f in d  a s ig n if ic a n tly  s h o r te r  d is e a s e  f r e e  s u rv iv a l in p 5 3 , V E G F  a n d  
m e ta l lo th io n e in  p o s it iv e  tu m o u r s  p o s t - t r e a tm e n t ,  it  is p o s s ib le  t h a t  th is  m a y  a c tu a lly  
r e f le c t  th e  a b il i ty  o f  n e o a d ju v a n t  c h e m o ra d io th e r a p y  to  im p ro v e  o u tc o m e .
W h i le  re s u lts  f r o m  o u r  s tu d y  a n d  o th e rs  s h o w  p o te n t ia l  fo r  c lin ic a l a p p lic a t io n  o f  
m o le c u la r  m a rk e rs  su ch  as p 5 3 , m e ta l lo th io n e in ,  V EG F a n d  m ic r o m e ta s ta t ic  s ta tu s ,
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th e r e  is a s ig n if ic a n t n e e d  to  c o n f irm  th e s e  o b s e rv a tio n s  in  a p ro s p e c t iv e  s tu d y  w ith  
s ta n d a rd is e d  te c h n iq u e s  in  w e ll -d e f in e d  p a t ie n t  c o h o rts  a n d  s h o u ld  b e  t h e  s u b je c t o f  
f u tu r e  re s e a rc h . O n ly  th e n  m a y  th e s e  te c h n iq u e s  b e  c o n s id e re d  to  be in c lu d e d  in 
p a th o lo g ic a l s ta g in g .
M o r e  a c c u ra te  in d ic a to rs  o f  c o m p le te  re s p o n s e  a re  n e e d e d  b u t  th e  issue o f  w h a t  to  d o  
w ith  c o m p le te  c lin ic a l re s p o n d e rs , e s p e c ia lly  th o s e  w h o  a r e  o ld e r  o r  less f i t  fo r  
re s e c tio n , re m a in s  c o n tro v e rs ia l. T h e  m a n a g e m e n t  o f  th is  c o h o r t  is fu r t h e r  
c o m p lic a te d  by th e  u n d e r r e p r e s e n ta t io n  o f  o ld e r  p a t ie n ts  in m o s t  ra n d o m is e d  tr ia ls .  
A ll th e  e ld e r ly  p a t ie n ts  in th is  s tu d y  w e r e  in v o lv e d  in t h e  d e c is io n  m a k in g  a b o u t th e ir  
o w n  c a re . M a n y  c h o s e  n o t to  h a v e  s u rg e ry , w h ile  o th e rs  w e r e  u n f it  fo r  a ra d ic a l  
p ro c e d u re . In  th e  p a s t, th e  m a jo r ity  o f  th e s e  p a t ie n ts  w o u ld  h a v e  b e e n  p a llia te d , b u t  
w e  b e lie v e  th e y  c o u ld  b e  o f fe r e d  m o re , in  C h a p te r  6 , w e  fo u n d  t h a t  a lm o s t h a lf  o f  a ll 
o ld e r  p a t ie n ts  c o m p le t in g  t r e a t m e n t  h a d  a c o m p le te  c lin ic a l re s p o n s e  a n d  t h a t  t w o -  
th ird s  o f  th e s e  w h o  u n d e r w e n t  re s e c tio n  h a d  a c o m p le te  p a th o lo g ic a l re s p o n s e .  
F u r th e r m o r e , th o s e  m a n a g e d  n o n -o p e r a t iv e ly  h a d  c o m p a ra b le  s u rv iv a l to  th o s e  
m a n a g e d  w ith  a d d it io n a l ra d ic a l s u rg e ry . T h e  3 -y e a r  s u rv iv a l o f  5 0 %  in  th is  c o h o rt  
c o m p a re s  w it h  t h e  b e s t re s u lts  o f  m o re  s e le c tiv e  s e rie s  o f  y o u n g e r  p a t ie n ts . W it h  th e s e  
re s u lts , t h e  a p p ro a c h  o f  a c tiv e  o b s e rv a t io n  o f  c o m p le te  re s p o n d e rs  w it h  th e  a d d e d  
o p t io n  o f  s a lv a g e  s u rg e ry  if  d is e a s e  r e -e m e rg e s  is a n  a t t r a c t iv e  o p t io n  to  p a t ie n ts  a n d  
c lin ic ia n s  a lik e . L a rg e r-s c a le  ra n d o m is e d  t r ia ls  in c lu s iv e  o f  o ld e r  p a t ie n ts  c o m p a r in g  
ra d ic a l c h e m o ra d io th e r a p y  a n d  s u rg e ry  a lo n e  in b o th  a d e n o c a rc in o m a  a n d  s q u a m o u s  
ce ll c a rc in o m a  a re  n e c e s s a ry  b u t a re  lik e ly  to  fa c e  d iff ic u lt ie s  in re c ru it in g  b o th  p a t ie n ts  
a n d  t r e a t in g  c lin ic ia n s .
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T h e  fo c u s  o f  th e  s c ie n tif ic , p h a rm a c o lo g ic a l a n d  m e d ic a l c o m m u n it ie s  n e e d s  to  a d a p t  
a c c o rd in g ly  a n d  b e  d ire c te d  to w a r d s  p ro v id in g  a c u re  th a t  b e n e f its  th e  w h o le  s p e c tru m  
o f  o e s o p h a g e a l c a n c e r  s u f fe re rs , n o t  ju s t  th e  y o u n g e s t a n d  f i t te s t .  W e  re m a in  u n c le a r  
as t o  th e  ro le  t h a t  s u rg e ry  w il l  p la y  in th e  fu tu r e  o f  o e s o p h a g e a l c a n c e r  c a re , b u t  a re  
s u re  t h a t  a d v a n c e s  in n e o a d ju v a n t  c h e m o ra d io th e r a p y  w il l  p ro v id e  th e  b e s t h o p e  o f  
c u re  a n d  a p o s it iv e  o u t lo o k  f o r  th o s e  w h o  a re  d ia g n o s e d  w ith  th is  fo rm id a b le  d is e a s e .
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CHAPTER IX: DIRECTION FOR FURTHER STUDIES
C u r re n t  n e o a d ju v a n t  c h e m o ra d io th e r a p y  p ro v id e s  a c o m p le te  p a th o lo g ic a l re s p o n s e  
r a te  o f  2 5 -4 0 %  a n d  has b e e n  p ro v e n  to  im p ro v e  o u tc o m e  (C h a p te r  3 ). W h ile  it  m a y  
re d u c e  th e  m ic r o m e ta s ta t ic  d is e a s e  b u rd e n , it d o e s  n o t c o m p le te ly  e r a d ic a te  it 
p ro v id in g  a n id u s  fo r  d is e a s e  re c u rre n c e  a n d  re s u ltin g  in th e  p re s e n t  h igh  re la p s e  ra te .
B e t te r  o u tc o m e s  fo r  o e s o p h a g e a l c a n c e r  can  b e  a n t ic ip a te d  i f /w h e n  n e w  re g im e n s  o f  
c h e m o ra d io th e r a p y  a re  in tro d u c e d  w h ic h  re lia b ly  a n d  c o n s is te n tly  p ro v id e  h ig h  ra te s  o f  
c o m p le te  s y s te m ic  a n d  loca l re s p o n s e  re s p o n s e  w ith  th e  m in im u m  o f  s id e  e ffe c ts .  
T o x ic ity  m u s t b e  lo w  so th e y  can  b e  o f fe r e d  to  a ll p a t ie n ts  a t  a ll s tag es  o f  d is e a s e  
re d u c in g  o r  o b v ia t in g  th e  n e c e s s ity  fo r  fo rm id a b le  s u rg e ry .
M a n y  p a t ie n ts  s till s u c c u m b  to  o e s o p h a g e a l c a n c e r , e v e n  fo llo w in g  a c o m p le te  
p a th o lo g ic a l re s p o n s e . T h e  re la p s e  p a t te r n  o f  o e s o p h g e a l c a n c e r  fo llo w in g  t r e a t m e n t  
w ith  n e o a d ju v a n t  c h e m o ra d io th e r a p y  m a y  b e  e x p la in e d  by a n u m b e r  o f  m e c h a n is m s  
a n d  th u s  id e n t if ie s  a n u m b e r  o f  p o te n t ia l  th e r a p e u t ic  ta rg e ts . O n e  o f  th e  m o s t o b v io u s  
is th a t  w h e n  g iv e n  c o n c u rre n t ly ,  c h e m o th e r a p y  e n h a n c e s  th e  e f fe c t  o f  r a d io th e ra p y  
lo c a lly , in c lu d in g  ly m p h  n o d e  d is e a s e  b u t s y s te m ic  d is e a s e  is n o t e x p o s e d  to  th is  
s y n e rg is tic  e f fe c t .  A n o th e r  e x p la n a t io n  m a y  b e  th a t  b e c a u s e  th e  m a jo r i ty  o f  
m ic r o m e ta s ta t ic  tu m o u r  ce lls  m a y  b e  n o n -p r o l i fe r a t in g 381, a n d  th u s  d is p la y  s im ila r  
c h a ra c te r is tic s  to  c a n c e r  s te m  c e lls 382,383 th e  s ta n d a rd  c y to to x ic  c h e m o th e r a p ie s  a im e d  
a t  p r o life r a t in g  cells  m a y  b e  less e f fe c t iv e  a llo w in g  d is e a s e  to  re c u r .
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R e c e n tly , th e r e  has b e e n  m u c h  re s e a rc h  in to  th e  c o n c e p t o f  th e  c a n c e r  s te m  ce ll s in c e  
t h e  f irs t  c o n c lu s iv e  e v id e n c e  f o r  th e s e  cells  w a s  p u b lis h e d  in  t h e  la te  1 9 9 0 s 417 a n d  th e y  
h a v e  n o w  b e e n  id e n t if ie d  in m a n y  ty p e s  o f  t u m o u r 417'422. T h e s e  cells  possess th e  s a m e  
c h a ra c te r is tic s  a s s o c ia te d  w ith  n o rm a l s te m  ce lls , g e n e ra t in g  a n d  p r o life r a t in g  tu m o u rs  
th ro u g h  s te m  ce ll p ro cesses  o f  s e lf - r e n e w a l a n d  d i f fe r e n t ia t in g  in to  m u lt ip le  ce ll ty p e s . 
M o u n t in g  e v id e n c e  su g g es ts  t h a t  c a n c e r  s te m  cells  a re  re s p o n s ib le  fo r  tu m o u r  
re s is ta n c e  a n d  r e -g r o w th ,  e s ta b lis h m e n t  o f  m e ta s ta s e s  a n d  re s is ta n c e  to  a v a r ie ty  o f  
t r e a t m e n t s 384'388. S e v e ra l re c e n t  re p o r ts  h a v e  s u g g e s te d  th a t  as m a n y  as o n e  q u a r t e r  o f  
th e  c a n c e r  ce lls  w ith in  c e r ta in  tu m o u r s  h a v e  th e  p ro p e r t ie s  o f  c a n c e r  s te m  ce lls 423,424 
b u t c o n v e n t io n a l c h e m o th e r a p y  re g im e n s  k ill d i f f e r e n t ia te d  o r  d if fe r e n t ia t in g  ce lls , 
w h ic h  fo r m  th e  b u lk  o f  th e  tu m o u r .  T h u s  b y  th is  m e c h a n is m , c a n c e r  s te m  cells  c o u ld  
r e m a in  u n a f fe c te d  a n d  re s u lt in a re la p s e  o f  t h e  d is e a s e .
T h e  p e rs is te n c e  o f  v ia b le  d is s e m in a te d  o r  m ic r o m e ta s ta t ic  t u m o u r  ce lls , s o m e  o r  a ll o f  
w h ic h  m a y  in d e e d  b e  c a n c e r  s te m  ce lls , fo llo w in g  n e o a d ju v a n t  c h e m o ra d io th e r a p y ,  
in c lu d in g  in th o s e  w ith  an  a p p a r e n t  c o m p le te  p a th o lo g ic a l re s p o n s e , h ig h lig h ts  th e  
n e e d  f o r  im p ro v e d  o r  a d d it io n a l s y s te m ic  th e ra p ie s . F u tu re  re g im e n s  m a y  id e n t ify  
ta r g e ts , such as ce ll s u r fa c e  m a rk e rs , o n  th e s e  cells  to  e l im in a te  th e m  s e le c tiv e ly  as p a r t  
o f  n e o a d ju v a n t  t r e a t m e n t  o r  a l lo w  " m o p p in g  u p "  o f  th e s e  cells  w ith  ta r g e t e d  a d ju v a n t  
th e r a p y ,  su ch  as a n t ib o d y -b a s e d  th e ra p ie s . A n o th e r  s tra te g y  m a y  b e  to  f in d  o th e r  
m e a n s  to  s e n s itis e  s y s te m ic a lly -c irc u la t in g  cells  to  c h e m o th e r a p e u t ic  a g e n ts  to  a llo w in g  
a s im ila r  s y n e rg is tic  e f fe c t  to  t h a t  w h ic h  ra d io th e ra p y  p ro v id e s  lo c o -re g io n a lly .
O e s o p h a g e a l c a n c e r  o f fe r  c le a rs  o p p o r tu n it ie s  fo r  c lin ic a l re s e a rc h  o f  ta r g e te d  
th e ra p ie s  w ith  th e  in c re a s in g  u n d e rs ta n d in g  o f  b o th  its c lin ic a l a n d  b io lo g ic a l b e h a v io u r
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a n d  re s p o n s e  to  c h e m o ra d io th e r a p y .  It  is p ro b a b le  t h a t  o p t im a l th e r a p e u t ic  re g im e n s  
w ill n e e d  to  in c o r p o ra te  a g e n ts  t h a t  ta r g e t  b o th  c a n c e r  s te m  ce lls  a n d  n o n -c a n c e r  s te m  
ce ils , b o th  in t h e  tu m o u r  a n d  m ic ro m e ta s ta s e s  in c irc u la t io n  i f  t r u ly  c u ra tiv e  th e ra p ie s  
a r e  e v e r  to  b e  a c h ie v e d . E lim in a t io n  o f  th e s e  cells  m a y  a c h ie v e  th e  u lt im a te  g o a l o f  
c a n c e r  t r e a t m e n t  -  a t r u e  c o m p le te  p a th o lo g ic a l a n d  s y s te m ic  re s p o n s e .
T o  a llo w  fo r  th e  g r e a te s t  im p a c t  o n  th is  d is e a s e , a ll p a t ie n ts , in c lu d in g  o ld e r  p a t ie n ts  
w ith  b o th  e a r ly  a n d  lo c o -re g io n a lly  a d v a n c e d  o e s o p h a g e a l c a n c e r  s h o u ld  b e  c o n s id e re d  
f o r  in c lu s io n  in c lin ic a l tr ia ls  o f  ta r g e t e d  a n d  ta i lo r e d  th e ra p ie s  in  th e  s e a rc h  fo r  m o re  
e ffe c t iv e  t r e a tm e n ts ,  w h ic h  m a y  a llo w  f o r  in c re a s e d  ra te s  o f  c o m p le te  p a th o lo g ic a l  
re s p o n s e  a n d  im p ro v e d  o u tc o m e s . W h e n  w e  h a v e  d e v e lo p e d  m e a n s  w ith  w h ic h  to  
re lia b ly  id e n t ify  p a t ie n ts  w ith  a c o m p le te  p a th o lo g ic a l re s p o n s e , w e  m a y  e l im in a te  th e  
n e e d  fo r  fo r m id a b le  s u rg e ry  a n d  a ll o f  its risks.
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